tenofovir has been researched along with guanine in 526 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (0.57) | 18.2507 |
| 2000's | 37 (7.03) | 29.6817 |
| 2010's | 316 (60.08) | 24.3611 |
| 2020's | 170 (32.32) | 2.80 |
| Authors | Studies |
|---|---|
| Balzarini, J; Casara, P; De Clercq, E; Egberink, H; Hartmann, K; Navé, JF; Pannecouque, C; Vahlenkamp, T; Witvrouw, M | 1 |
| Connelly, MC; Fridland, A; Lee, SH; Pisarev, VM | 1 |
| Bílá, V; Holý, A; Lesková, V; Mejsnarová, B; Otová, B; Sladká, M; Votruba, I | 1 |
| De Clercq, E; Neyts, J; Ying, C | 1 |
| De Clercq, E; Furman, P; Neyts, J; Nicholson, W; Ying, C | 1 |
| Buster, EH; Schalm, SW; van der Eijk, AA | 1 |
| Ala, A; Dieterich, DT | 1 |
| Avci, A; Erhardt, A; Häussinger, D; Heintges, T; Lörke, J; Sagir, A | 1 |
| Lok, AS | 1 |
| Buti, M; Esteban, R | 1 |
| Roche, B; Samuel, D | 2 |
| Sherman, M | 1 |
| Schiff, ER; Schreibman, IR | 1 |
| Grant, RM; Levy, V | 1 |
| Benhamou, Y | 1 |
| Lok, AS; Tan, J | 1 |
| Garcia-Gasco, P; Sheldon, J; Soriano, V | 1 |
| Janssen, HL; Reijnders, JG | 1 |
| Ayoub, WS; Keeffe, EB | 1 |
| Bläckberg, J; Duberg, AS; Fischler, B; Friman, S; Karlström, O; Lindh, M; Norkrans, G; Reichard, O; Sangfeldt, P; Söderström, A; Sönnerborg, A; Uhnoo, I; Weiland, O; Wejstål, R; Wiström, J | 1 |
| de Man, RA; Janssen, HL; Leemans, WF; Niesters, HG; Schalm, SW; van der Eijk, AA | 1 |
| Beckebaum, S; Cicinnati, VR; Gerken, G; Sotiropoulos, GC | 1 |
| Dieterich, DT; Han, SH; Jacobson, IM; Keeffe, EB; Martin, P; Schiff, ER; Tobias, H | 1 |
| Buti, M | 2 |
| Sarmento E Castro, R; Sheldon, J; Soriano, V | 1 |
| González-Diéguez, ML; Rodríguez, M | 1 |
| Barreiro, P; García-Samaniego, J; Martín-Carbonero, L | 1 |
| McHutchison, J; Patel, K; Tillmann, H | 1 |
| Buster, EH; Janssen, HL; Schalm, SW | 1 |
| Colombo, M; Lampertico, P | 1 |
| Lampertico, P | 1 |
| Amini-Bavil-Olyaee, S; Herbers, U; Luedde, T; Sheldon, J; Tacke, F; Trautwein, C | 1 |
| Ham, MY; Holt, C; Saab, S; Stone, MA; Tong, M | 1 |
| Angus, PW; Patterson, SJ | 1 |
| Borroto-Esoda, K; Curtis, M; Miller, MD; Qi, X; Zhu, Y | 1 |
| Buffet, C | 1 |
| Lok, AS; McMahon, BJ | 1 |
| Barreiro, P; Fernández, JV; Labarga, P; Medrano, J; Soriano, V; Tuma, P; Vispo, E | 1 |
| Lin, Q; Zhang, DZ | 1 |
| Funk, A; Helm, M; Olotu, C; Rockstroh, JK; Schildgen, O; Sirma, H; Zöllner, B | 1 |
| Gervain, J; Horváth, G; Hunyady, B; Makara, M; Pár, A; Szalay, F; Telegdy, L; Tornai, I | 1 |
| Marcellin, P; Piratvisuth, T; Sung, J | 1 |
| Marcellin, P; Perrillo, RP | 1 |
| Chee, GM; Poordad, F | 1 |
| Jiang, L; Yan, LN | 1 |
| Bao, H; Furman, PA; Korba, B; Micolochick Steuer, HM; Murakami, E; Niu, C; Tolstykh, T | 1 |
| Chien, RN | 1 |
| Einarson, TR; Heathcote, EJ; Kowgier, M; Krahn, M; Nishikawa, Y; Pham, B; Sherman, M; Tomlinson, G; Ungar, WJ; Wong, DK; Woo, G | 1 |
| Coffin, CS; Michalak, TI; Mulrooney-Cousins, PM; Peters, MG; Roberts, JP; Terrault, NA; van Marle, G | 1 |
| de Man, RA; de Vries-Sluijs, TE; Hansen, BE; Hoepelman, AI; Janssen, HL; Mulder, JW; Pas, SD; Prins, JM; Reijnders, JG; Richter, C; Schutten, M; van der Ende, ME; Zaaijer, HL | 1 |
| Bentley, A; Dakin, H; Dusheiko, G | 1 |
| Dakin, H; Fidler, C; Harper, C | 1 |
| Belvisi, V; Cenfra, N; Cimino, G; Del Borgo, C; Lichtner, M; Marocco, R; Mastroianni, CM; Mecarocci, S; Rago, A | 1 |
| Boroń-Kaczmarska, A; Cianciara, J; Flisiak, R; Gładysz, A; Halota, W; Juszczyk, J; Kryczka, W; Malkowski, P; Pawlowska, M; Simon, K | 1 |
| Einecke, D | 1 |
| Amini-Bavil-Olyaee, S; Herbers, U; Luedde, T; Tacke, F; Trautwein, C | 1 |
| Chotiyaputta, W; Ditah, FA; Goodwin, D; Lok, AS; Peterson, C | 1 |
| de la Cruz-Lombardo, J; Jiménez-Pérez, M; Lozano-Rey, JM; Mongil Poce, L; Rodrigo-López, JM; Sáez-Gómez, AB | 1 |
| Brost, S; Eisenbach, C; Schnitzler, P; Stremmel, W | 1 |
| Bourlière, M; Kahloun, A; Zoulim, F | 1 |
| Benhamou, Y; Pais, R | 1 |
| Marcellin, P | 1 |
| Bartels, M; Berg, T; Hartmann, J; Jonas, S; Karlas, T; Maier, M; Mössner, J; Tillmann, HL; Weimann, A; Wiegand, J | 1 |
| Janssen, HL; Rijckborst, V; Sonneveld, MJ | 1 |
| Janssen, HL; Sonneveld, MJ | 1 |
| Leung, N | 1 |
| Papatheodoridis, GV | 1 |
| Zoulim, F | 1 |
| Mallet, V; Pol, S; Vallet-Pichard, A | 1 |
| Bettocchi, D; Consales, G; Durval, A; Luzzio, MG; Zamidei, L | 1 |
| Akarca, US; Berg, T; Buti, M; Chang, TT; Frederick, D; Horban, A; Kitrinos, K; Kwan, P; Lee, CM; Liaw, YF; Mondou, E; Papatheodoridis, GV; Peschell, K; Prieto, M; Rousseau, F; Schiff, ER; Sheen, IS; Suet-Hing Wong, F; Wang, C | 1 |
| Hosaka, T; Kumada, H; Suzuki, F | 1 |
| Beadsworth, MB; Pennell, A; Phillips, M; Ratcliffe, L; Vilar, FJ | 1 |
| Liu, T; Wang, Y; Zhang, C | 1 |
| Harbord, N | 1 |
| Tornai, I | 1 |
| Andreoni, M; Bertoli, A; Ceccarelli, L; Perno, CF; Salpini, R; Sarrecchia, C; Sordillo, P; Svicher, V; Volpi, A | 1 |
| Benetti, S; Cassino, L; Fay, F; Quarleri, J; Tanno, H | 1 |
| Boucher, CA; Hansen, BE; Janssen, HL; van Vuuren, AJ; Zoutendijk, R | 1 |
| Chan, HL; Chan, HY; Locarnini, SA; Tse, CH; Wong, GL; Wong, VW; Yuen, LK | 1 |
| Antinori, S; Corbellino, M; Dodero, A; Foschi, A; Mazzocchi, A; Micheli, V; Milazzo, L; Montefusco, V; Zehender, G | 1 |
| Block, TM; Clearfield, E; Cuconati, A; Goddard, C; Guo, H; Mills, C; Morrey, JD; Motter, NE; Xiao, T; Xu, X; Yu, W; Zhao, K | 1 |
| Giles, M; Sasadeusz, J; Visvanathan, K | 1 |
| Chan, HL; Chan, HY; Ong, A; Tse, CH; Wong, GL; Wong, VW | 1 |
| Berg, T; Brown, A; Buggisch, P; Buti, M; Janssen, HL; Lampertico, P; Lutgehetmann, M; Petersen, J; Ratziu, V; Sarrazin, C; Schollmeyer, J; Sterneck, M; Wedemeyer, H; Zoulim, F | 1 |
| Lee, SS; Sherman, M | 1 |
| Campanale, F; D'Addiego, G; Fazio, V; Giammario, A; Scotto, G | 1 |
| Dalekos, GN; Tillmann, HL; Zachou, K | 1 |
| García-Alonso, FJ; Martín-Mateos, RM; Moreira Vicente, V | 1 |
| Brunetto, MR; Janssen, HL; Sonneveld, MJ | 1 |
| Cox, N; Tillmann, H | 1 |
| Fontana, RJ; Singal, AK | 1 |
| Bunchorntavakul, C; Chen, W; Hu, KQ; Pan, CQ; Reddy, KR; Yu, AS | 1 |
| Gervain, J; Horváth, G; Hunyady, B; Makara, M; Pár, A; Szalay, F; Telegdy, L; Tornai, I; Ujhelyi, E | 1 |
| Ridruejo, E; Silva, MO | 1 |
| Lee, WM; Tujios, SR | 2 |
| Lampertico, P; Liaw, YF | 1 |
| Baqai, S; Clark, MD; Gish, RG; Kane, SD; Mangahas, MF; Shaw, RE | 1 |
| Fernandes, CA; Gomes, Sde A; Mello, FC | 1 |
| Lampertico, P; Pol, S | 1 |
| Hadziyannis, SJ | 1 |
| Akriviadis, E; Antoniadis, N; Cholongitas, E; Goulis, I; Papanikolaou, V; Vasiliadis, T | 1 |
| Almasio, PL; Bertino, G; Brandolino, N; Bruno, S; Caroleo, B; Cosco, L; Di Marco, V; Foti, G; Frugiuele, P; Galdieri, A; Madonia, S; Montalto, G; Portelli, V; Russello, M; Sapienza, M; Scifo, G; Siciliano, R; Spadaro, A; Stroffolini, T; Surace, L | 1 |
| Alfieri, A; Boni, C; Brancaccio, G; Colombo, M; Ferrari, C; Gaeta, GB; Giuberti, T; Laccabue, D; Lampertico, P; Missale, G; Pesci, M; Schivazappa, S; Viganò, M | 1 |
| Akin, MS; Doğan, ÜB; Gümürdülü, Y; Kara, B; Soylu, A | 1 |
| Bozdayi, AM; Cevik, E; Idilman, R; Kabaçam, G; Karatayli, E; Karatayli, SC; Seven, G; Yakut, M; Yurdaydin, C | 1 |
| Ahmed, A; Chaung, K; Cheung, R; Nguyen, HA; Nguyen, MH; Trinh, HN; Wong, CR; Yip, B | 1 |
| Akbal, E; Akin, E; Alkan, E; Ataseven, H; Aygün, C; Başar, O; Baykal, O; Coban, S; Demir, M; Gülşen, MT; Ibiş, M; Koçkar, MC; Köklü, S; Köksal, AŞ; Küçükazman, M; Nadir, I; Ozdil, K; Pürnak, T; Tuna, Y; Yildirim, B; Yüksel, I; Yüksel, O | 1 |
| Baak, BC; Bakker, CM; Beuers, UH; Brouwer, JT; Buster, EH; Drenth, JP; Honkoop, P; Janssen, HL; Kerbert-Dreteler, MJ; Koek, GH; Tan, AC; van der Spek, BW; van Erpecum, KJ; van Hoek, B; van Nieuwkerk, KM; van Soest, H; Vrolijk, JM | 1 |
| Cholongitas, E; Papatheodoridis, GV | 1 |
| Hu, KQ; Pan, CQ; Tsai, N | 1 |
| Bahrami, S; Chevaliez, S; Grare, M; Hézode, C; Pawlotsky, JM | 1 |
| Buti, M; Petersen, J | 1 |
| Coffin, CS; Fung, SK; Ma, MM | 1 |
| Colle, I; Gamil, M; Horsmans, Y; Hulstaert, F; Nevens, F; Schwierz, C; Thiry, N; Van de Sande, S | 1 |
| Baietto, L; Boglione, L; Burdino, E; Cariti, G; Cusato, J; D'Avolio, A; De Rosa, FG; Di Perri, G; Ghisetti, V; Gregori, G | 1 |
| Cui, YJ; Song, ZL; Teng, DH; Zheng, H; Zheng, WP | 1 |
| Buti, M; Casado, MA; Lozano, V; Oyagüez, I | 1 |
| Fadda, V; Maratea, D; Messori, A; Trippoli, S | 1 |
| Bonino, F; Brunetto, MR; Caputo, A; Coco, B; Espinos, B; Iannazzo, S; Latour, A; Rossetti, F | 1 |
| Acurcio, Fde A; Almeida, AM; Andrade, EI; Araújo de Oliveira, GL; Brandão, CM; Carmo, RA; Cherchiglia, ML; Silva, AL | 1 |
| Amarapurkar, DN; Patel, N | 1 |
| Brown, RS; Chang, MS; Emond, JC; Guarrera, JV; Heese, S; Olsen, SK; Pichardo, EM; Stiles, JB | 1 |
| Brown, RS; Brubaker, WD; Chang, MS; Emond, JC; Guarrera, JV; Olsen, SK; Pichardo, EM; Rosenthal-Cogan, L; Stiles, JB | 1 |
| Acalovschi, M; Arama, V; Bjork, S; Kamar, D; Klauck, I; Leblebicioglu, H; Lescrauwaet, B; Marcellin, P; Mauss, S; Morais, E; Sieklucki, J; Simon, K; Usluer, G; Zarski, JP; Zeuzem, S | 1 |
| Fontana, RJ; Kuo, YF; Salameh, H; Singal, AK | 1 |
| Delaney, W; Furman, P; Hu, J; Jones, SA; Murakami, E | 1 |
| Goyal, N; Gupta, S; Kumar, A; Taneja, S; Wadhawan, M | 1 |
| Mendes-Correa, MC; Núñez, M | 1 |
| Horváth, G | 1 |
| Gulland, A | 1 |
| Asselah, T; Marcellin, P | 1 |
| Šperl, J | 1 |
| Buğdacı, MS; Sayan, M | 1 |
| Akkoyunlu, Y; Ceylan, B; Eren, G; Fincanci, M; Muderrisoglu, C; Tozalgan, U; Yardimci, C | 1 |
| Cholongitas, E; Papatheodoridis, G; Pipili, C | 1 |
| Arama, V; Bjork, S; Bludzin, W; Habersetzer, F; Jinga, M; Kamar, D; Klauck, I; Leblebicioglu, H; Lescrauwaet, B; Morais, E; Niederau, C; Simon, K; Ulusoy, S; Vermehren, J; Zarski, JP; Zeuzem, S | 1 |
| Acurcio, Fde A; Almeida, AM; Andrade, EI; Brandão, CM; Cherchiglia, ML; Oliveira, GL; Silva, AL | 1 |
| Calvaruso, V; Craxì, A | 1 |
| Lampertico, P; Mangia, G; Viganò, M | 2 |
| Colombo, M; Della Corte, C; Triolo, M | 1 |
| Esteban, R; Pérez-Cameo, C; Pons, M | 1 |
| Chung, RT; Fishman, JA; Wright, AJ | 1 |
| Gao, L; Li, J; Nguyen, MH; Trinh, HN | 3 |
| Price, J | 1 |
| Strasser, SI | 1 |
| Kang, Y; Lin, X; Liu, H; Lu, M; Mao, R; Qin, Y; Wang, J; Zhang, J; Zhang, Y; Zhu, H | 1 |
| Gervain, J; Horváth, G; Hunyady, B; Lengyel, G; Makara, M; Pár, A; Szalay, F; Telegdy, L; Tornai, I | 1 |
| Bradshaw, D; Danta, M | 1 |
| Coppola, N; Filippini, P; Martini, S; Pisaturo, M; Sagnelli, C; Sagnelli, E | 1 |
| Lee, SS; Sadler, MD | 1 |
| Cainelli, F; Comparcola, D; Della Corte, C; Nobili, V; Vento, S | 1 |
| Tang, CM; Yau, TO; Yu, J | 1 |
| De Vincentis, A; Dell'Unto, C; Galati, G; Gallo, P; Picardi, A; Solmone, MC; Vespasiani-Gentilucci, U; Vincenti, D | 1 |
| Cagatay, A; Ceylan, B; Erdem, L; Gokturk, K; Gunduz, A; Karaosmanoglu, H; Kocak, F; Mete, B; Ozaras, R; Ozgunes, N; Senates, E; Tabak, F | 1 |
| Gao, Y; Ke, W; Liu, L; Yang, Y; Ye, X; Zhang, C; Zhou, S | 1 |
| Akriviadis, E; Antoniadis, N; Cholongitas, E; Fouzas, I; Goulis, I; Imvrios, G; Papanikolaou, V | 1 |
| Kim, JH; Kim, KH; Park, ES; Park, YK | 1 |
| Ridruejo, E | 1 |
| Berg, T; van Bömmel, F | 1 |
| Gerlich, WH | 1 |
| Locarnini, S; Warner, N | 1 |
| Beggel, B; Kaiser, R; Neumann-Fraune, M; Obermeier, M | 1 |
| Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Mineta, R; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y; Watahiki, S | 1 |
| Afdhal, NH; Bonder, A; Lau, D; Patwardhan, VR; Sengupta, N | 1 |
| Shan, C; Wu, P; Yin, GQ | 1 |
| Ahn, H; Cho, EJ; Cho, H; Cho, Y; Cho, YY; Choi, WM; Kim, CY; Kim, YJ; Lee, DH; Lee, HS; Lee, JH; Lee, M; Lee, YB; Yoo, JJ; Yoon, JH; Yu, SJ | 1 |
| Brunetto, M; Carosi, G; Greenbloom, S; Jeffers, L; Llamoso, C; Mazur, W; Nguyen, T; Yu, S; Zoulim, F | 1 |
| Arends, P; Buti, M; Colombo, M; Dalekos, GN; Esteban, R; Galanis, K; Gatselis, N; Goulis, J; Hansen, BE; Idilman, R; Janssen, HL; Keskın, O; Lampertico, P; Mangia, G; Manolakopoulos, S; Papaioannou, C; Papatheodoridis, GV; Savvidou, S; Sypsa, V; Yurdaydin, C | 1 |
| Arslan, F; Batirel, A; Guclu, E; Karabay, O; Kocak, F; Mert, A; Ozer, S; Turanli, M | 1 |
| Deng, ZZ; Li, ZJ; Liu, SK; Ma, YT; Song, LY; Wang, CJ; Zhang, HY; Zuo, SR; Zuo, XC | 1 |
| Alcantara, L; Burak, KW; Coffin, CS; Klein, P; Myers, RP; Pang, JX; Rezaeeaval, M | 1 |
| Chan, S; Han, SH; Krishnan, G; Li, J; Lu, L; Nguyen, MH; Pan, CQ; Trinh, H; Wong, CC; Yip, B | 1 |
| Akarca, US; Elhan, AH; Gulsen, M; Gunsar, F; Idilman, R; Keskin, O; Koruk, M; Meral, CE; Yurdaydin, C | 1 |
| Brocchieri, A; Castelli, F; Colombo, M; Facchetti, F; Fugazza, A; Lampertico, P; Mangia, G; Spinetti, A; Viganò, M; Zaltron, S | 1 |
| Corouge, M; Fontaine, H; Mallet, V; Pol, S; Schwarzinger, M; Sogni, P; Vallet-Pichard, A | 1 |
| Ozdogan, OC; Yegin, EG | 1 |
| Fan, H; Fan, Y; Ge, Y; Li, D; Liu, X; Liu, Z; Lyu, W; Yang, H; Zhou, B | 1 |
| Papatheodoridis, GV; Vlachogiannakos, J | 1 |
| Invernizzi, F; Lampertico, P; Viganò, M | 1 |
| Borsa-Lebas, F; Cacoub, P; Carrat, F; Fillion, A; Lacombe, K; Lopes, A; Loustaud-Ratti, V; Miailhes, P; Piroth, L; Pol, S; Rosenthal, E; Salmon, D | 1 |
| An, J; Byun, KS; Kim, YJ; Kwon, SY; Lee, HC; Lee, YS; Lim, YS; Yoo, BC | 2 |
| Andrade, JR; Barros, LM; Bertolini, DA; Carrilho, FJ; Conde, SR; de Araújo, LV; Ferreira, AC; Ferreira, AS; Galvan, J; Gomes-Gouvêa, MS; Kliemann, DA; Kunyoshi, AS; Leite, AG; Lyra, AC; Mendes-Corrêa, MC; Nastri, AC; Oikawa, MK; Piccoli, LZ; Pinho, JR; Rezende, RE; Soares, MC; Teixeira, R | 1 |
| Choudhary, NS; Goja, S; Menon, PB; Mohanka, R; Rastogi, A; Saigal, S; Saraf, N; Soin, AS | 1 |
| Chen, WD; Gong, GZ; Luo, Y; Zhou, HY | 1 |
| Ha, FS; Han, T; Liu, H; Liu, L; Nie, CY; Zhang, Q | 1 |
| Caccuri, F; Caruso, A; Castelli, F; De Francesco, MA; Gargiulo, F; Giagulli, C; Spinetti, A; Zaltron, S | 1 |
| Alvey, N; Chan, EY; Cohen, E; Eswaran, S; Fayek, SA; Fleetwood, VA; Hertl, M; Shah, N; Singer, GA; Zielsdorf, S | 1 |
| Chang, KC; Chen, CH; Chiu, YC; Hu, TH; Hung, CH; Kee, KM; Kuo, YH; Lee, CM; Lu, SN; Tsai, MC; Wang, JH | 1 |
| Durantel, D; Zoulim, F | 1 |
| Akın, MS; Doğan, ÜB; Öztürk, AB; Sayan, M; Yalaki, S | 1 |
| Arora, SK; Bhattacharyya, R; Chakraborti, A; Chawla, YK; Das, A; Dhiman, RK; Duseja, A; Kapil, S; Sharma, BK; Singla, B | 1 |
| Chaung, KT; Ha, NB; Kim, LH; Kin, KC; Nguyen, HA; Nguyen, MH; Trinh, HN; Vu, VD | 1 |
| Fong, TL; Hsieh, MJ; Khemichian, S; Kim, J; Limurti, J; Zhang, SR | 1 |
| Bang, SJ; Jeong, ID; Jung, SW; Kim, BG; Kim, CJ; Kim, EH; Kim, JH; Kim, MH; Lee, BU; Park, BR; Park, JH; Park, NH; Shin, JW; Sung, SJ | 1 |
| Ha, NB; Nghiem, D; Nguyen, MH; Rosenblatt, L; Trinh, HN | 1 |
| Allegra, S; Boglione, L; D'Avolio, A; De Nicolò, A; Di Perri, G; Pensi, D; Simiele, M | 1 |
| Chang, KC; Chen, CH; Chiu, KW; Chou, YP; Hu, TH; Hung, CH; Lee, CM; Lin, MT; Lu, SN; Tsai, MC; Tseng, PL; Wang, JH; Yen, YH | 1 |
| Cho, EJ; Cho, Y; Kim, YJ; Lee, DH; Lee, HS; Lee, JH; Lee, M; Lee, YB; Yoo, JJ; Yoon, JH; Yu, SJ | 1 |
| Bae, HS; Chang, M; Cheung, E; Cho, YW; Chu, D; Cooper, SL; Fong, TL; Han, SB; Jo, KJ; LeDuc, VH; Mena, EA; Mohammed, W; Nguyen, N; Phan, QQ; Tien, A; Tong, MJ; Velasco, A; Yu, AS | 1 |
| Boettler, T; Thimme, R | 1 |
| Gross, JB; Kim, WR; Poterucha, JJ; Stadheim, LM; Wi, CI | 1 |
| Jansen, L; Kootstra, NA; Reesink, HW; Takkenberg, RB; van Dort, KA; Zaaijer, HL | 1 |
| Behera, M; Dixit, VK; Ghosh, J; Goyal, SK; Gupta, N; Jain, AK; Ranjan, A; Shukla, SK; Tripathi, M | 1 |
| Abradelo, M; Calvo, J; Cambra, F; Castellano, G; Fernández, I; García, A; Hernández, O; Jiménez, C; Loinaz, C; Manrique, A; Manzano, M | 1 |
| Ahn, SH; Chong, Y; Kang, HS; Kim, BK; Kim, DH; Kim, KH; Lee, AR; Park, ES; Park, S; Park, YK; Rhee, JK; Shin, GC; Yang, SI | 1 |
| Chu, CK; Konreddy, AK; Rawal, RK | 1 |
| Amani, A; Niederau, C; Thiel, A | 1 |
| Yin, GQ; Zhong, B | 1 |
| Kosinska, AD; Liu, J; Lu, M; Roggendorf, M | 1 |
| Park, JG; Park, SY | 1 |
| Hutton, DW; So, SK; Toy, M | 1 |
| Aliosmanoglu, I; Cetinkaya, R; Erbis, H; Kocak, H; Suleymanlar, G; Ulger, BV; Yilmaz, VT | 1 |
| Chaung, KT; Ha, NB; Nguyen, MH; Nguyen, NH; O'Brien, C; Trinh, HN | 1 |
| Kittitrakul, C; Leowattana, W; Nontprasert, A; Phumratanaprapin, W; Poovorawan, K; Sriboonvorakul, N; Tangkijvanich, P; Thu, AM; Wilairatana, P | 1 |
| Arslan, F; Batırel, A; Ceylan, B; Fersan, E; Fincancı, M; Mert, A; Paşaoğlu, E; Yardımcı, C; Yılmaz, M | 1 |
| Buti, M; Calleja, JL; Chi, H; Colombo, M; Dalekos, G; de la Revilla, J; Esteban, R; Galanis, K; Gatselis, N; Goulis, J; Hansen, BE; Idilman, R; Janssen, HL; Keskin, O; Lampertico, P; Mangia, G; Manolakopoulos, S; Papatheodoridis, G; Savvidou, S; Sypsa, V; Vlachogiannakos, I; Yurdaydin, C | 1 |
| Ahn, SH; Bae, SH; Han, KH; Jung, KS; Kim, CW; Kim, HY; Park, JY; Yoon, SK | 1 |
| Bair, MJ; Chang, CW; Chen, CJ; Chen, MJ; Chu, CH; Hu, KC; Lee, KH; Lin, CC; Lin, SC; Liou, TC; Liu, CY; Shih, SC; Wang, HY; Wang, TE | 1 |
| Cao, Y; Dai, CY; Hou, W; Jiang, B; Li, XM; Lu, W; Su, R; Xu, J | 1 |
| Andini, R; Durante-Mangoni, E; Falco, E; Iossa, D; Maiello, C; Parrella, A; Ragone, E; Utili, R; Vitrone, M; Zampino, R | 1 |
| Chong, Y; Huang, M; Jie, Y; Li, X; Lin, G; Shi, H; Wu, Y | 1 |
| Aykın, N; Çevik, F; Demirtürk, N; Doğan, N; Koca, B; Köken, T | 1 |
| Almeida, PR; Dal-Pupo, BB; Grossmann, TK; Mattos, AA; Mirenda, H; Pereira, CV; Tovo, CV | 1 |
| Berg, T; Chan, HL; Janssen, HL; Lampertico, P; Schindler, R; Strasser, SI | 1 |
| Bendahmane, S; Białkowska-Warzecha, J; Diculescu, MM; Goldis, AE; Heyne, R; Janssen, HL; Klauck, I; Mach, T; Marcellin, P; Petersen, J; Simon, K; Wasiak, W; Zoulim, F | 1 |
| Atay, K; Canbakan, B; Durcan, E; Gültepe, İ; Hatemi, İ; Köroğlu, E; Özdemir, S; Sonsuz, A; Tuncer, M; Yurttaş, B | 1 |
| Defresne, F; Sokal, E | 1 |
| Gao, Y; Ke, W; Liu, L; Yang, Y; Yao, Z; Ye, X; Zhang, C; Zhou, S | 1 |
| Ahn, SH; Choe, WH; Kim, JH; Kim, KH; Ko, SY; Kwon, SY | 1 |
| Arenas Ruiz Tapiador, J; Bonet Vidal, ML; Buti, M; Calleja, JL; Castro, Á; Crespo, J; Del Pino-Montes, J; Delgado Blanco, M; Diago, M; Fernández-Rodríguez, C; Fraga, E; García-Samaniego, J; González Diéguez, L; Morillas, R; Núñez, O; Pascasio, JM; Praga, M; Prieto, M; Rodríguez-Nóvoa, S; Romero-Gómez, M; Solá, R | 1 |
| Akyildiz, M; Balci, D; Cinar, K; Dayangac, M; Gungor, G; Hazinedaroglu, S; Idilman, R; Kalkan, C; Keskin, O; Tokat, Y; Yilmaz, TU | 1 |
| Akriviadis, E; Antoniadis, N; Cholongitas, E; Fouzas, I; Giakoustidis, D; Giouleme, O; Goulis, I; Imvrios, G; Papanikolaou, V; Vasiliadis, T | 1 |
| Chang, CY; Chen, TB; Hsu, YC; Lin, JT; Mo, LR; Tseng, CM | 1 |
| den Eynde, EV; Riveiro-Barciela, M | 1 |
| Brahmania, M; Brouwer, WP; Feld, J; Hansen, T; Janssen, HL; Kowgier, M; Mazzulli, T; Wong, D | 1 |
| Collado Borrell, R; Gutiérrez García, ML; López Centeno, B; Pérez Encinas, M; Sanmartin Fenollera, P | 1 |
| Chitturi, S; Farrell, GC; Kaye, G; Ooi, M; Shadbolt, B; Teoh, NC; Truong, J | 1 |
| Chen, CH; Hu, TH; Hung, CH; Lee, CM; Lu, SN; Tsai, MC; Wang, JH | 1 |
| Ahn, SH; Baatarkhuu, O; Han, K; Jung, KS; Kim, BK; Kim, DY; Kim, SU; Ku, HJ; Lee, S; Park, JY | 1 |
| Altınel, Ç; Demirkoparan, Ü; Karasu, Z; Turan, İ | 1 |
| He, J; Li, K; Li, W; Ning, HB; Shang, J; Zeng, YL | 1 |
| Asano, M; Dohi, T; Enomoto, N; Gatanaga, H; Honda, M; Inoue, T; Kaneko, S; Kawamura, YI; Matsumoto, A; Mizokami, M; Murata, K; Nishida, N; Oka, S; Sakamoto, M; Shirasaki, T; Shuno, Y; Sugiyama, M; Tanaka, E; Yano, H | 1 |
| Chen, Y; Ding, H; Han, Y; Liao, H; Liu, Y; Zeng, A | 1 |
| Anzai, N; Chiba, K; Fu, Z; Furihata, T; Ide, H; Morio, H; Suzuki, Y; Tsubota, A; Zhu, M | 1 |
| Anania, FA; Pearlman, BL; Pillai, AA | 1 |
| Grossi, G; Lampertico, P; Loglio, A; Viganò, M | 1 |
| Chen, GF; Lau, G; Wang, C | 1 |
| Acero, D; Aguirre, A; Buti, M; Calleja, JL; Comas, C; Crespo, J; de Cuenca, B; Esteban, R; Fernandez-Bermejo, M; García-Samaniego, J; Gutierrez, ML; Lens, S; Manzano, ML; Moreno, D; Moreno-Palomares, JJ; Pascasio, JM; Piqueras, B; Riveiro-Barciela, M; Rivero, M; Rodríguez, FG; Sánchez-Pobre, P; Suárez, E; Tabernero, D | 1 |
| Dixit, VK; Jain, AK; Nath, G; Singh, N; Srivastava, M | 1 |
| Arcaini, L; Gotti, M; Merli, M; Rattotti, S | 1 |
| Lim, YS | 1 |
| Chen, CH; Hu, TH; Hung, CH; Lee, CM; Lu, SN; Wang, JH; Wu, IT | 1 |
| Basile, M; Cicchetti, A; Coretti, S; Drago, C; Ruggeri, M | 1 |
| Jang, MK; Kim, DJ; Kim, HS; Kim, SE; Kwak, KM; Lee, MS; Park, CK; Park, JW; Park, SH; Suk, KT | 1 |
| Chen, FY; Cheng, Z; Huang, HH; Shi, KQ; Van Poucke, S; Zhang, MY; Zheng, JN; Zheng, MH; Zhu, GQ | 1 |
| Capobianchi, MR; D'Offizi, G; Menzo, S; Piselli, P; Solmone, M; Vincenti, D | 1 |
| Arends, P; Chen, L; Chi, H; de Knegt, RJ; Guo, Q; Guo, S; Hansen, BE; Janssen, HLA; Qi, X; Verhey, E; Wang, JY; Xie, Q; Zhang, NP | 1 |
| An, J; Byun, KS; Choi, J; Gwak, GY; Kim, YJ; Kwon, SY; Lee, HC; Lee, YS; Lim, YS; Yoo, BC | 1 |
| Celià-Terrassa, T; Gregori, J; Kang, Y; Luedde, T; Ploss, A; Rodríguez-Frías, F; Shirvani-Dastgerdi, E; Tabernero, D; Tacke, F; Trautwein, C; Winer, BY; Yagmur, E | 1 |
| He, L; Jiang, Y; Liu, X; Wang, X; Yang, Z; Zhang, S; Zhao, Y | 1 |
| Perricone, G; Pungolino, E; Vinci, M | 1 |
| Ahn, SH; Han, KH; Hwang, SG; Kim, BK; Kim, DY; Kim, MN; Kim, SU; Park, JY; Rim, KS | 1 |
| Hu, C; Huang, H; Li, Y; Liu, J; Yang, D; Yuan, G; Zhang, YY; Zhou, F; Zhou, Y | 1 |
| Berg, T; Buti, M; Calleja, JL; Chi, H; Colombo, M; Dalekos, GN; de la Revilla, J; Esteban, R; Galanis, K; Gatselis, N; Goulis, J; Hansen, BE; Idilman, R; Janssen, HLA; Keskın, O; Kourikou, A; Lampertico, P; Lehretz, M; Loglio, A; Manolakopoulos, S; Papatheodoridis, GV; Savvidou, S; Siakavellas, S; Sypsa, V; van Boemmel, F; Vlachogiannakos, I; Yurdaydin, C | 1 |
| Ahn, SH; Han, KH; Jung, KS; Kim, BK; Kim, DY; Kim, SU; Lee, HW; Park, J; Park, JY | 1 |
| Ahn, JS; Jeon, HJ; Jung, SW; Kim, HR; Lee, JH; Noh, JH; Park, NH; Shin, JW; Yang, Y | 1 |
| AlMattooq, M; Borman, MA; Burak, KW; Coffin, CS; Congly, SE; Lee, SS; Myers, RP; Shaheen, AA; Swain, MG; Yazdanfar, S | 1 |
| Aggeletopoulou, I; Anastassiou, ED; Assimakopoulos, S; Gogos, C; Kalafateli, M; Labropoulou-Karatza, C; Mandellou, M; Taprantzi, D; Thomopoulos, K; Triantos, C; Tselekouni, P; Tsiaoussis, G; Vourli, G | 1 |
| Akinci, E; Alpat, SN; Ari, A; Gunal, O; Guner, R; Kayaaslan, B; Tabak, F; Tosun, S; Tufan, ZK | 1 |
| Chen, J; Huang, Y; Huang, ZB; Liu, XX; Zhao, SS | 1 |
| Lee, JH; Lee, YB | 1 |
| Wang, Y; Zhao, LF | 1 |
| Coppola, N; Macera, M; Pisaturo, M; Sagnelli, C; Sagnelli, E | 1 |
| Chun, JM; Han, YS; Hur, K; Jang, SY; Kang, MK; Kweon, YO; Lee, HJ; Lee, HW; Lee, YR; Park, JG; Park, SY; Tak, WY | 1 |
| El-Serag, HB; Ho, HJ; Hsu, YC; Huang, YT; Lee, TY; Lin, JT; Wu, CY; Wu, MS | 1 |
| Burtin, M; Cova, L; Guerret, S; Jamard, C; Lemasson, M; Quinet, J; Sureau, C; Vaillant, A | 1 |
| Iio, E; Inoue, T; Kumada, T; Matsunami, K; Murakami, S; Nojima, M; Ogawa, S; Shinkai, N; Tanaka, Y; Toyoda, H | 1 |
| Chen, CL; Chen, DS; Chen, PJ; Kao, JH; Liou, JM; Liu, CH; Liu, CJ; Su, TH; Tseng, TC; Yang, HC | 1 |
| Angeli, P; Fasolato, S; Gambino, C; Mareso, S; Piano, S; Pilutti, C; Pontisso, P; Romano, A; Sartori, L; Stanco, M; Tonon, M | 1 |
| Ahn, H; Chang, Y; Cho, EJ; Cho, H; Cho, YY; Jung, YJ; Kim, YJ; Lee, DH; Lee, JH; Lee, JM; Nam, JY; Yoon, JH; Yu, SJ | 1 |
| Gadano, A; Marciano, S | 1 |
| Buti, M; Esteban, R; Riveiro-Barciela, M | 1 |
| Berg, T; Buti, M; Calleja, JL; Chi, H; Colombo, M; Dalekos, G; de la Revilla, J; Esteban, R; Galanis, K; Gatselis, N; Goulis, J; Hansen, BE; Idilman, R; Janssen, HLA; Keskın, O; Kourikou, A; Lampertico, P; Lehretz, M; Loglio, A; Manolakopoulos, S; Papatheodoridis, GV; Savvidou, S; Siakavellas, S; Sypsa, V; van Boemmel, F; Vlachogiannakos, I; Yurdaydin, C | 1 |
| Padma, UD; Surendran, S; Udayakumar, VP | 1 |
| Chang, KC; Chen, CH; Chou, YP; Hu, TH; Hung, CH; Kuo, MT; Kuo, YH; Lu, SN; Tsai, MC; Tseng, PL; Wang, JH | 1 |
| El-Serag, HB; Ho, HJ; Hsu, YC; Huang, YT; Lee, TY; Lin, JT; Wong, GL; Wong, VW; Wu, CY; Wu, MS; Yip, TC | 1 |
| Li, YH; Wan, YM; Wu, HM; Wu, XN; Xu, Y; Xu, ZY; Yang, JH | 1 |
| Satsangi, S | 1 |
| Chen, YL; Dai, L; Li, QH; Lin, JZ; Ma, JD; Mo, YQ; Wang, XY; Yan, T; Yang, ZH; Zheng, DH | 1 |
| Agarwal, K; Bruce, M; Carey, I; Considine, A; Heaton, N; Heneghan, M; Lampertico, P; Lim, TY; Manini, MA; Passerini, M; Suddle, A; Whitehouse, G | 1 |
| Chan, HL; Lam, KL; Lui, GC; Tse, YK; Wong, GL; Wong, VW; Yip, TC | 2 |
| Akbulut, S; Harputluoglu, M; Yilmaz, S | 1 |
| Cornberg, M; Crabé, S; Gineste, P; Höner Zu Siederdissen, C; Hui, AJ; Manns, MP; Nieto, GEG; Nitcheu, J; Stepien, S; Su, WW; Sukeepaisarnjaroen, W; Tangkijvanich, P; Trépo, C; Wedemeyer, H | 1 |
| Alkım, C; Alkım, H; Colak, T; İyisoy, MS; Karayakar, F; Koksal, AR; Sahin, M; Şen, İ; Yetim, A | 1 |
| Bang, SJ; Jeong, ID; Jung, SW; Kim, BG; Lee, BU; Lee, H; Lee, SB; Park, JH; Park, NH; Shin, JW | 1 |
| Caviglia, GP; Ngatchou, D; Olivero, A; Saracco, GM; Smedile, A | 1 |
| Dalekos, GN; Gatselis, N; Hadziyannis, E; Manolakopoulos, S; Papatheodoridi, M; Papatheodoridis, GV; Rigopoulou, EI; Vlachogiannakos, J; Xourafas, V; Zachou, K | 1 |
| Jiang, XW; Li, LJ; Li, YT; Ye, JZ | 1 |
| Chao, Y; Hou, MC; Huang, YH; Lan, KH; Lee, IC; Li, CP; Lin, HC; Su, CW | 1 |
| Chan, HL; Lam, KL; Lui, GC; Szeto, CC; Tse, YK; Wong, GL; Wong, VW; Yip, TC | 1 |
| Chang, ET; Cheung, R; Chung, M; Henry, L; Hoang, J; Jeong, D; Le, AK; Lee, MH; Nguyen, MH; Trinh, S; Wang, U | 1 |
| Domalakes, E; He, L; Lee, GT; Mason, CW; Parrott, J; Pfeifer, E; Zhou, H | 1 |
| Flemming, JA; Terrault, NA | 1 |
| Cho, S; Choi, J; Kim, HJ; Ko, MJ; Lee, J; Lim, YS | 1 |
| Balkan, A; Gülşen, MT; Karaoğlan, İ; Namıduru, M; Şahin, A | 1 |
| Chan, HLY | 1 |
| Li, YH; Wan, YM; Wu, HM; Wu, XN; Xu, Y; Xu, ZY | 1 |
| Ahn, SH; Han, KH; Jeon, MY; Kim, BK; Kim, DS; Kim, DY; Kim, SU; Lee, HW; Park, JY | 1 |
| Cabeza-Barrera, I; Cabezas-Fernández, MT; Cuenca-Gómez, JÁ; Estévez-Escobar, M; Lozano-Serrano, AB; Salas-Coronas, J; Soriano-Pérez, MJ; Vázquez-Villegas, J | 1 |
| Ahn, SH; Cho, YK; Choi, W; Han, KH; Hong, GY; Jang, JY; Jin, SY; Jung, YK; Kim, DJ; Kim, HS; Kim, JH; Kim, KH; Kim, MY; Kim, W; Kim, YJ; Kweon, YO; Lee, BS; Lee, JW; Lee, KS; Lee, WS; Lim, YS; Park, NH; Park, SJ; Sohn, JH; Um, SH; Yang, JM; Yim, HJ; Yoon, SK | 1 |
| Chang, CY; Chen, CC; Hsu, YC; Lin, JT; Mo, LR; Nguyen, MH; Tai, CM; Tanaka, Y; Tseng, CH; Wu, CY; Wu, MS; Yang, TH | 1 |
| Chen, CH; Hu, TH; Hung, CH; Kuo, MT; Lu, SN; Tsai, KL; Wang, JH | 1 |
| Szeto, CC; Wong, GL; Wong, VW | 1 |
| Ni, W; Wang, J; Wu, Z; Xin, H | 1 |
| Cai, D; Dang, S; Jiang, N; Li, J; Lin, F; Pan, C; Ren, H; Shen, B; Wang, M; Wu, S; Xin, S; Yang, Y; Yu, W; Zhang, Z | 1 |
| Lee, JW; Yu, JH | 1 |
| An, HY; Heo, NY; Jang, JW; Jin, YJ; Lee, JW; Suh, YJ; You, CR; Yu, JH | 1 |
| Chang, MS; Cheung, R; Hsu, H; Le, AK; Nguyen, MH; Nguyen, P; Wei, MT; Wong, C; Zhang, JQ | 1 |
| Brancaccio, G; Fasano, M; Gaeta, GB; Grossi, A; Santantonio, TA | 1 |
| Huang, R; Wang, J; Wu, C; Wu, W; Yao, R | 1 |
| Chen, CH | 1 |
| Ahn, SH; Han, KH; Hwang, SG; Kim, BK; Kim, DY; Kim, MN; Kim, SU; Kweon, YO; Lee, HA; Lee, HW; Lee, YR; Park, JY; Park, SY; Rim, KS; Seo, YS; Tak, WY; Um, SH | 1 |
| Atalay, S; Köse, Ş; Tatli Kiş, T | 1 |
| Jia, J; Kong, Y; Yang, HI | 1 |
| Choi, J; Ko, MJ; Lim, YS | 1 |
| Hou, J; Liu, Z; Sun, J | 1 |
| Zeng, W; Zhang, H | 1 |
| Chang, Y; Cho, EJ; Cho, H; Cho, YY; Kim, YJ; Lee, JH; Nam, JY; Yoon, JH; Yu, SJ | 1 |
| Abdurakhmanov, DT; Ibragimov, EK; Moiseev, SV; Nikulkina, EN; Odintsov, AV; Panevkina, SV; Rozina, TP; Tanaschuk, EL | 1 |
| Hu, K; Huang, Y; Yang, J; Zhang, Z; Zhou, Y | 1 |
| Fujii, T; Kawasoe, K; Nitta, K; Ohta, A | 1 |
| Dang, Z; Jiang, Y; Liu, X; Wang, X; Yan, Z; Yu, L | 1 |
| Hagiwara, S; Ida, H; Komeda, Y; Kudo, M; Minami, Y; Nishida, N; Takita, M; Ueshima, K | 1 |
| Lampertico, P; Wong, GL | 1 |
| Ji, J; Jia, Y; Shen, Y; Xun, P; Zhou, J | 1 |
| Ceriotti, F; Colombo, M; Cortinovis, I; Facchetti, F; Iavarone, M; Lampertico, P; Loglio, A; Lunghi, G; Occhipinti, V; Orenti, A; Rumi, M; Sangiovanni, A; Viganò, M | 1 |
| Choi, J; Lim, YS | 2 |
| Huang, R; Wang, J; Wu, C; Wu, W; Yan, X | 1 |
| Kim, BK | 2 |
| Chen, R; Huang, B; Li, Q; Li, X; Lin, S; Liu, L; Liu, Y; Luo, D; Niu, M; Wang, J; Xu, D | 1 |
| Chen, MB; Ding, YL; Fan, JN; Wang, H; Yue, MX; Zheng, QH; Zheng, XW | 1 |
| Koh, YH; McCartney, E; Morgan, J; Narayana, S; Ong, JHY; Tse, E | 1 |
| Jiang, D; Li, Y; Song, C; Wang, J; Wang, X; Zeng, H; Zhang, Q; Zhao, X | 1 |
| Kimura, A; Mizokami, M; Murata, K; Noguchi, M; Sugiyama, M; Suizu, F; Tsukuda, S; Watashi, K | 1 |
| Choe, WH; Choi, YM; Kim, BJ; Kim, JH; Kim, K; Kwon, SY; Lee, SY | 1 |
| Liaw, YF | 1 |
| Cui, FQ; Hou, JL; Jia, JD; Liu, J; Liu, YY; Liu, ZH; Tao, LB; Xie, L; Yin, XR; Zhuang, GH | 1 |
| Chan, HL; Lui, GC; Tse, YK; Wong, GL; Wong, VW; Yip, TC | 1 |
| Chen, CH; Hu, TH; Hung, CH; Lu, SN; Ma, TL; Wang, JH | 1 |
| Chen, EQ; Liao, J; Tang, H; Tao, YC; Wang, ML; Wang, YH; Wu, DB; Zhang, DM | 2 |
| Chen, CH; Cheung, KS; Eguchi, Y; Enomoto, M; Furusyo, N; Hoang, J; Hsu, YC; Huang, CF; Huang, R; Huang, YT; Jang, TY; Kozuka, R; Kumada, T; Lee, DH; Li, J; Liu, C; Liu, L; Nguyen, MH; Ogawa, E; Peng, CY; Takahashi, H; Tanaka, Y; Toyoda, H; Trinh, H; Tsai, PC; Wong, C; Wong, GL; Wu, C; Xie, Q; Yang, HI; Yasuda, S; Yeh, ML; Yu, ML; Yuen, MF; Zhang, JQ; Zhao, C | 1 |
| Ahn, SH; Ferrari, C; Gish, RG; Given, BD; Hamilton, J; Heo, J; Kim, JH; Klinker, H; Lai, CL; Lik Yuen Chan, H; Locarnini, SA; Manns, M; Petersen, J; Schiefke, I; Schluep, T; Yoon, JH; Yoon, KT; Yuen, MF | 1 |
| Bae, SH; Choi, JY; Han, NI; Jang, JW; Kwon, JH; Lee, HL; Lee, SW; Nam, HC; Nam, SW; Sung, PS; Yoo, SH; Yoon, SK | 1 |
| Agarwal, K; Carey, I; Cloherty, G; Dusheiko, G; Gersch, J; Kuhns, M; Moigboi, C; Wang, B | 1 |
| Liang, B; Zheng, X | 1 |
| Lampertico, P; Papatheodoridis, GV | 2 |
| Gao, J; Yu, Y; Zhang, B; Zhang, J | 1 |
| Chen, MB; Ding, YL; Fan, JN; Niu, JL; Wang, H; Zheng, QH; Zheng, XW | 1 |
| Lee, HW | 1 |
| Imai, Y; Kouyama, JI; Mochida, S; Motoya, D; Naiki, K; Nakao, M; Nakayama, N; Sugawara, K; Tomiya, T; Tsuji, S; Uchida, Y; Uemura, H | 1 |
| Jiang, D; Wang, X; Zeng, H | 1 |
| Li, MJ; Teng, YX; Xiang, BD; Zhong, JH | 1 |
| Arslan, F; Vahaboglu, H | 1 |
| Chan, HL; Hui, VW; Lee, HW; Liang, LY; Lui, GC; Tse, YK; Wong, GL; Wong, VW; Yip, TC | 1 |
| Chan, AC; Cheung, TT; Chok, KS; Dai, WC; Fung, J; Lai, CL; Lo, CM; Ma, KW; Mak, LY; Seto, WK; She, WH; Sin, SL; Wong, TC; Yuen, MF | 1 |
| Li, RH; Yuan, BH; Zhu, YK | 2 |
| Wong, GL; Yip, TC | 3 |
| Choi, J; Han, S; Kim, GA; Lim, YS | 1 |
| Chow, SC; Jia, J; Kong, Y; Li, M; Lv, T; Ma, H; Ou, X; Wei, W; Wu, S; Wu, X; You, H | 1 |
| Hsu, YC; Nguyen, MH | 1 |
| Chung, RT; Holmes, JA | 1 |
| Amano-Teranishi, Y; Enomoto, M; Kawada, N; Kawasaki, Y; Kioka, K; Nakai, T; Suoh, M; Tamori, A | 1 |
| Hayakawa, Y; Higuchi, M; Inada, K; Itakura, J; Izumi, N; Kaneko, S; Kirino, S; Kurosaki, M; Maeyashiki, C; Nakanishi, H; Okada, M; Osawa, L; Sekiguchi, S; Shimizu, T; Takahashi, Y; Takaura, K; Tamaki, N; Tsuchiya, K; Wang, W; Watakabe, K; Yamashita, K; Yasui, Y | 1 |
| Berg, T; Buti, M; Calleja, JL; Chi, H; Dalekos, GN; Esteban, R; Galanis, K; Gatselis, N; Goulis, J; Hansen, BE; Idilman, R; Janssen, HLA; Keskin, O; Kourikou, A; Lampertico, P; Loglio, A; Lopez-Gomez, M; Manolakopoulos, S; Papatheodoridis, GV; Savvidou, S; Sypsa, V; Van Boemmel, F; Veelken, R; Vlachogiannakos, J; Voulgaris, T; Yurdaydin, C | 1 |
| Ahn, SH; Han, KH; Kim, BK; Kim, DY; Kim, MN; Kim, SU; Kweon, YO; Lee, EJ; Lee, HA; Lee, HW; Lee, YR; Park, JY; Park, SY; Seo, YS; Shin, HJ; Tak, WY; Um, SH | 1 |
| Hayakawa, Y; Higuchi, M; Inada, K; Itakura, J; Izumi, N; Kaneko, S; Kirino, S; Kurosaki, M; Maeyashiki, C; Nakanishi, H; Okada, M; Osawa, L; Sekiguchi, S; Takahashi, Y; Takaura, K; Tamaki, N; Tsuchiya, K; Wang, W; Yamashita, K; Yasui, Y | 1 |
| Babudieri, S; Bagella, P; Bandiera, F; Calvisi, DF; Fiore, V; Garrucciu, G; Madeddu, G; Mannu, F; Melis, M; Muredda, AA; Ortu, S; Zaru, S | 1 |
| Yalaki, S; Yalcin, MS | 1 |
| Ahn, SH; Chan, HL; Lee, HW; Lui, GC; Tse, YK; Wong, GL; Wong, VW; Yip, TC | 1 |
| Ahmed, A; Kamal, F; Khan, MA; Nair, S | 1 |
| Arslan, K; Ataman Hatipoğlu, Ç; Çerçioğlu, D; Cesur, S; Gönültaş, M; Kınıklı, S | 1 |
| Chen, F; Fu, X; Gao, X; Lin, Z; Lou, H | 1 |
| Ahn, SB; Cho, YK; Jeong, JY; Jeong, SW; Jun, DW; Kim, HS; Kim, SE; Lee, HY; Oh, H; Shim, JJ; Sohn, JH; Yoon, EL | 1 |
| Chung, JW; Ha, I; Jang, ES; Jeong, SH; Kim, JW | 1 |
| Chen, B; Chen, P; Gu, L; He, Y; Mao, F; Ng, DM; Shen, Z; Yang, T; Yao, Q; Yu, Q | 1 |
| Kim, SU; Lee, HA; Seo, YS | 1 |
| Kamal, F; Khan, MA | 1 |
| Ahn, SH; Baek, YH; Chang, Y; Choe, WH; Jang, JW; Jang, JY; Kim, GA; Kim, HY; Kim, JH; Kim, M; Kim, MA; Kim, SG; Kim, SU; Kim, YJ; Kim, YS; Koh, M; Kwon, JH; Lee, HA; Lee, HW; Lee, JH; Lee, SW; Lee, YS; Lim, YS; Park, Y; Seo, YS; Shim, JJ; Sinn, DH; Yang, H; Yim, HJ; Yoon, JH; Zoulim, F | 1 |
| Bai, X; Chen, X; Fan, R; Hou, J; Niu, J; Peng, J; Ren, H; Sheng, J; Sun, J; Tan, D; Tang, H; Wang, H; Wang, M; Wu, Y; Xie, Q; Xu, M; Zhou, B | 1 |
| Berry, K; Ioannou, GN; Su, F | 1 |
| Adams, LA; Barnard, A; Dave, S; Loomba, R; Murad, MH; Park, S; Prokop, L; Singh, S | 1 |
| Kumada, T; Miyake, N; Tada, T; Tanaka, J; Toyoda, H; Yasuda, S | 1 |
| Joo, DJ; Kim, DG; Kim, MS; Kim, SI; Lee, J; Lee, JG; Lee, JY; Park, JY; Yang, SJ | 1 |
| Azuma, K; Dohmen, K; Furusyo, N; Hayashi, J; Kajiwara, E; Kato, M; Kawano, A; Koyanagi, T; Nakamuta, M; Nomura, H; Ogawa, E; Ooho, A; Satoh, T; Shimoda, S; Takahashi, K | 1 |
| Chang, HY; Kim, S; Lee, HW; Lee, JI; Lee, KS | 1 |
| Choi, J; Jo, C; Lim, YS | 1 |
| Bao, H; Chen, Y; Geng, J; Shi, L; Wang, Q; Yu, H | 1 |
| El-Serag, HB; Hsu, YC; Tseng, CH; Tseng, CM; Wu, JL | 1 |
| Chen, CH; Chiu, SM; Hu, TH; Hung, CH; Kuo, YH; Lu, SN; Wang, JH | 1 |
| Ahn, SH; Cho, YK; Han, KH; Hong, GY; Jang, JY; Jung, YK; Kim, DJ; Kim, HS; Kim, JH; Kim, MY; Kim, W; Kim, YJ; Kweon, YO; Lee, BS; Lee, JW; Lee, KS; Lee, WS; Lim, YS; Park, SJ; Sohn, JH; Um, SH; Yang, JM; Yim, HJ; Yoon, SK | 1 |
| Chen, CH; Hu, TH; Hung, CH; Jeng, WJ; Kuo, YH; Lu, SN; Tseng, TN; Wang, JH | 1 |
| Acar, Ş; Çakmak, E; Eminler, AT; Fidan, S; Hülagü, S; İskender, G; Koksal, AS; Sezikli, M; Şirin, G; Toka, B; Üsküdar, O; Uslan, MI; Yildirim, AE | 1 |
| Ahn, SH; Han, KH; Jeon, MY; Kim, BK; Kim, DY; Kim, SU; Lee, HW; Lee, JS; Park, JY | 1 |
| Chang, KC; Hu, TH; Lin, MT; Tsai, MC; Wu, CK; Yen, YH | 1 |
| Cheong, JY; Chung, WJ; Jang, BK; Jang, JY; Jeong, SW; Kim, IH; Kim, SG; Kim, SS; Kim, SU; Kim, YS; Lee, BS; Lee, CH; Lee, HA; Lee, HW; Lee, JI; Lee, JW; Lim, TS; Park, SY; Rou, WS; Seo, YS; Suh, SJ; Tak, WY; Yim, HJ; Yu, JH | 1 |
| Chen, MB; Cui, WY; Wang, H; Xu, HL; Zheng, QH; Zheng, XW | 1 |
| Chang, WY; Chen, DS; Chen, PJ; Cheng, PN; Chiu, FW; Chiu, YC; Hsu, YC; Kao, JH; Liu, CH; Liu, CJ; Su, TH; Tseng, TC; Yang, HC; Yang, SS | 1 |
| Choi, J; Choi, WM; Lim, YS | 1 |
| Ahn, SH; Bae, SH; Heo, J; Jang, JY; Kim, CW; Kim, DJ; Kim, IH; Park, JY; Tak, WY; Woo, HY | 1 |
| Berg, T; Buti, M; Calleja, JL; Dalekos, GN; Esteban, R; Galanis, K; Gatselis, N; Goulis, J; Hansen, BE; Idilman, R; Janssen, HLA; Kourikou, A; Lampertico, P; Loglio, A; Lopez-Gomez, M; Manolakopoulos, S; Papatheodoridi, M; Papatheodoridis, GV; Savvidou, S; Sypsa, V; Van Boemmel, F; Veelken, R; Vlachogiannakos, J; Yurdaydin, C | 1 |
| Berg, T; Botros, I; Buti, M; Flaherty, JF; Jump, B; Lampertico, P; Op den Brouw, ML; Pathil, A; Petersen, J; Ramroth, H; Ryder, SD; van Troostenburg, A; Zoulim, F | 1 |
| Huang, J; Lin, S; Wang, M; Zhang, K; Zhu, Y | 1 |
| Kim, BK; Kim, SU | 1 |
| Tang, X; Wang, XJ | 1 |
| Cheng, M; Feng, X; Ma, L; Wang, B; Wang, L; Yang, Y | 1 |
| Jang, BK | 1 |
| Borghi, M; Buti, M; di Paolo, D; Esteban, R; Facchetti, F; Lampertico, P; Loglio, A; Lunghi, G; Riveiro-Barciela, M; Roade, L; Soffredini, R; Tabernero, D | 1 |
| Eminler, AT; Koksal, AS; Parlak, E; Toka, B; Tozlu, M; Uslan, MI | 1 |
| Chon, YE; Ha, Y; Hwang, SG; Kim, MN; Lee, JH | 1 |
| Hsu, YC; Nguyen, MH; Tseng, CH | 2 |
| Kim, SU; Lee, SW | 1 |
| Chen, J; Wang, Y; Wu, J | 1 |
| Chen, EQ; Tao, YC | 1 |
| Hall, S; Howell, J; Thompson, A; Visvanathan, K | 1 |
| Con, D; Goodwin, T; Kemp, W; Majeed, A; Roberts, S | 1 |
| Lampertico, P; Papatheodoridis, G; Sypsa, V | 1 |
| Danta, M; Dore, GJ; Matthews, GV | 1 |
| Borghi, JA; Chen, IS; Chen, TH; Cheung, R; Enomoto, M; Hai, H; Hosaka, T; Hsu, YC; Ji, F; Nguyen, MH; Sezaki, H; Thuy, LTT; Tsai, YN; Tseng, CH | 1 |
| Feng, Y; Wen, Z; Yan, X | 1 |
| He, S; Xie, X; Yao, J; Yu, J; Yuan, G | 1 |
| Ahn, SH; Chang, JW; Hwang, SG; Kim, BK; Kim, DY; Kim, MN; Kim, SU; Kweon, YO; Lee, HA; Lee, HW; Lee, JS; Lee, YR; Park, JY; Park, SY; Rim, KS; Seo, YS; Tak, WY; Um, SH | 1 |
| Cheng, HM; Cheung, KS; Lai, CL; Liu, SH; Mak, LY; Seto, WK; Yuen, MF | 1 |
| Chang, KC; Chen, CH; Chien, RN; Hu, TH; Hung, CH; Kee, KM; Lin, MC; Lin, MT; Lu, SN; Tseng, PL; Wang, JH; Yueh-Hsia Chiu, S | 1 |
| Cloherty, G; Fung, J; Gersch, J; Mak, LY; Seto, WK; Wong, DK; Yuen, MF | 1 |
| Liu, Y; Mo, Y; Wu, A | 1 |
| Chang, JW; Kim, SU | 1 |
| Chen, G; Chen, SH; Fu, YM; Ji, D; Li, L; Li, ZB; Liu, Y; Niu, XX; Shao, Q; Wang, CY | 1 |
| Lai, J; Li, J; Li, X; Peng, L; Shu, X; Xie, C; Xie, J; Xu, W; Zhang, Y; Zhu, X | 1 |
| Choi, J; Choi, WM; Han, S; Lim, YS; Wong, GL | 1 |
| Chang, TS; Chen, WM; Hsieh, YY; Hung, CH; Lee, CP; Lu, SN; Shen, CH; Tsai, ML; Tung, SY; Yang, YH; Yen, CW | 1 |
| Pol, S | 1 |
| Ahn, SH; Cho, YK; Han, KH; Hong, GY; Jang, JY; Jung, YK; Kim, DJ; Kim, HS; Kim, JH; Kim, KH; Kim, MY; Kim, W; Kim, YJ; Kweon, YO; Lee, BS; Lee, JW; Lee, KS; Lee, WS; Lim, YS; Park, SJ; Sohn, JH; Song, DS; Um, SH; Yang, JM; Yim, HJ; Yoon, SK | 1 |
| Enomoto, M; Kawada, N; Nishiguchi, S; Tamori, A; Yoshida, K | 1 |
| Carrat, F; Fontaine, H; Luzivika Nzinga, C; Pol, S | 1 |
| Chen, R; Li, J; Li, L; Li, X; Liu, LM; Liu, Y; Shao, J; Xu, D; Zhao, L; Zhou, Y | 1 |
| Boglione, L; Cariti, G; Cusato, J; De Benedetto, I; Di Perri, G; Lupia, T | 1 |
| Adalı, G; Bahadır, Ö; Can, G; Değirmenci Saltürk, AG; Doğanay, HL; Gökçen, P; Güzelbulut, F; Özdil, K | 1 |
| Hao, FB; Peng, Y; Wang, CR; Wang, YQ; Yuan, J; Zhong, GC | 1 |
| Jain, MK; Kshirsagar, O; Niu, B; Thamer, M; Therapondos, G; Wong, RJ | 1 |
| Tseng, TC | 1 |
| Bhan, AK; Chung, RT; Ghany, MG; Hinerman, AS; Jain, MK; Khalili, M; King, WC; Kleiner, DE; Lisker-Melman, M; Sterling, RK; Sulkowski, M; Wahed, AS; Wong, DK | 1 |
| Chan, HL; Hui, VW; Lui, GC; Tse, YK; Wong, GL; Wong, VW; Yip, TC | 1 |
| Ahn, SH; Kim, BK; Kim, DY; Kim, SU; Lee, JH; Park, JY; Park, SY; Sinn, DH; Tak, WY | 1 |
| Carrat, F; Lusivika Nzinga, C; Pol, S | 1 |
| Huang, R; Liu, J; Wang, J; Wu, C | 1 |
| Chen, R; Wang, JG; Wang, LC | 1 |
| Chang, KC; Chien, RN; Chiu, SY; Hu, TH | 1 |
| Choi, H; Seo, GH | 1 |
| Cho, Y; Jeong, S; Kim, W; Park, SM | 1 |
| de Carvalho Santana, R; de Lourdes Candolo Martinelli, A; Dessordi, R; Guimarães, MP; Navarro, AM; Romão, EA; Watanabe, LM | 1 |
| Chang, SH | 1 |
| Accarino, EV; Buti, M; Chen, CH; Cheung, KS; Cheung, R; Chuang, WL; Dai, CY; Enomoto, M; Hoang, J; Hsu, YC; Huang, CF; Huang, JF; Istratescu, D; Kozuka, R; Lee, DH; Liu, L; Nguyen, MH; Peng, CY; Preda, C; Riveiro-Barciela, M; Trinh, H; Tsai, PC; Wong, GL; Wong, VW; Wu, JL; Xie, Q; Yeh, ML; Yeo, YH; Yu, ML; Yuen, MF | 1 |
| Sonneveld, MJ; van Erpecum, KJ | 1 |
| Ahn, SH; Jung, CY; Kim, BS; Kim, HW; Kim, SU | 1 |
| Arai, T; Atsukawa, M; Cheung, R; Chuma, M; Dang, H; Enomoto, M; Fukunishi, S; Hsu, YC; Ishikawa, T; Jun, DW; Kawada, N; Maeda, M; Nguyen, MH; Nozaki, A; Ogawa, E; Takaguchi, K; Takahashi, H; Toyoda, H; Trinh, HN; Tseng, CH; Watanabe, T; Yasuda, S; Yokohama, K | 1 |
| Chen, T; Chen, Y; Fu, M; Fu, S; Gao, Z; He, Y; Hu, C; Li, J; Liu, J; Yan, T; Yang, Y; Zhang, R; Zhao, Y; Zhou, M | 1 |
| Choi, J; Kim, SU; Lee, SW; Lim, YS | 1 |
| Adalı, G; Aslan, E; Can, G; Değirmenci Saltürk, AG; Doğanay, HL; Gökçen, P; Güzelbulut, F; Özdil, K | 1 |
| Chen, CH; Fang, HW; Hu, TH; Hung, CH; Lu, SN; Wang, JH; Yen, YH | 1 |
| Baek, SY; Choi, MS; Gwak, GY; Jang, HJ; Kang, WS; Kim, KA; Kim, YJ; Koh, KC; Lee, JH; Na, JE; Paik, SW; Paik, YH; Sinn, DH; Yoon, JH | 1 |
| Chen, G; Gu, D; Huang, R; Jia, B; Liu, J; Liu, Y; Wang, J; Wu, C; Xiang, X; Yan, X; Yang, Y; Zhang, Z; Zhao, XA | 1 |
| Ahn, SH; Cho, YY; Kim, BK; Kim, DY; Kim, SU; Lee, H; Lee, HW; Lee, JS; Park, JY; Park, SY | 1 |
| Ahn, SH; Chon, YE; Kim, BK; Kim, DY; Kim, MN; Kim, SU; Lee, HA; Lee, HW; Park, JY; Park, SY; Roh, YH; Seo, YS; Tak, WY | 1 |
| Jin, YJ; Lee, JW; Lim, JH; Suh, YJ; Yu, JH | 1 |
| Ahn, SB; Berg, T; Buti, M; Calleja, JL; Cho, YK; Dalekos, GN; Goulis, J; Idilman, R; Jang, ES; Jang, MJ; Janssen, HLA; Jeong, SW; Jun, DW; Jung, YJ; Kim, HS; Kim, HY; Kim, SE; Kim, SU; Kim, YJ; Lampertico, P; Lee, HA; Lee, HC; Lee, JH; Lee, YB; Lim, YS; Manolakopoulos, S; Nam, JY; Papatheodoridis, GV; Park, SY; Seo, YS; Shim, JJ; Sinn, DH; Sohn, JH; Sypsa, V; Yoon, EL; Yoon, JH | 1 |
| Baik, SK; Cho, DH; Choi, J; Gwon, JG; Kang, SH; Kim, MY | 1 |
| Chen, L; Liu, X; Zhao, L | 1 |
| Dai, J; Gao, F; Leng, S; Li, C; Peng, W; Qi, W; Ran, S; Shen, J; Wen, T; Wu, Y; Zhang, X; Zhang, Y | 1 |
| Jeong, S; Kim, HI; Shin, HP | 1 |
| Brakenhoff, SM; Chan, HLY; Chen, CH; Chien, RN; Choi, HSJ; Cornberg, M; Feld, J; Forns, X; Hansen, BE; Hirode, G; Hsu, YC; Janssen, HLA; Jeng, WJ; Kao, JH; Lens, S; Papatheodoridi, M; Papatheodoridis, GV; Seto, WK; Sonneveld, MJ; Su, TH; Van Hees, S; Vanwolleghem, T; Wong, G; Yuen, MF | 1 |
| Ahn, SH; Chon, HY; Kim, SU; Kim, YJ; Lee, JH; Sinn, DH; Yoon, JH | 1 |
| Ahn, SB; Chen, CH; Cheung, R; Cho, YK; Chuang, WL; Dai, CY; Dao, A; Enomoto, M; Hoang, J; Huang, CF; Huang, DQ; Huang, JF; Huang, R; Hui, RW; Jeong, JY; Jeong, SW; Jun, DW; Khine, HHTW; Kim, HS; Kim, SE; Kozuka, R; Lee, DH; Lim, SG; Liu, L; Mak, LY; Nguyen, MH; Ogawa, E; Oh, H; Peng, CY; Quek, S; Shim, JJ; Trinh, H; Trinh, L; Tsai, PC; Tsui, V; Wong, GLH; Wu, C; Xie, Q; Yeh, ML; Yoon, E; Yu, ML; Yuen, MF | 1 |
| Chen, CH; Hu, TH; Hung, CH; Kuo, YH; Lu, SN; Peng, CY; Wang, JH | 1 |
| Chien, RN; Jeng, WJ; Liaw, YF; Liu, YC; Peng, CW | 1 |
| Dai, J; Jiang, K; Leng, S; Li, C; Qi, W; Ran, S; Shen, J; Wen, T; Zhang, Y | 1 |
| Çalhan, T; Doğanay, L; Kahraman, R; Kanat, E; Özdil, K; Öztürk, O; Şahin, A; Sayar, S | 1 |
| Ito, T; Kumada, T; Tanaka, J; Toyoda, H; Yasuda, S | 1 |
| Huo, RR; Li, MJ; Li, RH; Papatheodoridis, G; Yuan, BH; Zhong, JH | 1 |
| Chokkalingam, AP; Flaherty, J; Gaggar, A; Gordon, SC; Jump, B; Kim, WR; Lu, M; Ramroth, H; Telep, LE | 1 |
| Chen, MS; Fu, YZ; Hou, JY; Hu, ZL; Li, WX; Wang, XH; Xu, L; Zhang, YJ; Zhou, QF; Zhou, ZG | 1 |
| Imai, Y; Kouyama, JI; Mochida, S; Naiki, K; Nakao, M; Nakayama, N; Sugawara, K; Tomiya, T; Tsuji, S; Uchida, Y; Uemura, H; Yamada, S | 1 |
| Chien, RN; Liaw, YF | 1 |
| Huang, SJ; Huang, Y; Huang, ZH; Liu, XH; Lu, GY; Qiu, LX; Su, YY; Wang, YB; Wu, T; Xia, NS; Yao, XM; Yuan, Q; Zhang, J; Zhong, GH | 1 |
| Chen, M; Hou, J; Hu, Z; Wang, J; Xu, L; Zeng, H; Zhang, Y; Zhou, Z | 1 |
| Cho, JY; Choi, D; Choi, DL; Hong, G; Hwang, S; Kang, KJ; Kim, BW; Kim, DS; Kim, JM; Kim, MS; Lee, J; Lee, JG; Lee, KW; Moon, JI; Nah, YW; Ryu, JH; You, YK; Yu, HC | 1 |
| Chen, LW; Chien, CH; Chien, RN; Hu, CC; Huang, TS; Liang, KH; Lin, CL; Lin, YL; Shyu, YC; Yeh, CT | 1 |
| Chokkalingam, AP; Kim, WR; Telep, LE | 1 |
| Tonthat, AV; Zhou, K | 1 |
| Chang, ML; Cheng, JS; Chien, RN; Lee, KC; Liaw, YF | 1 |
| Chen, CH; Hu, TH; Hung, CH; Kuo, YH; Lu, SN; Tseng, TN; Wang, JH | 1 |
| Fung, J; Huang, DQ; Kim, BK; Lim, GEH; Lim, KE; Lim, WH; Loomba, R; Muthiah, MD; Ng, CH; Nguyen, MH; Syn, N; Tamaki, N; Tan, DJH; Tang, ASP; Tay, PWL; Teng, MLP | 1 |
| Fan, R; Jiang, Y; Liang, J; Liao, X; Wu, L; Yin, J; Yu, N; Zhang, Q; Zhao, S | 1 |
| Ahn, SH; Kim, BK; Oh, J; Yoon, JH; Yun, B | 1 |
| Atalay, R; Ayrancı, FG; Çakmak, Ş; Doğanay, L; Özdil, K; Sayar, S; Tanboğa, İH | 1 |
| Ahn, SH; Jung, CY; Kim, BS; Kim, HW; Kim, SU; Lee, HW; Lee, JI | 1 |
| Akahane, T; Inoue, J; Iwata, T; Kisara, N; Kobayashi, T; Masamune, A; Ninomiya, M; Onuki, M; Sano, A; Sato, K; Sato, S; Tsuruoka, M | 1 |
| Xu, D; Yu, J | 1 |
120 review(s) available for tenofovir and guanine
| Article | Year |
|---|---|
Doctor to patient transmission of hepatitis B virus: implications of HBV DNA levels and potential new solutions.
Topics: Adenine; Antiviral Agents; DNA, Viral; Guanine; Hepatitis B; Hepatitis B e Antigens; Hepatitis B virus; Humans; Infectious Disease Transmission, Professional-to-Patient; Interferon-alpha; Lamivudine; Organophosphonates; Organophosphorus Compounds; Physicians; Risk Factors; Risk Management; Tenofovir; Viral Load | 2003 |
Editorial comment: HIV and HBV coinfection--a coming-of-age in treatment strategies.
Topics: Adenine; Antiviral Agents; Comorbidity; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Guanine; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2004 |
[New approaches in the treatment of hepatitis B].
Topics: 2-Aminopurine; Adenine; Antiviral Agents; Arabinofuranosyluracil; Carcinoma, Hepatocellular; Contraindications; Deoxycytidine; Emtricitabine; Famciclovir; Guanine; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Neoplasms; Organophosphonates; Organophosphorus Compounds; Polyethylene Glycols; Prodrugs; Prognosis; Recombinant Proteins; Tenofovir; Zalcitabine | 2004 |
New treatment of chronic hepatitis B.
Topics: Adenine; Animals; Antiviral Agents; Arabinofuranosyluracil; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Organophosphonates; Organophosphorus Compounds; Pyrimidinones; Telbivudine; Tenofovir; Thymidine; Treatment Outcome | 2004 |
Drugs in development for hepatitis B.
Topics: Adenine; Antiviral Agents; Arabinofuranosyluracil; Deoxycytidine; Emtricitabine; Guanine; Hepatitis B; Humans; Interferon alpha-2; Interferon-alpha; Nucleosides; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Tenofovir | 2005 |
[Liver transplantation for complications of hepatitis B].
Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Drug Resistance, Viral; Drug Therapy, Combination; Follow-Up Studies; Guanine; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunoglobulins; Lamivudine; Liver Cirrhosis; Liver Transplantation; Mutation; Organophosphonates; Recurrence; Reverse Transcriptase Inhibitors; Tenofovir; Time Factors; Vaccination; Viral Load; Virus Replication | 2006 |
Personal view: the management of chronic hepatitis B infection.
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Organophosphonates; Tenofovir | 2006 |
Prevention and treatment of recurrent Hepatitis B after liver transplantation: the current role of nucleoside and nucleotide analogues.
Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Guanine; Hepatitis B; Humans; Immunoglobulins; Lamivudine; Liver Transplantation; Nucleosides; Nucleotides; Organophosphonates; Recurrence; Tenofovir | 2006 |
Antiretroviral therapy for hepatitis B virus-HIV-coinfected patients: promises and pitfalls.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Antiviral Agents; Deoxycytidine; Drug Combinations; Emtricitabine; Guanine; Hepatitis B; Hepatitis B virus; HIV Infections; HIV-1; Humans; Lamivudine; Organophosphonates; Preventive Medicine; Tenofovir | 2006 |
[Treating chronic lamivudine-resistant hepatitis B in HIV co-infected patients].
Topics: Adenine; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2006 |
Treatment of chronic hepatitis B in HIV-infected patients in 2007.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; HIV Infections; Humans; Interferon-alpha; Lamivudine; Nucleosides; Organophosphonates; Pyrimidinones; Telbivudine; Tenofovir; Thymidine | 2007 |
Review article: current antiviral therapy of chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Cirrhosis; Nucleosides; Organophosphonates; Polyethylene Glycols; Pyrimidinones; Recombinant Proteins; Reverse Transcriptase Inhibitors; Telbivudine; Tenofovir; Thymidine; Virus Replication | 2008 |
Treatment of chronic hepatitis B infection: an update of Swedish recommendations.
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Guanine; Hepatitis B, Chronic; HIV Infections; Humans; Immunocompromised Host; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Cirrhosis; Liver Transplantation; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Sweden; Tenofovir | 2008 |
Hepatitis B and liver transplantation: 2008 update.
Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Guanine; Hepatitis B; Hepatitis B Vaccines; Humans; Immunoglobulins; Lamivudine; Liver Transplantation; Nucleosides; Organophosphonates; Pyrimidinones; Telbivudine; Tenofovir; Thymidine | 2009 |
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update.
Topics: Adenine; Antiviral Agents; Case Management; DNA, Viral; Guanine; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Tenofovir; Treatment Outcome; United States | 2008 |
[Nucleoside and nucleotide analogs in the treatment of chronic hepatitis B].
Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Genotype; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Multicenter Studies as Topic; Nucleosides; Organophosphonates; Pyrimidinones; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Telbivudine; Tenofovir; Thymidine; Treatment Outcome; Virus Replication | 2008 |
[Resistance in hepatitis B virus].
Topics: Adenine; Antiviral Agents; Drug Resistance, Multiple, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Gene Products, pol; Genotype; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Models, Molecular; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Virus Replication | 2008 |
[Clinical management of patients with chronic hepatitis B virus infection].
Topics: Adenine; Antiviral Agents; Biopsy; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; Genotype; Guanine; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Liver; Liver Transplantation; Male; Nucleosides; Organophosphonates; Pyrimidinones; Reverse Transcriptase Inhibitors; Telbivudine; Tenofovir; Thymidine; Virus Replication | 2008 |
[Hepatitis B in patients with HIV infection].
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Comorbidity; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Guanine; Hepatitis B; Hepatitis B Vaccines; Hepatitis B virus; HIV; HIV Infections; Humans; Interferon-alpha; Lamivudine; Nucleosides; Organophosphonates; Practice Guidelines as Topic; Pyrimidinones; Reverse Transcriptase Inhibitors; Telbivudine; Tenofovir; Thymidine; Virus Replication | 2008 |
Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues.
Topics: Adenine; Antiviral Agents; DNA, Viral; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Nucleosides; Organophosphonates; Polyethylene Glycols; Practice Guidelines as Topic; Pyrimidinones; Randomized Controlled Trials as Topic; Recombinant Proteins; Telbivudine; Tenofovir; Thymidine; Treatment Outcome | 2008 |
HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Organophosphonates; Pyrimidinones; Telbivudine; Tenofovir; Thymidine; Virus Replication | 2009 |
Post-liver transplant hepatitis B prophylaxis: the role of oral nucleos(t)ide analogues.
Topics: Adenine; Administration, Oral; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Graft Survival; Guanine; Hepatitis B; Humans; Immunoglobulins; Injections, Intramuscular; Lamivudine; Liver Transplantation; Nucleosides; Nucleotides; Organophosphonates; Secondary Prevention; Tenofovir; Treatment Outcome | 2009 |
[Chronic hepatitis B: current therapy].
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Guanine; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Humans; Immunotherapy, Active; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Neoplasms; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Tenofovir; Treatment Outcome | 2008 |
Avoiding and managing lamivudine resistance in chronic hepatitis B: current approaches and potential strategies including pegylated interferon.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Tenofovir | 2010 |
Effect of newer oral antiviral agents on future therapy of chronic hepatitis B.
Topics: Adenine; Administration, Oral; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Hepatitis B, Chronic; Humans; Nucleosides; Organophosphonates; Pyrimidinones; Telbivudine; Tenofovir; Thymidine; Treatment Outcome | 2010 |
Current therapeutic strategies for recurrent hepatitis B virus infection after liver transplantation.
Topics: Adenine; Antiviral Agents; Asia; Guanine; Hepatitis B; Hepatitis B virus; Humans; Interferons; Lamivudine; Liver Transplantation; Organophosphonates; Recurrence; Reverse Transcriptase Inhibitors; Tenofovir | 2010 |
On-treatment monitoring of chronic hepatitis B virus infection: an Asian-Pacific perspective.
Topics: Adenine; Antiviral Agents; Asia; Biomarkers; DNA, Viral; Drug Monitoring; Drug Resistance, Viral; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Organophosphonates; Pyrimidinones; Telbivudine; Tenofovir; Thymidine; Time Factors; Treatment Outcome; Viral Load; Virus Replication | 2010 |
Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses.
Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Tenofovir | 2010 |
Mixed treatment comparison meta-analysis evaluating the relative efficacy of nucleos(t)ides for treatment of nucleos(t)ide-naive patients with chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Nucleotides; Organophosphonates; Tenofovir; Treatment Outcome; Viral Load | 2010 |
Review article: chronic hepatitis B - anti-viral or immunomodulatory therapy?
Topics: Adenine; Antiviral Agents; Decision Making; Guanine; Hepatitis B, Chronic; Humans; Immunomodulation; Interferon alpha-2; Interferon-alpha; Nucleosides; Organophosphonates; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Tenofovir; Treatment Outcome | 2011 |
Chronic hepatitis B: peginterferon or nucleos(t)ide analogues?
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Tenofovir; Treatment Outcome | 2011 |
Treatment of HBeAg-positive chronic hepatitis B with nucleos(t)ide analogues.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Organophosphonates; Pyrimidinones; Telbivudine; Tenofovir; Thymidine; Treatment Outcome | 2011 |
Hepatitis B virus resistance to antiviral drugs: where are we going?
Topics: Adenine; Antiviral Agents; Capsid; Clinical Protocols; Drug Resistance, Viral; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Organophosphonates; Pyrimidinones; Telbivudine; Tenofovir; Thymidine; Virus Internalization; Virus Replication | 2011 |
The impact of human immunodeficiency virus on viral hepatitis.
Topics: Adenine; Antiviral Agents; Deoxycytidine; Disease Progression; Drug Therapy, Combination; Emtricitabine; Guanine; Hepatitis B; Hepatitis C; Hepatitis Viruses; HIV Infections; Humans; Interferon-alpha; Lamivudine; Nucleosides; Organophosphonates; Pyrimidinones; Telbivudine; Tenofovir; Thymidine | 2011 |
Novel nephrotoxins.
Topics: Adenine; Alcohols; Angiogenesis Inhibitors; Anticonvulsants; Antipsychotic Agents; Dasatinib; Diphosphonates; Glutamates; Guanine; HIV Protease Inhibitors; Humans; Indoles; Kidney Diseases; Organophosphonates; Oxalates; Pamidronate; Pemetrexed; Phenindione; Plants, Toxic; Proton Pump Inhibitors; Pyrimidines; Pyrroles; Selective Serotonin Reuptake Inhibitors; Sunitinib; Tenofovir; Thiazoles; Triazines | 2011 |
[Interferon-based versus direct antiviral therapy in patients with chronic hepatitis B].
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Nucleosides; Nucleotides; Organophosphonates; Polyethylene Glycols; Pyrimidinones; Recombinant Proteins; Telbivudine; Tenofovir; Thymidine; Treatment Outcome | 2011 |
Antiviral therapy for hepatitis B infection during pregnancy and breastfeeding.
Topics: Adenine; Antiviral Agents; Breast Feeding; Female; Guanine; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Nucleosides; Organophosphonates; Placenta; Pregnancy; Pregnancy Complications, Infectious; Pyrimidinones; Telbivudine; Tenofovir; Thymidine | 2011 |
Management of severe acute to fulminant hepatitis B: to treat or not to treat or when to treat?
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B; Humans; Interferons; Lamivudine; Liver Failure, Acute; Organophosphonates; Tenofovir | 2012 |
[Pharmacological treatment of acute hepatitis B].
Topics: Acute Disease; Adenine; Antiviral Agents; Guanine; Hepatitis B; Humans; Lamivudine; Nucleosides; Organophosphonates; Practice Guidelines as Topic; Pyrimidinones; Spain; Telbivudine; Tenofovir; Thymidine; Treatment Outcome | 2012 |
Quantification of serum hepatitis B surface antigen: is it useful for the management of chronic hepatitis B?
Topics: Adenine; Antiviral Agents; Biomarkers; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Tenofovir; Viral Load | 2012 |
Emerging pipeline drugs for hepatitis B infection.
Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Drug Design; Drugs, Investigational; Guanine; Hepatitis B Antigens; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Humans; Organophosphonates; Tenofovir; Treatment Outcome; Virus Replication | 2011 |
Meta-analysis: oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis.
Topics: Adenine; Administration, Oral; Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Nucleosides; Organophosphonates; Pyrimidinones; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Telbivudine; Tenofovir; Thymidine; Time Factors; Treatment Outcome; Viral Load | 2012 |
New advances in chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Coinfection; Disease Progression; Drug Resistance, Viral; Female; Guanine; Guidelines as Topic; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis D; HIV Infections; Humans; Interferons; Liver Cirrhosis; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Risk Factors; Tenofovir | 2012 |
New perspectives in the therapy of chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Drug Monitoring; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferons; Interleukins; Organophosphonates; Polymorphism, Genetic; Prognosis; Tenofovir | 2012 |
First-line treatment of chronic hepatitis B with entecavir or tenofovir in 'real-life' settings: from clinical trials to clinical practice.
Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Guanine; Hepatitis B, Chronic; Humans; Nucleosides; Nucleotides; Organophosphonates; Tenofovir; Treatment Outcome; Viral Load | 2012 |
High genetic barrier nucleos(t)ide analogue(s) for prophylaxis from hepatitis B virus recurrence after liver transplantation: a systematic review.
Topics: Adenine; Antiviral Agents; DNA, Viral; Guanine; Hepatitis B; Hepatitis B virus; Humans; Immunoglobulins; Liver Failure; Liver Transplantation; Nucleotides; Organophosphonates; Recurrence; Tenofovir; Time Factors; Treatment Outcome | 2013 |
Long-term therapy with nucleoside/nucleotide analogues for chronic hepatitis B in Asian patients.
Topics: Adenine; Antiviral Agents; Asian People; Carcinoma, Hepatocellular; Disease Progression; Drug Resistance, Viral; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Organophosphonates; Tenofovir; Treatment Outcome | 2013 |
Considerations for the long-term treatment of chronic hepatitis B with nucleos(t)ide analogs.
Topics: Adenine; Age Factors; Antiviral Agents; Comorbidity; DNA, Viral; Drug Resistance, Viral; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Life Style; Organophosphonates; Severity of Illness Index; Telbivudine; Tenofovir; Thymidine; Time Factors | 2012 |
Diagnostic and therapeutic progress of multi-drug resistance with anti-HBV nucleos(t)ide analogues.
Topics: Adenine; Antiviral Agents; Drug Resistance, Multiple; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferons; Lamivudine; Liver Transplantation; Mutation; Nucleosides; Nucleotides; Organophosphonates; Prognosis; Tenofovir; Viral Load | 2012 |
Cost effectiveness of first-line oral antiviral therapies for chronic hepatitis B : a systematic review.
Topics: Adenine; Antiviral Agents; Cost-Benefit Analysis; Guanine; Health Care Costs; Hepatitis B, Chronic; Humans; Models, Economic; Organophosphonates; Reproducibility of Results; Tenofovir | 2013 |
Letter: First-line monotherapies for chronic hepatitis B - indirect comparison between entecavir and tenofovir.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2013 |
Update in the management of chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Drug Monitoring; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Interferon Type I; Organophosphonates; Practice Guidelines as Topic; Tenofovir | 2013 |
Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B.
Topics: Adenine; Administration, Oral; Age Factors; Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Organophosphonates; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Telbivudine; Tenofovir; Thymidine; Treatment Outcome | 2013 |
Viral hepatitis and HIV: update and management.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Antiviral Agents; Coinfection; Drug Therapy, Combination; Guanine; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Organophosphonates; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; Tenofovir | 2013 |
[Interdisciplinary aspects of and new drugs for chronic hepatitis B].
Topics: Adenine; Antiviral Agents; Comorbidity; Drug Interactions; Drug Therapy, Combination; Female; Gastroenterology; Guanine; Hematology; Hepatitis B, Chronic; Humans; Hungary; Infant, Newborn; Infant, Newborn, Diseases; Infectious Disease Transmission, Vertical; Interdisciplinary Communication; Interferons; Lamivudine; Medical Oncology; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Rheumatology; Tenofovir | 2013 |
Long-term results of treatment with nucleoside and nucleotide analogues (entecavir and tenofovir) for chronic hepatitis B.
Topics: Adenine; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Organophosphonates; Tenofovir; Treatment Outcome; Virus Replication | 2013 |
[Reactivation of chronic hepatitis B].
Topics: Adenine; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antiviral Agents; Biomarkers; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunocompromised Host; Immunosuppressive Agents; Inflammation; Lamivudine; Organophosphonates; Rituximab; Tenofovir; Virus Activation | 2013 |
Review article: nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Organophosphonates; Renal Insufficiency, Chronic; Telbivudine; Tenofovir; Thymidine | 2014 |
Regression of fibrosis after HBV antiviral therapy. Is cirrhosis reversible?
Topics: Adenine; Administration, Oral; Antiviral Agents; Carcinoma, Hepatocellular; Fibrosis; Guanine; Hepatitis B; Hepatitis B virus; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Nucleosides; Organophosphonates; Telbivudine; Tenofovir; Thymidine | 2014 |
HBeAg-positive chronic hepatitis B: why do i treat my patients with Nucleos(t)ide analogs?
Topics: Adenine; Age Factors; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Nucleosides; Organophosphonates; Polyethylene Glycols; Precision Medicine; Recombinant Proteins; Sex Factors; Telbivudine; Tenofovir; Thymidine; Treatment Outcome | 2014 |
HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues?
Topics: Adenine; Age Factors; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Nucleosides; Organophosphonates; Polyethylene Glycols; Precision Medicine; Recombinant Proteins; Sex Factors; Tenofovir; Treatment Outcome | 2014 |
Impact of HBV therapy on the incidence of hepatocellular carcinoma.
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Nucleosides; Organophosphonates; Tenofovir | 2014 |
New therapeutic perspectives in HBV: when to stop NAs.
Topics: Adenine; Algorithms; Antiviral Agents; Biomarkers; DNA, Viral; Drug Therapy, Combination; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Nucleosides; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Telbivudine; Tenofovir; Thymidine | 2014 |
An update on hepatitis B, D, and E viruses.
Topics: Adenine; Drug Therapy, Combination; Guanine; Hepatitis B, Chronic; Hepatitis D, Chronic; Hepatitis E; Humans; Interferon-alpha; Liver Cirrhosis; Liver Failure; Organophosphonates; Tenofovir; Treatment Outcome | 2014 |
Managing hepatitis B to prevent liver cancer: recent advances.
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2014 |
Advances in the treatment of hepatitis B virus/hepatitis C virus coinfection.
Topics: Adenine; Antiviral Agents; Coinfection; DNA, Viral; Drug Therapy, Combination; Guanine; Hepacivirus; Hepatitis B; Hepatitis B virus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Organophosphonates; Ribavirin; RNA, Viral; Tenofovir; Virus Replication | 2014 |
Management of chronic hepatitis B in children: an unresolved issue.
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Carrier State; Child; Databases, Bibliographic; Guanine; Hepatitis B, Chronic; Humans; Immune Tolerance; Incidence; Interferons; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Nucleosides; Organophosphonates; Risk; Tenofovir | 2014 |
Management of chronic hepatitis B infection: current treatment guidelines, challenges, and new developments.
Topics: Adenine; Antiviral Agents; Disease Management; DNA, Viral; Drug Delivery Systems; Drug Resistance, Viral; Genotype; Guanine; Hepatitis B, Chronic; Humans; Interferons; Organophosphonates; Polyethylene Glycols; Practice Guidelines as Topic; Tenofovir; Viral Load | 2014 |
Comparison of efficacy and safety of tenofovir and entecavir in chronic hepatitis B virus infection: a systematic review and meta-analysis.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Safety; Tenofovir | 2014 |
Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapy.
Topics: Adenine; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Monoclonal, Murine-Derived; Antiviral Agents; Arthritis, Rheumatoid; Autoimmune Diseases; Carrier State; Disease Management; DNA, Viral; Guanine; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Organophosphonates; Rituximab; Tenofovir; Virus Activation | 2014 |
Molecular diagnosis and treatment of drug-resistant hepatitis B virus.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Molecular Diagnostic Techniques; Mutation; Nucleic Acid Hybridization; Organophosphonates; Phenotype; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; RNA-Directed DNA Polymerase; Sequence Analysis, DNA; Tenofovir; Treatment Outcome | 2014 |
Treatment of chronic hepatitis B in clinical practice with entecavir or tenofovir.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Organophosphonates; Tenofovir; Treatment Outcome | 2014 |
Prevention of hepatitis B virus reinfection in liver transplant recipients.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B; Hepatitis B virus; Humans; Immunoglobulins; Liver; Liver Cirrhosis; Liver Transplantation; Organophosphonates; Recurrence; Reverse Transcriptase Inhibitors; Tenofovir; Transplant Recipients; Virus Replication | 2014 |
A meta-analysis comparing the efficacy of entecavir and tenofovir for the treatment of chronic hepatitis B infection.
Topics: Antiviral Agents; Chi-Square Distribution; Clinical Trials as Topic; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Odds Ratio; Patient Selection; Risk Factors; Tenofovir; Treatment Outcome; Viral Load | 2015 |
Optimal therapy of chronic hepatitis B: how do I treat HBeAg-positive patients?
Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon-alpha; Long-Term Care; Organophosphonates; Tenofovir; Treatment Outcome | 2015 |
Optimal therapy of chronic hepatitis B: how do I treat my HBeAg-negative patients?
Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon-alpha; Long-Term Care; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Tenofovir; Treatment Outcome; Virus Replication | 2015 |
Hepatitis B virus mutation may play a role in hepatocellular carcinoma recurrence: A systematic review and meta-regression analysis.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Databases, Bibliographic; Female; Guanine; Hepatitis B; Hepatitis B virus; Humans; Liver Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Prognosis; Regression Analysis; Tenofovir | 2015 |
Antiviral therapies and prospects for a cure of chronic hepatitis B.
Topics: Animals; Antiviral Agents; Disease Management; Disease Models, Animal; Drug Therapy, Combination; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Mice; Randomized Controlled Trials as Topic; Tenofovir; Treatment Outcome | 2015 |
The Woodchuck, a Nonprimate Model for Immunopathogenesis and Therapeutic Immunomodulation in Chronic Hepatitis B Virus Infection.
Topics: Animals; Antiviral Agents; Disease Models, Animal; Guanine; Hepatitis B Virus, Woodchuck; Hepatitis B, Chronic; Humans; Immunization Schedule; Marmota; T-Lymphocytes; Tenofovir; Vaccines, DNA; Virus Replication | 2015 |
Review article: long-term safety of nucleoside and nucleotide analogues in HBV-monoinfected patients.
Topics: Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Nucleosides; Nucleotides; Tenofovir; Treatment Outcome | 2016 |
Chronic hepatitis B in children: Therapeutic challenges and perspectives.
Topics: Adenine; Alanine Transaminase; Antigens, Viral; Antiviral Agents; Child; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immune Tolerance; Interferon-alpha; Lamivudine; Molecular Targeted Therapy; Organophosphonates; Practice Guidelines as Topic; Seroconversion; Telbivudine; Tenofovir; Thymidine; Viral Envelope Proteins | 2017 |
[Management and treatment of patients with hepatitis B].
Topics: Antiviral Agents; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Polyethylene Glycols; Recombinant Proteins; Tenofovir | 2016 |
The efficacy and safety comparison between tenofovir and entecavir in treatment of chronic hepatitis B and HBV related cirrhosis: A systematic review and Meta-analysis.
Topics: Acute Kidney Injury; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Hypophosphatemia; Liver Cirrhosis; Tenofovir; Treatment Outcome; Viral Load | 2017 |
Hepatitis B virus long-term impact of antiviral therapy nucleot(s)ide analogues (NUCs).
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Safety; Sustained Virologic Response; Tenofovir | 2017 |
Treatment of chronic hepatitis B infection-2017.
Topics: Antiviral Agents; Biomarkers; Clinical Trials as Topic; Drug Design; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunosuppressive Agents; Interferon-alpha; Tenofovir | 2017 |
Antiviral therapies for managing viral hepatitis in lymphoma patients.
Topics: Antiviral Agents; Guanine; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis C; Humans; Lamivudine; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Rituximab; Tenofovir; Virus Activation | 2017 |
Management of Antiviral Resistance in Chronic Hepatitis B.
Topics: Adenine; Antiviral Agents; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Tenofovir | 2017 |
Nucleos(t)ide analogues for preventing HBV reactivation in immunosuppressed patients with hematological malignancies: a network meta-analysis.
Topics: Adenine; Antiviral Agents; Controlled Clinical Trials as Topic; Guanine; Hematologic Neoplasms; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunocompromised Host; Lamivudine; Organophosphonates; Survival Analysis; Telbivudine; Tenofovir; Thymidine; Treatment Outcome; Virus Activation | 2017 |
Efficacy of Nucleot(s)ide Analogs Therapy in Patients with Unresectable HBV-Related Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
Topics: Adenine; Antiviral Agents; Arabinofuranosyluracil; Carcinoma, Hepatocellular; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Neoplasms; Organophosphonates; Retrospective Studies; Survival Analysis; Telbivudine; Tenofovir; Thymidine | 2017 |
Comparison of the Efficacy of Tenofovir Versus Tenofovir plus Entecavir in the Treatment of Chronic Hepatitis B in Patients With Poor Efficacy of Entecavir: A Systematic Review and Meta-analysis.
Topics: Antiviral Agents; Drug Therapy, Combination; Guanine; Hepatitis B, Chronic; Humans; Tenofovir; Treatment Outcome | 2017 |
An update on the treatment options for HBV/HCV coinfection.
Topics: Anti-HIV Agents; Antiviral Agents; Coinfection; Guanine; Hepatitis C; HIV Infections; Humans; Tenofovir | 2017 |
Why not to stop antiviral treatment in patients with chronic hepatitis B.
Topics: Alanine Transaminase; Antiviral Agents; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Recurrence; Tenofovir; Treatment Outcome | 2018 |
Long-term safety and efficacy of nucleo(t)side analogue therapy in hepatitis B.
Topics: Adenine; Administration, Oral; Alanine; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Guanine; Hepatitis B, Chronic; Humans; Nucleosides; Randomized Controlled Trials as Topic; Tenofovir; Time Factors; Treatment Outcome | 2018 |
Hepatitis B reactivation in patients receiving direct-acting antiviral therapy or interferon-based therapy for hepatitis C: A systematic review and meta-analysis.
Topics: Antibiotic Prophylaxis; Antiviral Agents; Coinfection; Disease Progression; Guanine; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis C; Humans; Incidence; Interferons; Recurrence; Tenofovir; Treatment Outcome; Virus Activation | 2018 |
Okuda lecture: Challenges of hepatitis B in the era of antiviral therapy.
Topics: Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; Guanine; Hepatitis B; Hepatitis B e Antigens; Humans; Immune Tolerance; Liver Neoplasms; Nucleotides; Tenofovir; Withholding Treatment | 2019 |
The effectiveness of TDF versus ETV on incidence of HCC in CHB patients: a meta analysis.
Topics: Adult; Carcinoma, Hepatocellular; Controlled Clinical Trials as Topic; Female; Guanine; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Male; Middle Aged; Prospective Studies; Retrospective Studies; Tenofovir | 2019 |
Nucleos(t)ide Analogues for Reducing Hepatocellular Carcinoma in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Male; Middle Aged; Nucleotides; Randomized Controlled Trials as Topic; Tenofovir; Treatment Outcome | 2020 |
Bayesian Network Meta-Analysis for Assessing Adverse Effects of Anti-hepatitis B Drugs.
Topics: Adenine; Antiviral Agents; Bayes Theorem; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Network Meta-Analysis; Organophosphonates; Prospective Studies; Telbivudine; Tenofovir | 2019 |
Finite nucleos(t)ide analog therapy in HBeAg-negative chronic hepatitis B: an emerging paradigm shift.
Topics: Antiviral Agents; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Nucleosides; Nucleotides; Tenofovir; Treatment Outcome | 2019 |
Comparative efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naive chronic hepatitis B: A systematic review and meta-analysis.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Randomized Controlled Trials as Topic; Tenofovir; Treatment Outcome | 2019 |
[Long Term Efficacy of Antiviral Therapy: Mortality and Incidence of Hepatocellular Carcinoma].
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Proportional Hazards Models; Tenofovir; Treatment Outcome | 2019 |
Tenofovir versus entecavir in lowering the risk of hepatocellular carcinoma development in patients with chronic hepatitis B: a critical systematic review and meta-analysis.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Tenofovir | 2020 |
New approaches in viraemic organ transplantation and antiviral therapies.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Cyclopropanes; Guanine; Hepatitis B, Chronic; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Liver Neoplasms; Liver Transplantation; Macrocyclic Compounds; Proline; Quinoxalines; Salvage Therapy; Sofosbuvir; Sulfonamides; Tenofovir; Transplants | 2020 |
Comparison of tenofovir versus entecavir on reducing incidence of hepatocellular carcinoma in chronic hepatitis B patients: A systematic review and meta-analysis.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Tenofovir | 2020 |
Comparative Effectiveness of Entecavir Versus Tenofovir for Preventing Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: A Systematic Review and Meta-Analysis.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Incidence; Liver Cirrhosis; Liver Neoplasms; Observational Studies as Topic; Randomized Controlled Trials as Topic; Risk; Tenofovir | 2021 |
Nucleos(t)ide analogues for the treatment of chronic hepatitis B: a systematic review with network meta-analysis.
Topics: Adult; Antiviral Agents; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Network Meta-Analysis; Randomized Controlled Trials as Topic; Telbivudine; Tenofovir; Treatment Outcome | 2020 |
Magnitude of and prediction for risk of hepatocellular carcinoma in patients with chronic hepatitis B taking entecavir or tenofovir therapy: A systematic review.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Comorbidity; Female; Forecasting; Guanine; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Male; Middle Aged; Risk; Tenofovir | 2020 |
Effects of Tenofovir vs Entecavir on Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection: A Systematic Review and Meta-analysis.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Tenofovir; Treatment Outcome | 2021 |
The Yin and the Yang of Treatment for Chronic Hepatitis B-When to Start, When to Stop Nucleos(t)ide Analogue Therapy.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Duration of Therapy; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Public Health Practice; Tenofovir; Treatment Outcome; Viral Load; Withholding Treatment | 2020 |
Comparison of 48-week efficacy of tenofovir vs entecavir for patients with chronic hepatitis B: A network meta-analysis.
Topics: Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Network Meta-Analysis; Tenofovir | 2021 |
Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Tenofovir | 2020 |
Entecavir vs Tenofovir in Hepatocellular Carcinoma Prevention in Chronic Hepatitis B Infection: A Systematic Review and Meta-Analysis.
Topics: Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Observational Studies as Topic; Risk Assessment; Tenofovir; Treatment Outcome | 2020 |
Combination of Entecavir or Tenofovir with Pegylated Interferon-α for Long-Term Reduction in Hepatitis B Surface Antigen Levels: Simultaneous, Sequential, or Add-on Combination Therapy.
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Genotype; Guanine; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Interferon-alpha; Lamivudine; Organophosphonates; Randomized Controlled Trials as Topic; Reproducibility of Results; Tenofovir; Treatment Outcome; Viral Load | 2021 |
No difference in hepatocellular carcinoma risk in chronic hepatitis B patients treated with tenofovir vs entecavir: evidence from an updated meta-analysis.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Risk Factors; Tenofovir | 2021 |
Differential Effectiveness of Tenofovir and Entecavir for Prophylaxis of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Depending on Coexisting Cirrhosis and Prior Exposure to Antiviral Therapy: A Systematic Review and Meta-analysis.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Tenofovir; Treatment Outcome | 2021 |
Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Tenofovir; Treatment Outcome | 2021 |
Lower risk of hepatocellular carcinoma with tenofovir than entecavir treatment in subsets of chronic hepatitis B patients: an updated meta-analysis.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Retrospective Studies; Tenofovir; Treatment Outcome | 2022 |
Current Trend in Antiviral Therapy for Chronic Hepatitis B.
Topics: Antiviral Agents; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Nucleosides; Nucleotides; Randomized Controlled Trials as Topic; Symptom Flare Up; Tenofovir; Treatment Outcome | 2022 |
Risk of hepatocellular carcinoma in antiviral treatment-naïve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Incidence; Liver Cirrhosis; Liver Neoplasms; Tenofovir; Treatment Outcome | 2022 |
Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir Treatment for Chronic Hepatitis B Virus: A Reconstructed Individual Patient Data Meta-analysis.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Middle Aged; Tenofovir | 2022 |
31 trial(s) available for tenofovir and guanine
| Article | Year |
|---|---|
Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus.
Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; CD4 Lymphocyte Count; DNA, Viral; Drug Resistance, Viral; Female; Follow-Up Studies; Guanine; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Kaplan-Meier Estimate; Kidney; Male; Middle Aged; Organophosphonates; Prospective Studies; Tenofovir; Time Factors; Virus Replication | 2010 |
Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease.
Topics: Adenine; Adolescent; Adult; Aged; Creatinine; Deoxycytidine; DNA, Viral; Drug Combinations; Emtricitabine; Female; Guanine; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Tenofovir; Viral Load | 2011 |
Clonal analysis of the quasispecies of antiviral-resistant HBV genomes in patients with entecavir resistance during rescue treatment and successful treatment of entecavir resistance with tenofovir.
Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genome, Viral; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Tenofovir; Treatment Outcome; Young Adult | 2013 |
First-line monotherapies of tenofovir and entecavir have comparable efficacies in hepatitis B treatment.
Topics: Adenine; Adolescent; Adult; Antiviral Agents; Cohort Studies; Drug Resistance, Viral; Female; Follow-Up Studies; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Young Adult | 2014 |
Quantification of HBsAg in nucleos(t)ide-naïve patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study.
Topics: Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Tenofovir | 2015 |
Long-term entecavir or tenofovir disoproxil fumarate therapy in treatment-naïve chronic hepatitis B patients in the real-world setting.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Creatinine; DNA, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Prospective Studies; Retrospective Studies; Tenofovir; Treatment Outcome; Viral Load | 2015 |
Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial.
Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Mutation; Tenofovir; Treatment Failure | 2016 |
Tenofovir versus entecavir in treatment of chronic hepatitis B virus with severe acute exacerbation.
Topics: Adult; Antiviral Agents; Creatinine; Female; Guanine; Hepatitis B, Chronic; Humans; Male; Middle Aged; Tenofovir; Treatment Outcome | 2015 |
Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial.
Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Republic of Korea; Tenofovir; Treatment Outcome | 2016 |
Hepatitis B Virus Pregenomic RNA Is Present in Virions in Plasma and Is Associated With a Response to Pegylated Interferon Alfa-2a and Nucleos(t)ide Analogues.
Topics: Adenine; Adult; Amantadine; Antiviral Agents; Biomarkers; DNA, Viral; Drug Therapy, Combination; Female; Guanine; Hep G2 Cells; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Reproducibility of Results; RNA, Viral; Tenofovir; Virion | 2016 |
Tenofovir/entecavir monotherapy after hepatitis B immunoglobulin withdrawal is safe and effective in the prevention of hepatitis B in liver transplant recipients.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Administration Schedule; Female; Follow-Up Studies; Guanine; Hepatitis B; Humans; Immunoglobulins; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Prospective Studies; Recurrence; Tenofovir; Treatment Outcome; Young Adult | 2015 |
Entecavir plus tenofovir combination therapy in patients with multidrug-resistant chronic hepatitis B: results of a multicentre, prospective study.
Topics: Adult; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Prospective Studies; Republic of Korea; Tenofovir; Treatment Outcome | 2016 |
Entecavir plus tenofovir combination therapy for chronic hepatitis B in patients with previous nucleos(t)ide treatment failure.
Topics: Adult; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Tenofovir; Treatment Outcome; Viral Load | 2016 |
Pegylated Interferon Alfa-2b Add-on Treatment in Hepatitis B Virus Envelope Antigen-Positive Chronic Hepatitis B Patients Treated with Nucleos(t)ide Analogue: A Randomized, Controlled Trial (PEGON).
Topics: Adult; Antiviral Agents; China; DNA, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Netherlands; Polyethylene Glycols; Recombinant Proteins; Tenofovir; Treatment Outcome | 2017 |
Contrasting Timing of Virological Relapse After Discontinuation of Tenofovir or Entecavir in Hepatitis B e Antigen-Negative Patients.
Topics: Adult; Aged; Antiviral Agents; DNA, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Prospective Studies; Recurrence; Tenofovir; Treatment Outcome; Young Adult | 2018 |
Efficacy and Safety of Besifovir Dipivoxil Maleate Compared With Tenofovir Disoproxil Fumarate in Treatment of Chronic Hepatitis B Virus Infection.
Topics: Absorptiometry, Photon; Adult; Alanine Transaminase; Antiviral Agents; Bone Density; Bone Diseases, Metabolic; DNA, Viral; Double-Blind Method; Drug Resistance, Viral; Female; Glomerular Filtration Rate; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Hip; Humans; Lumbar Vertebrae; Male; Maleates; Middle Aged; Organophosphonates; Osteoporosis; Renal Insufficiency; Sustained Virologic Response; Tenofovir; Treatment Outcome | 2019 |
Comparison of the long-term efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naïve HBeAg-positive patients with chronic hepatitis B: A large, multicentre, randomized controlled trials.
Topics: Adult; Antiviral Agents; China; DNA, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Tenofovir; Treatment Outcome | 2019 |
Switching from entecavir to tenofovir alafenamide versus maintaining entecavir for chronic hepatitis B.
Topics: Adenine; Adult; Aged; Alanine; Antiviral Agents; Female; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Male; Middle Aged; Tenofovir | 2019 |
RNA Interference Therapy With ARC-520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients With Chronic Hepatitis B Infection.
Topics: Adult; Aged; Antiviral Agents; Double-Blind Method; Drug Combinations; Female; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Male; Middle Aged; RNA, Small Interfering; RNAi Therapeutics; Tenofovir; Time Factors; Young Adult | 2020 |
Mitochondrial toxicity and body shape changes during nucleos(t)ide analogues administration in patients with chronic hepatitis B.
Topics: Adenine; Adiposity; Antiviral Agents; Cross-Sectional Studies; DNA, Mitochondrial; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Leukocytes, Mononuclear; Male; Middle Aged; Mitochondria; Organophosphonates; RNA, Mitochondrial; Tenofovir | 2020 |
Combining Hepatitis B Virus RNA and Hepatitis B Core-Related Antigen: Guidance for Safely Stopping Nucleos(t)ide Analogues in Hepatitis B e Antigen-Positive Patients With Chronic Hepatitis B.
Topics: Adult; Antiviral Agents; DNA, Viral; Female; Guanine; Hepatitis B Core Antigens; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Kaplan-Meier Estimate; Male; Nucleosides; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Recurrence; Tenofovir; Treatment Outcome; Withholding Treatment | 2020 |
Besifovir Dipivoxil Maleate 144-Week Treatment of Chronic Hepatitis B: An Open-Label Extensional Study of a Phase 3 Trial.
Topics: Adult; Antiviral Agents; Bone Density; Double-Blind Method; Drug Administration Schedule; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Republic of Korea; Tenofovir; Treatment Outcome; Viral Load | 2020 |
Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Prospective Studies; Sustained Virologic Response; Telbivudine; Tenofovir | 2020 |
Comparison of Tenofovir Disoproxil Fumarate and Entecavir in the Prophylaxis of HBV Reactivation.
Topics: Aged; Antiviral Agents; DNA, Viral; Female; Guanine; Hepatitis B, Chronic; Humans; Immunocompromised Host; Immunosuppressive Agents; Male; Middle Aged; Tenofovir; Viral Load | 2021 |
Long-term risk of primary liver cancers in entecavir versus tenofovir treatment for chronic hepatitis B.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Male; Middle Aged; Risk Factors; Tenofovir; Time Factors | 2021 |
Similar 5-year HCC occurrence in Tenofovir- and Entecavir-treated HBV chronic infection in the French AFEF/ANRS CO22 Hepather cohort.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Prospective Studies; Tenofovir; Treatment Outcome | 2021 |
Continuing besifovir dipivoxil maleate versus switching from tenofovir disoproxil fumarate for treatment of chronic hepatitis B: Results of 192-week phase 3 trial.
Topics: Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Tenofovir; Treatment Outcome; Viral Load | 2021 |
Bone loss in hepatitis B virus-infected patients can be associated with greater osteoclastic activity independently of the retroviral use.
Topics: Absorptiometry, Photon; Adult; Anti-Retroviral Agents; Body Composition; Bone Density; Bone Resorption; Cross-Sectional Studies; Female; Femur Neck; Fibroblast Growth Factor-23; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Hip; Humans; Lamivudine; Lumbar Vertebrae; Male; Middle Aged; Osteoclasts; Tenofovir | 2021 |
Incidences and Determinants of Functional Cure During Entecavir or Tenofovir Disoproxil Fumarate for Chronic Hepatitis B.
Topics: Alanine Transaminase; Antiviral Agents; Bilirubin; China; Cohort Studies; DNA, Viral; Fatty Liver; Female; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Incidence; Male; Middle Aged; Tenofovir; Treatment Outcome; Viremia | 2021 |
Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B.
Topics: Acute-On-Chronic Liver Failure; Adenine; Adult; Alanine; Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Tenofovir; Treatment Outcome | 2021 |
Switching to tenofovir alafenamide versus continued therapy in chronic hepatitis B patients who were treated with entecavir: A prospective, multicenter, randomized controlled study.
Topics: Adenine; Alanine; Antiviral Agents; DNA, Viral; Female; Fumarates; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Male; Middle Aged; Prospective Studies; Tenofovir; Treatment Outcome | 2022 |
375 other study(ies) available for tenofovir and guanine
| Article | Year |
|---|---|
Antiretroviral activities of acyclic nucleoside phosphonates [9-(2-phosphonylmethoxyethyl)adenine, 9-(2-phosphonylmethoxyethyl)guanine, (R)-9-(2-phosphonylmethoxypropyl)adenine, and MDL 74,968] in cell cultures and murine sarcoma virus-infected newborn NM
Topics: Adenine; Animals; Animals, Newborn; Antiviral Agents; Cell Line; Fibroblasts; Guanine; Humans; Mice; Mice, Inbred C3H; Organophosphonates; Organophosphorus Compounds; Retroviridae; Retroviridae Infections; Sarcoma Viruses, Murine; Tenofovir | 1997 |
Intracellular metabolism and action of acyclic nucleoside phosphonates on DNA replication.
Topics: Adenine; Antineoplastic Agents; Cell Line; DNA Replication; DNA-Directed DNA Polymerase; Guanine; Humans; Organophosphonates; Organophosphorus Compounds; Simian virus 40; Tenofovir | 1997 |
Genotoxicity of purine acyclic nucleotide analogs.
Topics: Adenine; Animals; Antiviral Agents; Cell Line; Female; Guanine; Humans; Male; Molecular Structure; Mutagenicity Tests; Mutagens; Organophosphonates; Organophosphorus Compounds; Purines; Rats; Rats, Inbred BN; Rats, Inbred Lew; Tenofovir; Teratogens; Thioguanine | 1997 |
Lamivudine, adefovir and tenofovir exhibit long-lasting anti-hepatitis B virus activity in cell culture.
Topics: Acyclovir; Adenine; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Guanine; Hepatitis B virus; Lamivudine; Organophosphonates; Organophosphorus Compounds; Tenofovir; Tumor Cells, Cultured | 2000 |
Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir.
Topics: Acyclovir; Adenine; Antiviral Agents; Arabinofuranosylcytosine Triphosphate; Cell Line; Dioxolanes; DNA-Directed DNA Polymerase; DNA, Viral; Guanine; Hepatitis B virus; Humans; Organophosphonates; Organophosphorus Compounds; Purine Nucleosides; Tenofovir; Virus Replication | 2000 |
Antiviral therapy for pre- and post-liver transplantation patients with hepatitis B.
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Hepatitis B; Hepatitis B virus; Humans; Kidney Diseases; Lamivudine; Liver Transplantation; Organophosphonates; Secondary Prevention; Tenofovir | 2007 |
Potency of tenofovir in chronic hepatitis B: mono or combination therapy?
Topics: Adenine; Antiviral Agents; Deoxycytidine; DNA, Viral; Drug Therapy, Combination; Emtricitabine; Guanine; Hepatitis B; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Viral Load | 2008 |
Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: successful rescue therapy with tenofovir.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Multiple, Viral; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Organophosphonates; Tenofovir; Viral Load | 2008 |
[Protocol for the antiviral therapy of chronic hepatitis B].
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Lamivudine; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Tenofovir | 2008 |
Hepatitis B virus viral load and treatment decision.
Topics: Adenine; Algorithms; Antiviral Agents; Decision Making; DNA, Viral; Drug Resistance, Viral; Female; Guanine; Hepatitis C, Chronic; Humans; Male; Organophosphonates; Patient Selection; RNA, Viral; Tenofovir; Viral Load | 2009 |
Partial virological response to nucleos(t)ide analogues in naïve patients with chronic hepatitis B: From guidelines to field practice.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Nucleosides; Nucleotides; Organophosphonates; Tenofovir | 2009 |
The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains.
Topics: Adenine; Anti-HIV Agents; Cell Line, Tumor; DNA-Directed DNA Polymerase; Drug Resistance, Viral; Guanine; Hepatitis B; Hepatitis B e Antigens; Hepatitis B virus; Humans; Lamivudine; Mutation; Nucleosides; Organophosphonates; Pyrimidinones; Telbivudine; Tenofovir; Thymidine; Viral Proteins; Virus Replication | 2009 |
Decision analysis model for hepatitis B prophylaxis one year after liver transplantation.
Topics: Adenine; Administration, Oral; Antiviral Agents; Cost Savings; Cost-Benefit Analysis; Decision Support Techniques; Drug Costs; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Health Care Costs; Hepatitis B, Chronic; Humans; Immunoglobulins; Injections, Intramuscular; Lamivudine; Liver Transplantation; Markov Chains; Models, Economic; Organophosphonates; Retrospective Studies; Salvage Therapy; Secondary Prevention; Tenofovir; Time Factors; Treatment Failure; Treatment Outcome | 2009 |
Anti-hepatitis B virus activity in vitro of combinations of tenofovir with nucleoside/nucleotide analogues.
Topics: Adenine; Antiviral Agents; Cell Line; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Emtricitabine; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Nucleotides; Organophosphonates; Pyrimidinones; Reverse Transcriptase Inhibitors; Telbivudine; Tenofovir; Thymidine | 2009 |
Chronic hepatitis B: update 2009.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Practice Guidelines as Topic; Tenofovir | 2009 |
Hepatitis B in HIV patients: what is the current treatment and what are the challenges?
Topics: Adenine; Antiviral Agents; Deoxycytidine; DNA, Viral; Drug Therapy, Combination; Emtricitabine; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Cirrhosis; Nucleosides; Organophosphonates; Polyethylene Glycols; Pyrimidinones; Recombinant Proteins; Telbivudine; Tenofovir; Thymidine; Transaminases | 2009 |
[The efficacy of nucleoside/nucleotide analogue on chronic hepatitis B].
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Organophosphonates; Pyrimidinones; Reverse Transcriptase Inhibitors; Telbivudine; Tenofovir; Thymidine; Treatment Outcome; Virus Replication | 2009 |
Selection and counterselection of the rtI233V adefovir resistance mutation during antiviral therapy.
Topics: Adenine; Adult; Amino Acid Sequence; Amino Acid Substitution; Antiviral Agents; Drug Resistance, Viral; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Molecular Sequence Data; Mutation, Missense; Organophosphonates; Selection, Genetic; Sequence Alignment; Tenofovir; Treatment Failure; Viremia; Young Adult | 2010 |
[Protocol for the antiviral therapy of hepatitis B and D].
Topics: Adenine; Antiviral Agents; Biopsy; Guanine; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis D; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Lamivudine; Liver Cirrhosis; Nucleotides; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Tenofovir | 2010 |
Viral resistance in hepatitis B: prevalence and management.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Genetic Testing; Genotype; Guanine; Hepatitis B; Humans; Lamivudine; Nucleosides; Organophosphonates; Phenotype; Pyrimidinones; Telbivudine; Tenofovir; Thymidine | 2010 |
Evaluation of the in vitro anti-HBV activity of clevudine in combination with other nucleoside/nucleotide inhibitors.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Arabinofuranosyluracil; Cell Line; Cells, Cultured; Drug Antagonism; Drug Synergism; Drug Therapy, Combination; Guanine; Hepatitis B virus; Hepatocytes; Humans; Lamivudine; Microbial Sensitivity Tests; Nucleosides; Nucleotides; Organophosphonates; Pyrimidinones; Reverse Transcriptase Inhibitors; Telbivudine; Tenofovir; Thymidine | 2010 |
Molecular characterization of intrahepatic and extrahepatic hepatitis B virus (HBV) reservoirs in patients on suppressive antiviral therapy.
Topics: Adenine; Adult; Aged; Antiviral Agents; Asian People; DNA, Circular; DNA, Viral; Drug Resistance; Female; Gene Products, pol; Genetic Variation; Genome, Viral; Guanine; Hepatitis B; Hepatitis B virus; Humans; Lamivudine; Liver; Liver Transplantation; Male; Middle Aged; Organophosphonates; Phylogeny; Tenofovir; Trans-Activators; Viral Envelope Proteins; Viral Regulatory and Accessory Proteins; Virus Replication | 2011 |
Cost-utility analysis of tenofovir disoproxil fumarate in the treatment of chronic hepatitis B.
Topics: Adenine; Cost-Benefit Analysis; Guanine; Hepatitis B, Chronic; Humans; Markov Chains; Organophosphonates; Quality-Adjusted Life Years; Reverse Transcriptase Inhibitors; State Medicine; Tenofovir; United Kingdom | 2010 |
Antiviral treatment including entecavir plus tenofovir disoproxil fumarate for HBV reactivation following a rituximab-based regimen.
Topics: Adenine; Antibodies, Monoclonal, Murine-Derived; Antiviral Agents; Drug Combinations; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Organophosphonates; Rituximab; Tenofovir; Virus Activation | 2010 |
[Antiviral treatment of chronic B hepatitis; 2010 - therapeutic recommendations].
Topics: Adenine; Antiviral Agents; Drug Administration Schedule; Drug Resistance, Viral; Guanine; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Organophosphonates; Polyethylene Glycols; Practice Guidelines as Topic; Recombinant Proteins; Tenofovir; Treatment Failure; Viral Load | 2010 |
[Treatment of chronic hepatitis B. High response rate in general practice].
Topics: Adenine; Antiviral Agents; Cross-Sectional Studies; Germany; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Long-Term Care; Organophosphonates; Patient Care Team; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load | 2010 |
Impact of hepatitis B e antigen-suppressing mutations on the replication efficiency of entecavir-resistant hepatitis B virus strains.
Topics: Adenine; Antiviral Agents; Cell Line, Tumor; Drug Resistance, Viral; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Mutation; Organophosphonates; Polymorphism, Single Nucleotide; Tenofovir; Viral Load; Viral Proteins; Virus Replication | 2011 |
Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Antiviral Agents; Cohort Studies; Drug Resistance, Viral; Female; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Male; Medication Adherence; Middle Aged; Organophosphonates; Retrospective Studies; Tenofovir; Young Adult | 2011 |
Efficacy and safety of entecavir and/or tenofovir for prophylaxis and treatment of hepatitis B recurrence post-liver transplant.
Topics: Adenine; Adult; Aged; Antiviral Agents; Combined Modality Therapy; Female; Guanine; Hepatitis B; Humans; Liver Transplantation; Male; Middle Aged; Organophosphonates; Secondary Prevention; Tenofovir | 2010 |
Entecavir as treatment for reactivation of hepatitis B in immunosuppressed patients.
Topics: Adenine; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Guanine; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Immunocompromised Host; Immunosuppressive Agents; Male; Middle Aged; Organophosphonates; Retrospective Studies; Tenofovir; Treatment Outcome | 2010 |
[Analogs combination therapy in chronic hepatitis B: when and how?].
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Organophosphonates; Pyrimidinones; Telbivudine; Tenofovir; Thymidine | 2010 |
[Long-term therapy for chronic hepatitis B in HIV co-infected patients].
Topics: Adenine; Antiretroviral Therapy, Highly Active; Antiviral Agents; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Guanine; Hepatitis B, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Nucleosides; Organophosphonates; Pyrimidinones; Recombinant Proteins; Telbivudine; Tenofovir; Thymidine | 2010 |
[Treatment has a positive impact on the long-term evolution of chronic hepatitis B].
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Clinical Trials as Topic; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Tenofovir | 2010 |
Prevention of lamivudine-resistant hepatitis B recurrence after liver transplantation with entecavir plus tenofovir combination therapy and perioperative hepatitis B immunoglobulin only.
Topics: Adenine; Antiviral Agents; Combined Modality Therapy; Drug Resistance, Viral; Guanine; Hepatitis B; Hepatitis B virus; Humans; Immunization, Passive; Immunoglobulins; Lamivudine; Liver Transplantation; Male; Middle Aged; Organophosphonates; Perioperative Care; Secondary Prevention; Tenofovir; Treatment Outcome | 2011 |
Treatment of HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Nucleosides; Organophosphonates; Pyrimidinones; Telbivudine; Tenofovir; Thymidine; Time Factors; Treatment Outcome | 2011 |
Hyperlipidemic acute pancreatitis: a possible role of antiretroviral therapy with entecavir.
Topics: Abdominal Pain; Acute Disease; Adenine; Adult; Alcoholism; Antiretroviral Therapy, Highly Active; Critical Care; Diabetes Mellitus, Type 2; Fever; Guanine; Hepatitis B, Chronic; Humans; Hyperlipidemias; Hypertriglyceridemia; Male; Organophosphonates; Pancreatitis; Plasmapheresis; Reverse Transcriptase Inhibitors; Tenofovir; Tomography, X-Ray Computed; Triglycerides | 2011 |
[Efficacy and treatment strategy for drug resistances of nucleos(t)ide analogues for chronic hepatitis B].
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Tenofovir | 2011 |
Managing hepatitis B/HIV co-infected: adding entecavir to truvada (tenofovir disoproxil/emtricitabine) experienced patients.
Topics: Adenine; Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Deoxycytidine; DNA, Viral; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; Guanine; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Prospective Studies; Tenofovir; Treatment Outcome | 2011 |
Proper antiviral therapy for hepatitis B virus-associated acute-on-chronic liver failure.
Topics: Adenine; Antiviral Agents; End Stage Liver Disease; Guanine; Hepatitis B, Chronic; Humans; Liver Failure, Acute; Organophosphonates; Tenofovir | 2011 |
Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; Bone Marrow; DNA, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunocompromised Host; Italy; Organophosphonates; Tenofovir; Treatment Outcome; Viremia | 2011 |
Unsuccessful therapy with adefovir and entecavir-tenofovir in a patient with chronic hepatitis B infection with previous resistance to lamivudine: a fourteen-year evolution of hepatitis B virus mutations.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Evolution, Molecular; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Middle Aged; Mutation; Organophosphonates; Tenofovir; Treatment Failure | 2011 |
Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Male; Organophosphonates; Tenofovir | 2011 |
Antiviral drug resistance testing in patients with chronic hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; Data Collection; Decision Making; DNA, Viral; Drug Resistance, Viral; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Mutation; Organophosphonates; Retrospective Studies; Surveys and Questionnaires; Tenofovir; Treatment Outcome; Viral Load | 2012 |
Late onset of hepatitis B virus reactivation following hematopoietic stem cell transplantation: successful treatment with combined entecavir plus tenofovir therapy.
Topics: Adenine; Age of Onset; Antiviral Agents; Drug Therapy, Combination; Female; Guanine; Hematopoietic Stem Cell Transplantation; Hepatitis B; Hepatitis B virus; Humans; Middle Aged; Organophosphonates; Tenofovir; Transplantation, Homologous; Treatment Outcome; Virus Activation | 2012 |
Design, synthesis, and biological evaluation of triazolo-pyrimidine derivatives as novel inhibitors of hepatitis B virus surface antigen (HBsAg) secretion.
Topics: Adenine; Animals; Antiviral Agents; Biological Availability; Drug Design; Drug Resistance, Viral; Guanine; Hep G2 Cells; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Lamivudine; Male; Mice; Models, Chemical; Molecular Structure; Mutation; Organophosphonates; Pyrimidines; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Tenofovir; Tetrazoles | 2011 |
Management options for lamivudine-resistant chronic hepatitis B patients with suboptimal virological suppression by adefovir.
Topics: Adenine; Adult; Antiviral Agents; Cohort Studies; DNA, Viral; Drug Resistance, Viral; Female; Follow-Up Studies; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2011 |
Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study.
Topics: Adenine; Adult; Aged; Antiviral Agents; Cohort Studies; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Guanine; Hepatitis B, Chronic; Humans; Internationality; Male; Middle Aged; Organophosphonates; Retrospective Studies; Tenofovir; Treatment Outcome; Viremia; Young Adult | 2012 |
Canadian patients with chronic hepatitis B cannot access appropriate drug treatments: a call for change.
Topics: Adenine; Antiviral Agents; Canada; Drug Approval; Guanine; Health Services Accessibility; Hepatitis B, Chronic; Humans; Insurance Coverage; Lamivudine; Liver Cirrhosis; National Health Programs; Organophosphonates; Tenofovir | 2011 |
Tenofovir plus entecavir as rescue therapy for multidrug-resistant chronic hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Multiple, Viral; Drug Substitution; Drug Therapy, Combination; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Mutation; Organophosphonates; Tenofovir; Treatment Outcome; Viral Load; Virus Replication | 2012 |
Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir.
Topics: Adenine; Adult; Antiviral Agents; Cohort Studies; Female; Follow-Up Studies; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Medication Adherence; Middle Aged; Organophosphonates; Tenofovir; Treatment Outcome; Young Adult | 2012 |
[Hungarian consensus guideline for the diagnosis and treatment of B, C, and D viral hepatitis].
Topics: Adenine; Antiviral Agents; Comorbidity; Consensus; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Guanine; Hepacivirus; Hepatitis B; Hepatitis C; Hepatitis D; Humans; Hungary; Interferon-alpha; Interferons; Lamivudine; Oligopeptides; Organophosphonates; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; RNA, Viral; Tenofovir; Time Factors; Treatment Outcome | 2012 |
Safety of long-term nucleos(t)ide treatment in chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Drug Administration Schedule; Evidence-Based Medicine; Guanine; Hepatitis B, Chronic; Humans; Organophosphonates; Patient Safety; Risk Assessment; Risk Factors; Tenofovir; Time Factors; Treatment Outcome | 2012 |
Similar risk of renal events among patients treated with tenofovir or entecavir for chronic hepatitis B.
Topics: Adenine; Adult; Aged; Antiviral Agents; Cohort Studies; Creatinine; Female; Glomerular Filtration Rate; Guanine; Hepatitis B, Chronic; Humans; Kidney Diseases; Male; Middle Aged; Organophosphonates; Retrospective Studies; Risk Assessment; Tenofovir; Young Adult | 2012 |
Antiviral therapy against chronic hepatitis B in Brazil: high rates of lamivudine resistance mutations and correlation with HBV genotypes.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Cross-Sectional Studies; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Tenofovir; Viral Load; Young Adult | 2012 |
Commentary: combination therapy with two nucleos(t)ide analogues in chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Drug Resistance; Drug Therapy, Combination; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2012 |
Hepatitis B prophylaxis post liver transplantation with newer nucleos(t)ide analogues after hepatitis B immunoglobulin discontinuation.
Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Guanine; Hepatitis B; Hepatitis B virus; Humans; Immunoglobulins; Lamivudine; Liver Transplantation; Male; Middle Aged; Nucleotides; Organophosphonates; Secondary Prevention; Tenofovir; Treatment Outcome; Young Adult | 2012 |
Current practice of chronic hepatitis B treatment in Southern Italy.
Topics: Adenine; Adult; Age Factors; Aged; Aged, 80 and over; Antiviral Agents; Female; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon-alpha; Italy; Lamivudine; Male; Middle Aged; Nucleosides; Organophosphonates; Polyethylene Glycols; Practice Patterns, Physicians'; Pyrimidinones; Recombinant Proteins; Telbivudine; Tenofovir; Thymidine; Young Adult | 2012 |
Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues.
Topics: Adenine; Antiviral Agents; Cells, Cultured; DNA, Viral; Genotype; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-gamma; Interleukin-1; Lamivudine; Organophosphonates; T-Lymphocytes; Tenofovir; Tumor Necrosis Factor-alpha | 2012 |
Comparison of the efficacy of tenofovir and entecavir for the treatment of nucleos(t)ide-naive patients with chronic hepatitis B.
Topics: Adenine; Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Retrospective Studies; Tenofovir; Treatment Outcome; Young Adult | 2012 |
Tenofovir monotherapy and tenofovir plus entecavir combination as rescue therapy for entecavir partial responders.
Topics: Adenine; Adult; Analysis of Variance; Antiviral Agents; Chi-Square Distribution; Drug Therapy, Combination; Female; Guanine; Hepatitis B, Chronic; Humans; Liver Function Tests; Male; Middle Aged; Organophosphonates; Polymerase Chain Reaction; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2012 |
Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis.
Topics: Adenine; Adult; Aged; Alanine Transaminase; Antiviral Agents; Blood Chemical Analysis; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Organophosphonates; Retrospective Studies; Tenofovir; Treatment Outcome; Turkey | 2013 |
The 2012 revised Dutch national guidelines for the treatment of chronic hepatitis B virus infection.
Topics: Adenine; Antiviral Agents; Drug Approval; Drug Resistance, Viral; Female; Guanine; Hepatitis B, Chronic; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Milk, Human; Netherlands; Nucleosides; Organophosphonates; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications, Infectious; Renal Insufficiency; Telbivudine; Tenofovir; Thymidine | 2012 |
Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kinetics; Lamivudine; Longitudinal Studies; Male; Middle Aged; Nucleosides; Nucleotides; Organophosphonates; Tenofovir | 2013 |
Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines.
Topics: Adenine; Allied Health Personnel; Antibodies, Viral; Antiviral Agents; Canada; Coinfection; Drug Resistance, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C; Humans; Interferons; Kidney Diseases; Liver; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Tenofovir | 2012 |
Should chronic hepatitis B be treated as early as possible?
Topics: Adenine; Adult; Antiviral Agents; Belgium; Cost-Benefit Analysis; Early Diagnosis; Guanine; Health Care Surveys; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Markov Chains; Middle Aged; Organophosphonates; Quality of Life; Secondary Prevention; Tenofovir; Treatment Outcome; Viral Load | 2013 |
Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D.
Topics: Adenine; Aged; Antiviral Agents; Biomarkers; Chi-Square Distribution; DNA, Viral; Female; Genotype; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kinetics; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Telbivudine; Tenofovir; Thymidine; Treatment Outcome | 2013 |
Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.
Topics: Adenine; Adult; Antiviral Agents; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Drug Administration Schedule; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Male; Markov Chains; Organophosphonates; Polyethylene Glycols; Precision Medicine; Prognosis; Quality-Adjusted Life Years; Recombinant Proteins; Tenofovir; Viral Load | 2013 |
[Cost-effectiveness of nucleoside/nucleotide analogues in chronic hepatitis B].
Topics: Adenine; Antiviral Agents; Cost-Benefit Analysis; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Hepatitis B, Chronic; Humans; Markov Chains; Models, Theoretical; Organophosphonates; Quality-Adjusted Life Years; Tenofovir | 2012 |
Increased eGFR with telbivudine in combination therapy of chronic hepatitis B infection.
Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Glomerular Filtration Rate; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Telbivudine; Tenofovir; Thymidine | 2014 |
Prevention of de novo hepatitis B with adefovir plus vaccination in recipients of liver transplants from core antibody-positive donors.
Topics: Adenine; Adult; Aged; Antiviral Agents; Biomarkers; Deoxycytidine; DNA, Viral; Drug Substitution; Emtricitabine; Guanine; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Core Antigens; Hepatitis B Vaccines; Hepatitis B virus; Humans; Liver Transplantation; Middle Aged; Organophosphonates; Tenofovir; Time Factors; Tissue Donors; Treatment Outcome | 2013 |
Prevention of de novo hepatitis B in recipients of core antibody-positive livers with lamivudine and other nucleos(t)ides: a 12-year experience.
Topics: Adenine; Adult; Aged; Analysis of Variance; Antiviral Agents; Biomarkers; Chi-Square Distribution; DNA, Viral; Donor Selection; Female; Guanine; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Immunosuppressive Agents; Lamivudine; Liver Transplantation; Logistic Models; Male; Middle Aged; Organophosphonates; Retrospective Studies; Risk Factors; Tenofovir; Time Factors; Tissue Donors; Treatment Outcome; Viral Load | 2013 |
Chronic hepatitis B treatment initiation and modification patterns in five European countries: a 2-year longitudinal, non-interventional study.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antiviral Agents; Disease Management; DNA, Viral; Europe; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Longitudinal Studies; Male; Middle Aged; Organophosphonates; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Tenofovir | 2014 |
Noncompetitive inhibition of hepatitis B virus reverse transcriptase protein priming and DNA synthesis by the nucleoside analog clevudine.
Topics: Adenine; Arabinofuranosyluracil; DNA, Viral; Guanine; HEK293 Cells; Hepatitis B virus; Humans; Organophosphonates; Protein Binding; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Tenofovir; Viral Proteins | 2013 |
Living related liver transplantation for hepatitis B-related liver disease without hepatitis B immune globulin prophylaxis.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance; Drug Therapy, Combination; Female; Follow-Up Studies; Guanine; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Immunoglobulins; Immunosuppression Therapy; Immunosuppressive Agents; Lamivudine; Liver Transplantation; Living Donors; Male; Middle Aged; Organophosphonates; Prospective Studies; Recurrence; Tenofovir; Treatment Outcome | 2013 |
WHO survey finds half of countries do not have clinical guidelines for treating hepatitis.
Topics: Adenine; Antiviral Agents; Drugs, Essential; Global Health; Guanine; Health Priorities; Hepatitis B; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Organophosphonates; Polyethylene Glycols; Practice Guidelines as Topic; Recombinant Proteins; Tenofovir; World Health Organization | 2013 |
[HBV vaccine escape mutations in a chronic hepatitis B patient treated with nucleos(t)ide analogues].
Topics: Adenine; Biopsy; Drug Resistance, Multiple, Viral; Female; Genes, pol; Guanine; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver; Middle Aged; Mutation; Nucleosides; Nucleotides; Organophosphonates; Tenofovir | 2013 |
Comparison of tenofovir and entecavir in patients with chronic HBV infection.
Topics: Adenine; Adult; Aged; DNA, Viral; Female; Guanine; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Retrospective Studies; Tenofovir | 2013 |
Chronic hepatitis B monitoring and treatment patterns in five European countries with different access and reimbursement policies.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Europe; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Hospitalization; Humans; Insurance, Health, Reimbursement; Interferon-alpha; Lamivudine; Longitudinal Studies; Male; Middle Aged; Monitoring, Ambulatory; Organophosphonates; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Tenofovir | 2014 |
Incorporated antivirals for chronic hepatitis B in Brazil: a cost-effectiveness analysis.
Topics: Adenine; Adult; Analysis of Variance; Antiviral Agents; Brazil; Cost-Benefit Analysis; Disease Progression; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Markov Chains; Organophosphonates; Tenofovir; Treatment Outcome | 2013 |
Lamivudine compared with newer antivirals for prophylaxis of hepatitis B core antibody positive livers: a cost-effectiveness analysis.
Topics: Adenine; Antiviral Agents; Cohort Studies; Cost-Benefit Analysis; Decision Trees; Follow-Up Studies; Graft Survival; Guanine; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Core Antigens; Hepatitis B virus; Humans; Lamivudine; Liver Transplantation; Markov Chains; Organophosphonates; Prognosis; Quality-Adjusted Life Years; Survival Rate; Tenofovir | 2014 |
Tenofovir is superior to entecavir for achieving complete viral suppression in HBeAg-positive chronic hepatitis B patients with high HBV DNA.
Topics: Adenine; Adult; Antiviral Agents; California; Cohort Studies; DNA, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Retrospective Studies; Tenofovir; Treatment Outcome | 2014 |
Generation of a human hepatoma cell line supporting efficient replication of a lamivudine resistant hepatitis B virus.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Guanine; Hep G2 Cells; Hepatitis B virus; Hepatocytes; Humans; Lamivudine; Organophosphonates; Tenofovir; Virus Replication | 2014 |
[Diagnosis and treatment of chronic hepatitis B and D. Hungarian national consensus guideline].
Topics: Adenine; Antiviral Agents; Consensus; Drug Administration Schedule; Drug Therapy, Combination; Evidence-Based Medicine; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis D, Chronic; Hepatitis Delta Virus; Humans; Hungary; Interferon-alpha; Lamivudine; Liver Neoplasms; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Tenofovir | 2014 |
Commentary: tenofovir is superior to entecavir in HBeAg-positive chronic hepatitis B patients.
Topics: Adenine; Antiviral Agents; Female; Guanine; Hepatitis B, Chronic; Humans; Male; Organophosphonates; Tenofovir | 2014 |
Commentary: tenofovir is superior to entecavir in HBeAg-positive chronic hepatitis B patients--authors' reply.
Topics: Adenine; Antiviral Agents; Female; Guanine; Hepatitis B, Chronic; Humans; Male; Organophosphonates; Tenofovir | 2014 |
Letter: Treatment of HBeAg+ chronic hepatitis B--is tenofovir truly superior to entecavir?
Topics: Adenine; Antiviral Agents; Female; Guanine; Hepatitis B, Chronic; Humans; Male; Organophosphonates; Tenofovir | 2014 |
Letter: Treatment of HBeAg+ chronic hepatitis B--is tenofovir truly superior to entecavir? Authors' reply.
Topics: Adenine; Antiviral Agents; Female; Guanine; Hepatitis B, Chronic; Humans; Male; Organophosphonates; Tenofovir | 2014 |
Coexistence of HBsAg and HBsAb in a difficult-to-treat chronic hepatitis B: loss of HBsAg with entecavir plus tenofovir combination.
Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Guanine; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Organophosphonates; Recombinant Proteins; Tenofovir; Treatment Failure; Treatment Outcome; Viral Load | 2014 |
New nucleos(t)ide analogue monoprophylaxis after cessation of hepatitis B immunoglobulin is effective against hepatitis B recurrence.
Topics: Adenine; Adult; Cohort Studies; Female; Follow-Up Studies; Graft Rejection; Graft Survival; Guanine; Hepatitis B, Chronic; Humans; Immunoglobulins; Immunosuppressive Agents; Liver Cirrhosis; Liver Transplantation; Male; Organophosphonates; Prospective Studies; Recurrence; Retreatment; Risk Assessment; Statistics, Nonparametric; Tenofovir; Transplantation Immunology; Treatment Outcome | 2014 |
Antiviral therapy of chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Arabinofuranosyluracil; Carcinoma, Hepatocellular; Gene Products, pol; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver; Liver Cirrhosis; Liver Neoplasms; Organophosphonates; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Telbivudine; Tenofovir; Thymidine; Treatment Outcome; Virus Replication | 2014 |
Reduction of infectivity in chronic hepatitis B virus carriers among healthcare providers and pregnant women by antiviral therapy.
Topics: Adenine; Antiviral Agents; DNA, Viral; Female; Guanine; Health Personnel; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infectious Disease Transmission, Professional-to-Patient; Infectious Disease Transmission, Vertical; Lamivudine; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Reverse Transcriptase Inhibitors; Telbivudine; Tenofovir; Thymidine; Viral Load; Viremia | 2014 |
Mechanisms of hepatitis B virus resistance development.
Topics: Adenine; Amino Acid Substitution; Antiviral Agents; Deoxycytidine; Drug Resistance, Multiple, Viral; Emtricitabine; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Telbivudine; Tenofovir; Thymidine; Virus Replication | 2014 |
Hepatitis B virus drug resistance tools: one sequence, two predictions.
Topics: Adenine; Antiviral Agents; Base Sequence; Drug Resistance, Multiple, Viral; Genotype; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immune Evasion; Lamivudine; Microbial Sensitivity Tests; Organophosphonates; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Sequence Analysis, DNA; Telbivudine; Tenofovir; Thymidine | 2014 |
Virologic breakthrough in a patient with chronic hepatitis B by combination treatment with tenofovir disoproxil fumarate and entecavir.
Topics: Adenine; Amino Acid Substitution; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Middle Aged; Organophosphonates; Tenofovir; Treatment Outcome | 2014 |
Treatment cessation in noncirrhotic, e-antigen negative chronic hepatitis B is safe and effective following prolonged anti-viral suppression with nucleosides/nucleotides.
Topics: Adenine; Adult; Antiviral Agents; Female; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Nucleosides; Nucleotides; Organophosphonates; Recurrence; Tenofovir; Withholding Treatment; Young Adult | 2014 |
Efficacy and safety of tenofovir in a kidney transplant patient with chronic hepatitis B and nucleos(t)ide multidrug resistance: a case report.
Topics: Adenine; Antiviral Agents; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Follow-Up Studies; Guanine; Hepatitis B, Chronic; Humans; Kidney Transplantation; Male; Middle Aged; Nucleosides; Nucleotides; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Viral Load | 2014 |
Efficacy of entecavir-tenofovir combination therapy for chronic hepatitis B patients with multidrug-resistant strains.
Topics: Adenine; Adult; Aged; Antiviral Agents; Base Sequence; Cohort Studies; DNA, Viral; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Retrospective Studies; Reverse Transcriptase Inhibitors; Sequence Analysis, DNA; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2014 |
Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir.
Topics: Adenine; Adult; Antiviral Agents; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Greece; Guanine; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Male; Middle Aged; Netherlands; Organophosphonates; Retrospective Studies; Reverse Transcriptase Inhibitors; Risk Factors; Spain; Tenofovir; Time Factors; Turkey; White People | 2015 |
Comparable efficacy of tenofovir versus entecavir and predictors of response in treatment-naïve patients with chronic hepatitis B: a multicenter real-life study.
Topics: Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Tenofovir | 2014 |
The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy.
Topics: Adenine; Adult; Antiviral Agents; Canada; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Incidence; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Nucleosides; Organophosphonates; Retrospective Studies; Risk Factors; Telbivudine; Tenofovir; Thymidine | 2014 |
Tenofovir-based alternate therapies for chronic hepatitis B patients with partial virological response to entecavir.
Topics: Adult; Aged; Antiviral Agents; DNA, Viral; Drug Therapy; Female; Guanine; Hepatitis B, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2015 |
Tenofovir-induced Fanconi syndrome in chronic hepatitis B monoinfected patients that reverted after tenofovir withdrawal.
Topics: Adenine; Antiviral Agents; Fanconi Syndrome; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Tenofovir; Treatment Outcome; Viral Load; Withholding Treatment | 2014 |
Effect of nucleoside and nucleotide analogues on renal function in patients with chronic hepatitis B virus monoinfection.
Topics: Adult; Antiviral Agents; Female; France; Glomerular Filtration Rate; Guanine; Hepatitis B, Chronic; Humans; Kidney; Longitudinal Studies; Male; Middle Aged; Tenofovir | 2015 |
Partial virological response to three different nucleotide analogues in naive patients with chronic hepatitis B.
Topics: Adult; Antiviral Agents; DNA, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Retrospective Studies; Tenofovir; Time Factors; Treatment Outcome; Viral Load | 2014 |
[Tenofovir rescue therapy for chronic hepatitis B patients after suboptimal response to treatment with lamivudine plus adefovir dipivoxil].
Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Retrospective Studies; Tenofovir; Treatment Failure; Treatment Outcome | 2014 |
Therapeutic management and evolution of chronic hepatitis B: does HIV still have an impact? The EPIB 2012 study.
Topics: Adult; Antiviral Agents; Cohort Studies; Comorbidity; Disease Progression; Female; France; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; HIV Infections; HIV Seronegativity; HIV Seropositivity; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Logistic Models; Male; Middle Aged; Multivariate Analysis; Reference Values; Retrospective Studies; Risk Assessment; Statistics, Nonparametric; Survival Analysis; Tenofovir; Treatment Outcome | 2015 |
HBV carrying drug-resistance mutations in chronically infected treatment-naive patients.
Topics: Adenine; Antibodies, Viral; Antiviral Agents; Brazil; DNA, Viral; Drug Resistance, Viral; Gene Products, pol; Genotype; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Microbial Sensitivity Tests; Mutation; Organophosphonates; Retrospective Studies; Sequence Analysis, DNA; Tenofovir; Virus Replication | 2015 |
Low-dose short-term hepatitis B immunoglobulin with high genetic barrier antivirals: the ideal post-transplant hepatitis B virus prophylaxis?
Topics: Adenine; Adult; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Guanine; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Immunoglobulins; Lamivudine; Liver Transplantation; Male; Middle Aged; Organophosphonates; Prospective Studies; Recurrence; Tenofovir | 2015 |
Tenofovir rescue regimen following prior suboptimal response to entecavir and adefovir combination therapy in chronic hepatitis B patients exposed to multiple treatment failures.
Topics: Adenine; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; High-Throughput Nucleotide Sequencing; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; ROC Curve; Tenofovir; Treatment Failure; Treatment Outcome | 2015 |
Clinical course of chronic hepatitis B patients receiving nucleos(t)ide analogues after virological breakthrough during monotherapy with lamivudine.
Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Tenofovir; Treatment Outcome; Viral Load; Viral Matrix Proteins; Young Adult | 2015 |
Limited hepatitis B immunoglobulin with potent nucleos(t)ide analogue is a cost-effective prophylaxis against hepatitis B virus after liver transplantation.
Topics: Adenine; Adult; Aged; Antiviral Agents; Cost-Benefit Analysis; Drug Costs; Female; Graft Survival; Guanine; Hepatitis B; Hepatitis B Surface Antigens; Humans; Immunoglobulins; Liver Transplantation; Male; Middle Aged; Organophosphonates; Retrospective Studies; Tenofovir; Treatment Outcome; United States | 2015 |
A case of entecavir resistance which is developed after complete viral suppression during entecavir treatment for nucleoside-naive chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Nucleosides; Organophosphonates; Remission Induction; Tenofovir | 2014 |
Response to potent anti-HBV agents in chronic hepatitis B and combined effect of HBV reverse transcriptase mutations.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Mutation; Organophosphonates; RNA-Directed DNA Polymerase; Tenofovir | 2015 |
Tenofovir monotherapy after achieving complete viral suppression on entecavir plus tenofovir combination therapy.
Topics: Adult; Antiviral Agents; Biomarkers; Chi-Square Distribution; DNA, Viral; Drug Administration Schedule; Drug Therapy, Combination; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Medication Adherence; Middle Aged; Multivariate Analysis; Odds Ratio; Recurrence; Retrospective Studies; Risk Factors; Tenofovir; Time Factors; Treatment Outcome; Viral Load | 2015 |
Nucleoside-Nucleotide Analog Combination Therapy Is Effective in Preventing Recurrent Hepatitis B After Liver Transplantation.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Immunoglobulins; Lamivudine; Liver Transplantation; Male; Middle Aged; Organophosphonates; Prospective Studies; Recurrence; Tenofovir | 2015 |
Tenofovir-based rescue therapy for chronic hepatitis B patients who had failed treatment with lamivudine, adefovir, and entecavir.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Multiple; Drug Therapy, Combination; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Multivariate Analysis; Organophosphonates; Tenofovir; Treatment Failure | 2015 |
Treatment Outcomes With First-line Therapies With Entecavir and Tenofovir in Treatment-Naive Chronic Hepatitis B Patients in a Routine Clinical Practice.
Topics: Adult; Antiviral Agents; Biomarkers; DNA, Viral; Drug Resistance, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Medication Adherence; Middle Aged; Remission Induction; Retrospective Studies; Tenofovir; Time Factors; Treatment Outcome; United States; Viral Load | 2016 |
UPLC-MS/MS method for the simultaneous quantification of anti-HBV nucleos(t)ides analogs: Entecavir, lamivudine, telbivudine and tenofovir in plasma of HBV infected patients.
Topics: Antiviral Agents; Calibration; Chemistry Techniques, Analytical; Chromatography; Chromatography, High Pressure Liquid; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Limit of Detection; Nucleosides; Reproducibility of Results; Tandem Mass Spectrometry; Telbivudine; Tenofovir; Thymidine | 2015 |
Comparison of renal safety and efficacy of telbivudine, entecavir and tenofovir treatment in chronic hepatitis B patients: real world experience.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Female; Glomerular Filtration Rate; Guanine; Hepatitis B, Chronic; Humans; Kidney Diseases; Kidney Function Tests; Male; Middle Aged; Retrospective Studies; Telbivudine; Tenofovir; Thymidine; Treatment Outcome | 2016 |
Comparison of the Efficacy of Entecavir and Tenofovir in Nucleos(T)ide Analogue-Experienced Chronic Hepatitis B Patients.
Topics: Adult; Antiviral Agents; Cohort Studies; DNA, Viral; Drug Resistance, Viral; Female; Genotype; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Multivariate Analysis; Nucleotides; Probability; Retrospective Studies; Tenofovir; Time Factors; Treatment Outcome | 2015 |
Durability of Hepatitis B e Antigen Seroconversion in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Biomarkers; DNA, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Recurrence; Remission Induction; Retrospective Studies; Risk Factors; Tenofovir; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2015 |
Antiviral Therapy in Hepatitis B Virus-Associated Liver Cirrhosis.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Polyethylene Glycols; Recombinant Proteins; Reverse Transcriptase Inhibitors; Tenofovir | 2015 |
Potential Efficacy of Pegylated Interferon-α and a Nucleos(t)ide Analogue as Combination Therapy for HBeAg-Positive Chronic Hepatitis B.
Topics: Adolescent; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Tenofovir; Treatment Outcome | 2016 |
Prolonged use of tenofovir and entecavir in hepatitis B virus-related cirrhosis.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Guanine; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Tenofovir; Time Factors; Treatment Outcome; Young Adult | 2015 |
Substitution at rt269 in Hepatitis B Virus Polymerase Is a Compensatory Mutation Associated with Multi-Drug Resistance.
Topics: Adenine; Amino Acid Substitution; Antiviral Agents; Arabinofuranosyluracil; Cell Line, Tumor; Drug Resistance, Multiple, Viral; Gene Products, pol; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Microbial Sensitivity Tests; Models, Molecular; Organophosphonates; Tenofovir; Virus Replication | 2015 |
Mechanism of Adefovir, Tenofovir and Entecavir Resistance: Molecular Modeling Studies of How A Novel Anti-HBV Agent (FMCA) Can Overcome the Drug Resistance.
Topics: Adenine; Adenosine; Amino Acid Sequence; Antiviral Agents; Binding Sites; Catalytic Domain; Databases, Protein; Drug Resistance, Viral; Gene Products, pol; Guanine; Hepatitis B; Hepatitis B virus; HIV Reverse Transcriptase; Humans; Hydrogen Bonding; Molecular Dynamics Simulation; Molecular Sequence Data; Mutation; Organophosphonates; Sequence Alignment; Tenofovir | 2015 |
Long-term follow-up of HBsAg-positive patients in Germany.
Topics: Adenine; Adult; Age Factors; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Germany; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Mass Screening; Middle Aged; Organophosphonates; Prognosis; Prospective Studies; Retrospective Studies; Telbivudine; Tenofovir; Thymidine; Time Factors; Turkey | 2016 |
Efficacy of interferon for chronic hepatitis B in patients with nucleoside and nucleotide combination therapy failure.
Topics: Adult; Antiviral Agents; Drug Substitution; Drug Therapy, Combination; Female; Follow-Up Studies; Guanine; Hepatitis B, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Tenofovir; Treatment Failure; Treatment Outcome | 2016 |
Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Odds Ratio; Organophosphonates; Real-Time Polymerase Chain Reaction; Retrospective Studies; Tenofovir; Viral Load | 2015 |
Cost-Effectiveness and Cost Thresholds of Generic and Brand Drugs in a National Chronic Hepatitis B Treatment Program in China.
Topics: Antiviral Agents; China; Cost-Benefit Analysis; Drugs, Generic; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Markov Chains; National Health Programs; Quality-Adjusted Life Years; Tenofovir | 2015 |
Effects of hepatitis B surface antigen (HBsAg) positivity of donors in HBsAg(+) renal transplant recipients: comparison of outcomes with HBsAg(+) and HBsAg(-) donors.
Topics: Adult; Antiviral Agents; Female; Glomerular Filtration Rate; Graft Rejection; Graft Survival; Guanine; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Kidney Transplantation; Lamivudine; Liver; Male; Middle Aged; Postoperative Complications; Tenofovir; Tissue Donors; Transplant Recipients | 2016 |
Alternative Therapies for Chronic Hepatitis B Patients With Partial Virological Response to Standard Entecavir Monotherapy.
Topics: Adult; Antiviral Agents; Biomarkers; Chi-Square Distribution; DNA, Viral; Drug Administration Schedule; Drug Combinations; Drug Substitution; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Proportional Hazards Models; Retrospective Studies; Tenofovir; Time Factors; Treatment Outcome; United States; Viral Load | 2016 |
Nephrotoxicity caused by oral antiviral agents in patients with chronic hepatitis B treated in a hospital for tropical diseases in Thailand.
Topics: Adenine; Adult; Antiviral Agents; Creatinine; Female; Follow-Up Studies; Guanine; Hepatitis B, Chronic; Hospitals; Humans; Incidence; Kidney Diseases; Lamivudine; Male; Middle Aged; Nephrons; Organophosphonates; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Risk Factors; Telbivudine; Tenofovir; Thailand; Thymidine; Tropical Medicine | 2015 |
Impact of fatty liver on hepatitis B virus replication and virologic response to tenofovir and entecavir.
Topics: Adult; Age Factors; Aged; Antiviral Agents; DNA, Viral; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lipoproteins, HDL; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Odds Ratio; Retrospective Studies; Tenofovir; Treatment Outcome; Virus Replication; Young Adult | 2016 |
PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Middle Aged; Proportional Hazards Models; Risk; Tenofovir | 2016 |
Off-treatment efficacy of 3-year nucleos(t)ide analogues in chronic hepatitis B patients.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; Female; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Telbivudine; Tenofovir; Thymidine; Treatment Outcome | 2016 |
Head-To-Head Comparison of Two Years Efficacy of Entecavir and Tenofovir in Patients with Treatment-Naïve Chronic Hepatitis B--The Real Life Data.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Cohort Studies; DNA, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Prospective Studies; Retrospective Studies; Tenofovir; Treatment Outcome; Viral Load | 2015 |
[Drug-resistant mutations in hepatitis B virus found in chronic HBV carriers using PCR sequencing technology].
Topics: Adenine; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Genotype; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Mutation; Organophosphonates; Polymerase Chain Reaction; Telbivudine; Tenofovir; Thymidine | 2016 |
Efficacy and safety of tenofovir, entecavir, and telbivudine for chronic hepatitis B in heart transplant recipients.
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; DNA, Viral; Female; Follow-Up Studies; Guanine; Heart Transplantation; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Prospective Studies; Telbivudine; Tenofovir; Thymidine; Treatment Outcome; Viremia | 2016 |
Efficacy Comparison of Tenofovir and Entecavir in HBeAg-Positive Chronic Hepatitis B Patients with High HBV DNA.
Topics: Adult; DNA, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Tenofovir; Viral Load | 2016 |
[Effect of IL-28B polymorphisms on the natural course of HBV infection].
Topics: Adult; Antiviral Agents; Carrier State; Female; Guanine; Hepatitis B, Chronic; Humans; Interferons; Interleukins; Lamivudine; Male; Middle Aged; Polymorphism, Genetic; Prospective Studies; Real-Time Polymerase Chain Reaction; Telbivudine; Tenofovir; Thymidine; Turkey | 2016 |
Efficacy of entecavir and tenofovir in chronic hepatitis B under treatment in the public health system in southern Brazil.
Topics: Antiviral Agents; Cross-Sectional Studies; DNA, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Public Health; Tenofovir; Treatment Outcome; Viral Load | 2016 |
Five-year results of oral antiviral therapy in HBeAg-negative chronic Hepatitis B.
Topics: Adult; Age Factors; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Proportional Hazards Models; Regression Analysis; Retrospective Studies; Risk Factors; Sustained Virologic Response; Tenofovir; Time Factors; Treatment Outcome | 2016 |
Cost-effectiveness analysis of tenofovir disoproxil fumarate for treatment of chronic hepatitis B in China.
Topics: Adenine; Antiviral Agents; Cost-Benefit Analysis; Female; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Male; Markov Chains; Organophosphonates; Quality-Adjusted Life Years; Telbivudine; Tenofovir; Thymidine; Treatment Outcome | 2016 |
The efficacy of tenofovir-based therapy in patients showing suboptimal response to entecavir-adefovir combination therapy.
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Polymerase Chain Reaction; Republic of Korea; Retrospective Studies; Tenofovir; Treatment Outcome | 2016 |
Altered Underlying Renal Tubular Function in Patients With Chronic Hepatitis B Receiving Nucleos(t)ide Analogs in a Real-World Setting: The MENTE Study.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Creatinine; Cross-Sectional Studies; Disease Progression; Female; Glomerular Filtration Rate; Guanine; Hepatitis B, Chronic; Humans; Kidney Tubules, Proximal; Male; Middle Aged; Nucleosides; Nucleotides; Retinol-Binding Proteins; Retrospective Studies; Spain; Tenofovir; Young Adult | 2016 |
The long-term efficacy of combining nucleos(t)ide analog and low-dose hepatitis B immunoglobulin on post-transplant hepatitis B virus recurrence.
Topics: Adenine; Administration, Oral; Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Guanine; Hepatitis B, Chronic; Humans; Immunoglobulins; Immunologic Factors; Kaplan-Meier Estimate; Lamivudine; Liver Transplantation; Male; Middle Aged; Organophosphonates; Postoperative Complications; Proportional Hazards Models; Recurrence; Retrospective Studies; Tenofovir; Treatment Outcome | 2016 |
Nucleos(t)ide analog(s) prophylaxis after hepatitis B immunoglobulin withdrawal against hepatitis B and D recurrence after liver transplantation.
Topics: Adenine; Adult; Antiviral Agents; Coinfection; DNA, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis D, Chronic; Humans; Immunoglobulins; Lamivudine; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Organophosphonates; Secondary Prevention; Tenofovir; Treatment Outcome; Withholding Treatment; Young Adult | 2016 |
Comparative effectiveness of nucleos(t)ide analogues in chronic hepatitis B patients undergoing cytotoxic chemotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antiviral Agents; Cytotoxins; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Neoplasms; Retrospective Studies; Telbivudine; Tenofovir; Thymidine; Virus Activation; Young Adult | 2016 |
Prevalence and risk factors for viral blipping in chronic hepatitis B patients treated with nucleos (t) ide analogues.
Topics: Adult; Antiviral Agents; Drug Monitoring; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Retrospective Studies; Tenofovir; Treatment Outcome; Viral Load | 2016 |
Comparison of the effectiveness and renal safety of tenofovir versus entecavir in patients with chronic hepatitis B.
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Female; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Kidney Diseases; Male; Middle Aged; Retrospective Studies; Tenofovir; Treatment Outcome | 2016 |
Week 4 viral load predicts long-term suppression of hepatitis B virus DNA during antiviral therapy: improving hepatitis B treatment in the real world.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Australia; DNA, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models; Tenofovir; Treatment Outcome; Viral Load | 2017 |
Long-term outcomes of hepatitis B virus-related cirrhosis treated with nucleos(t)ide analogs.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Proportional Hazards Models; Renal Insufficiency, Chronic; Telbivudine; Tenofovir; Thymidine; Treatment Outcome | 2017 |
Tenofovir versus tenofovir plus entecavir for chronic hepatitis B with lamivudine resistance and entecavir resistance.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2017 |
The development of dry eye disease during tenofovir and entecavir therapy in a patient with chronic hepatitis B.
Topics: Adult; Antiviral Agents; Dry Eye Syndromes; Female; Guanine; Hepatitis B, Chronic; Humans; Tenofovir | 2016 |
[Changes in serum β2-microglobulin, retinol-binding protein, and cystatin C and their value in identifying early renal dysfunction in patients with chronic hepatitis B undergoing tenofovir or entecavir monotherapy: a comparative analysis].
Topics: Adult; Antiviral Agents; beta 2-Microglobulin; Creatinine; Cystatin C; Female; Guanine; Hepatitis B, Chronic; Humans; Kidney Diseases; Kidney Function Tests; Male; Middle Aged; Predictive Value of Tests; Renal Insufficiency; Retinol-Binding Proteins; Serum Albumin; Tenofovir; Treatment Outcome | 2016 |
Induction of IFN-λ3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antiviral Agents; Asymptomatic Infections; Carcinoma, Hepatocellular; Culture Media, Conditioned; DNA, Viral; Female; Gene Expression; Genotype; Guanine; Hep G2 Cells; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HT29 Cells; Humans; Interferons; Interleukins; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Organophosphonates; Polymorphism, Genetic; Recombinant Proteins; Tenofovir; Up-Regulation; Young Adult | 2018 |
Human organic anion transporter 2 is an entecavir, but not tenofovir, transporter.
Topics: Biological Transport; Guanine; Hepatocytes; Humans; Organic Anion Transporters, Sodium-Independent; Sulfobromophthalein; Temperature; Tenofovir | 2017 |
Caution: Reactivation of Hepatitis B during Hepatitis C Treatment with Direct-Acting Antiviral Therapy.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Guanine; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Male; Middle Aged; Simeprevir; Sofosbuvir; Tenofovir; Viral Load; Virus Activation | 2016 |
Effectiveness and Safety of Entecavir or Tenofovir in a Spanish Cohort of Chronic Hepatitis B Patients: Validation of the Page-B Score to Predict Hepatocellular Carcinoma.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Female; Follow-Up Studies; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Middle Aged; Prognosis; Research Design; Risk Assessment; Spain; Tenofovir; Treatment Outcome | 2017 |
Comparative evaluation of long-term monotherapies & combination therapies in patients with chronic hepatitis B: A pilot study.
Topics: Adenine; Adult; Drug Combinations; Drug Resistance, Viral; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Pilot Projects; Tenofovir | 2016 |
Comparison of the efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue-naive chronic hepatitis B patients with high viraemia: a retrospective cohort study.
Topics: Acute Kidney Injury; Adult; Aged; Antiviral Agents; DNA, Viral; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Tenofovir; Treatment Outcome; Viral Load | 2017 |
Economic Analysis and Budget Impact of Tenofovir and Entecavir in the First-Line Treatment of Hepatitis B Virus in Italy.
Topics: Antiviral Agents; Cost-Benefit Analysis; Guanine; Health Care Costs; Hepatitis B, Chronic; Humans; Italy; Markov Chains; Quality-Adjusted Life Years; Tenofovir; Treatment Outcome | 2017 |
Comparison of the long-term efficacy between entecavir and tenofovir in treatment- naïve chronic hepatitis B patients.
Topics: Adult; Antiviral Agents; DNA, Viral; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Multivariate Analysis; Propensity Score; Tenofovir; Treatment Outcome; Viral Load | 2017 |
Evolutionary trends of resistance mutational patterns of HBV reverse transcriptase over years (2002-2012) of different treatment regimens: The legacy of lamivudine/adefovir combination treatment.
Topics: Adenine; Antiviral Agents; DNA Mutational Analysis; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Evolution, Molecular; Genotype; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Mutation; Organophosphonates; Polymorphism, Genetic; RNA-Directed DNA Polymerase; Sequence Analysis; Tenofovir; Treatment Failure | 2017 |
Monotherapy with tenofovir disoproxil fumarate for multiple drug-resistant chronic hepatitis B: 3-year trial.
Topics: Adult; Aged; Analysis of Variance; Antiviral Agents; DNA, Viral; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Patient Safety; Randomized Controlled Trials as Topic; Republic of Korea; Severity of Illness Index; Tenofovir; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2017 |
Selection of the highly replicative and partially multidrug resistant rtS78T HBV polymerase mutation during TDF-ETV combination therapy.
Topics: Adult; Antiviral Agents; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; Gene Products, pol; Genes, Viral; Guanine; Hepatitis B virus; Hepatitis B, Chronic; High-Throughput Nucleotide Sequencing; Humans; Male; Middle Aged; Mutation; RNA-Directed DNA Polymerase; Selection, Genetic; Sequence Analysis, DNA; Tenofovir; Virus Replication | 2017 |
Occult hepatitis B infection reactivation after ruxolitinib therapy.
Topics: Aged; Antiviral Agents; Drug Resistance; Enzyme Inhibitors; Guanine; Hepatitis B, Chronic; Humans; Hydroxyurea; Janus Kinase Inhibitors; Male; Middle Aged; Nitriles; Polycythemia Vera; Primary Myelofibrosis; Pyrazoles; Pyrimidines; Tenofovir; Virus Activation | 2017 |
Validation of PAGE-B model in Asian chronic hepatitis B patients receiving entecavir or tenofovir.
Topics: Adult; Antiviral Agents; Asian People; Carcinoma, Hepatocellular; Cohort Studies; Female; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Middle Aged; Models, Theoretical; Risk Assessment; Tenofovir | 2017 |
A different inhibitor is required for overcoming entecavir resistance: a comparison of four rescue therapies in a retrospective study.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Practice Guidelines as Topic; Retrospective Studies; Tenofovir; Treatment Outcome; Viral Load | 2017 |
The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Europe; Female; Guanine; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Male; Middle Aged; Risk Factors; Tenofovir; White People | 2017 |
Effects of Entecavir and Tenofovir on Renal Function in Patients with Hepatitis B Virus-Related Compensated and Decompensated Cirrhosis.
Topics: Antiviral Agents; Female; Glomerular Filtration Rate; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kidney; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Retrospective Studies; Seoul; Tenofovir; Treatment Outcome | 2017 |
Efficacy of tenofovir-based rescue therapy for chronic hepatitis B patients with resistance to lamivudine and entecavir.
Topics: Adult; Aged; Antiviral Agents; Area Under Curve; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Proportional Hazards Models; ROC Curve; Tenofovir; Treatment Outcome | 2017 |
Tenofovir disoproxil fumarate significantly decreases serum lipoprotein levels compared with entecavir nucleos(t)ide analogue therapy in chronic hepatitis B carriers.
Topics: Aged; Antiviral Agents; Cohort Studies; Female; Guanine; Hepatitis B, Chronic; Humans; Lipoproteins; Male; Middle Aged; Propensity Score; Retrospective Studies; Tenofovir; Treatment Outcome | 2017 |
Lactate serum concentrations during treatment with nucleos(t)ide analogues in hepatitis B with or without cirrhosis.
Topics: Acidosis, Lactic; Adenine; Adult; Aged; Aged, 80 and over; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Guanine; Hepatitis B, Chronic; Humans; Lactic Acid; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Organophosphonates; Prospective Studies; Risk Factors; Sex Factors; Tenofovir; Time Factors; Treatment Outcome; Up-Regulation; Young Adult | 2017 |
A long-term multicenter study: Entecavir versus Tenofovir in treatment of nucleos(t)ide analogue-naive chronic hepatitis B patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Middle Aged; Nucleosides; Retrospective Studies; Tenofovir; Time Factors; Treatment Outcome; Young Adult | 2018 |
Is tenofovir monotherapy a sufficient defense line against multi-drug resistant hepatitis B virus?
Topics: Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Tenofovir | 2017 |
[Effect of clinical first-line Antiviral Agents on outcome of chronic hepatitis B treatment].
Topics: Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Liver Cirrhosis; Liver Neoplasms; Tenofovir; Treatment Outcome | 2017 |
Tenofovir, entecavir, and lamivudine in patients with severe acute exacerbation and hepatic decompensation of chronic hepatitis B.
Topics: Adult; Antiviral Agents; Disease Progression; DNA, Viral; Drug Resistance, Viral; End Stage Liver Disease; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Transplantation; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Republic of Korea; ROC Curve; Severity of Illness Index; Tenofovir; Treatment Outcome | 2018 |
Temporal trend and risk determinants of hepatocellular carcinoma in chronic hepatitis B patients on entecavir or tenofovir.
Topics: Adult; Age Factors; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Comorbidity; Female; Follow-Up Studies; Guanine; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Male; Middle Aged; Risk Assessment; Sex Factors; Taiwan; Tenofovir | 2018 |
Nucleic acid polymer REP 2139 and nucleos(T)ide analogues act synergistically against chronic hepadnaviral infection in vivo in Pekin ducks.
Topics: Animals; Antiviral Agents; Chronic Disease; Drug Synergism; Drug Therapy, Combination; Ducks; Guanine; Hepadnaviridae Infections; Hepatitis B Virus, Duck; Hepatitis, Viral, Animal; Nucleic Acids; Polymers; Tenofovir | 2018 |
High levels of serum Mac-2-binding protein glycosylation isomer (M2BPGi) predict the development of hepatocellular carcinoma in hepatitis B patients treated with nucleot(s)ide analogues.
Topics: Adult; alpha-Fetoproteins; Antigens, Neoplasm; Antiviral Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Carrier Proteins; Female; Follow-Up Studies; Glycoproteins; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Incidence; Japan; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Research Design; Retrospective Studies; Sex Factors; Tenofovir | 2018 |
Distinct Relapse Rates and Risk Predictors After Discontinuing Tenofovir and Entecavir Therapy.
Topics: Adult; Antiviral Agents; DNA, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Prospective Studies; Recurrence; Risk Factors; Tenofovir | 2018 |
Assessment of bone mineral density in patients with cirrhosis treated with third-generation nucleos(t)ide analogues: comparison between tenofovir and entecavir.
Topics: Absorptiometry, Photon; Adolescent; Adult; Aged; Antiviral Agents; Bone Density; Female; Guanine; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Osteoporosis; Osteoporotic Fractures; Parathyroid Hormone; Prospective Studies; Risk Assessment; Tenofovir; Vitamin D Deficiency; Young Adult | 2018 |
Entecavir and tenofovir reduce hepatitis B virus-related hepatocellular carcinoma recurrence more effectively than other antivirals.
Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Guanine; Hepatitis B, Chronic; Humans; Male; Middle Aged; Secondary Prevention; Tenofovir; Treatment Outcome | 2018 |
Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Follow-Up Studies; Guanine; Hepatitis B, Chronic; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Tenofovir | 2018 |
Utilization of hepatitis B core antibody positive grafts in living donor liver transplantation.
Topics: Adolescent; Adult; Antiviral Agents; Female; Guanine; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Core Antigens; Hepatitis B virus; Humans; Immunosuppressive Agents; Lamivudine; Liver Transplantation; Living Donors; Male; Middle Aged; Postoperative Complications; Retrospective Studies; Risk; Tenofovir; Transplants; Virus Activation; Young Adult | 2018 |
Role of hepatitis B surface antigen in hepatitis B virus relapse after entecavir or tenofovir prophylaxis in patients undergoing cancer chemotherapy.
Topics: Adult; Aged; Biomarkers; Female; Follow-Up Studies; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasms; Predictive Value of Tests; Recurrence; Secondary Prevention; Tenofovir; Time Factors | 2018 |
Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Data Accuracy; Female; Guanine; Hepatitis B, Chronic; Hong Kong; Humans; Incidence; Liver Neoplasms; Male; Middle Aged; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Research Design; Risk Assessment; Risk Factors; Taiwan; Tenofovir | 2018 |
Tenofovir Versus Entecavir for the Treatment of Acute-on-Chronic Liver Failure due to Reactivation of Chronic Hepatitis B With Genotypes B and C.
Topics: Acute-On-Chronic Liver Failure; Adult; Aged; Antiviral Agents; DNA, Viral; Female; Genotype; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Tenofovir; Treatment Outcome; Virus Activation; Young Adult | 2019 |
To use entecavir, tenofovir disoproxil fumarate or tenofovir alafenamide: it's all about choosing the right patient!
Topics: Adenine; Alanine; Anti-HIV Agents; Guanine; HIV Infections; Humans; Tenofovir | 2018 |
Deleterious role of hepatitis B virus infection in therapeutic response among patients with rheumatoid arthritis in a clinical practice setting: a case-control study.
Topics: Adult; Antirheumatic Agents; Antiviral Agents; Arthritis, Rheumatoid; Case-Control Studies; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Logistic Models; Male; Middle Aged; Outcome Assessment, Health Care; Remission Induction; Retrospective Studies; Severity of Illness Index; Tenofovir | 2018 |
Entecavir or tenofovir monotherapy prevents HBV recurrence in liver transplant recipients: A 5-year follow-up study after hepatitis B immunoglobulin withdrawal.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Drug Therapy, Combination; Female; Follow-Up Studies; Guanine; Hepatitis B; Hepatitis B Surface Antigens; Humans; Immunoglobulins; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Recurrence; Retrospective Studies; Tenofovir; Young Adult | 2018 |
Normal on-treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Cohort Studies; DNA, Viral; Female; Guanine; Hepatitis B, Chronic; Humans; Male; Middle Aged; Tenofovir | 2018 |
Successful Management of De Novo Acute Hepatitis B Virus Infection With Entecavir in a Living-Donor Liver Transplant Patient.
Topics: Adult; Antiviral Agents; Drug Substitution; Guanine; Hepatitis B; Hepatitis B virus; Humans; Immunocompromised Host; Immunosuppressive Agents; Liver Transplantation; Living Donors; Male; Tenofovir; Time Factors; Treatment Outcome | 2018 |
Changes in Liver Tissue Trace Element Concentrations During Hepatitis B Viral Infection Treatment.
Topics: Adult; Antiviral Agents; Biopsy; Female; Fibrosis; Guanine; Hepatitis B; Humans; Lamivudine; Liver; Liver Function Tests; Male; Middle Aged; Telbivudine; Tenofovir; Trace Elements; Young Adult | 2019 |
Mortality, liver transplantation and hepatic complications in patients with treatment-naïve chronic hepatitis B treated with entecavir vs tenofovir.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B, Chronic; Humans; Korea; Liver Failure; Liver Transplantation; Longitudinal Studies; Male; Middle Aged; Survival Analysis; Tenofovir; Treatment Outcome; Young Adult | 2018 |
Long-term results of chronic hepatitis B antiviral treatment with nucleos(t)ide analogues: a single center experience.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Female; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Telbivudine; Tenofovir; Young Adult | 2019 |
DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B.
Topics: Adult; Aged; Female; Follow-Up Studies; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Function Tests; Male; Middle Aged; Proportional Hazards Models; Recurrence; Retreatment; Tenofovir; Treatment Outcome; Viral Load | 2018 |
Risk of renal events during tenofovir disoproxil fumarate and entecavir antiviral prophylaxis in HBsAg-positive cancer patients undergoing chemotherapy.
Topics: Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Antiviral Agents; Chemoprevention; Drug-Related Side Effects and Adverse Reactions; Female; Guanine; Hepatitis B; Hepatitis B Surface Antigens; Humans; Incidence; Male; Middle Aged; Neoplasms; Retrospective Studies; Risk Assessment; Tenofovir | 2018 |
Chronic kidney disease progression in patients with chronic hepatitis B on tenofovir, entecavir, or no treatment.
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Disease Progression; Female; Glomerular Filtration Rate; Guanine; Hepatitis B, Chronic; Humans; Middle Aged; Registries; Renal Insufficiency, Chronic; Tenofovir; Treatment Outcome | 2018 |
Changes in Renal Function in Patients With Chronic HBV Infection Treated With Tenofovir Disoproxil Fumarate vs Entecavir.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Biostatistics; Creatinine; Female; Glomerular Filtration Rate; Guanine; Hepatitis B, Chronic; Humans; Longitudinal Studies; Male; Middle Aged; Renal Insufficiency; Retrospective Studies; Tenofovir | 2019 |
Regulation of human placental drug transporters in HCV infection and their influence on direct acting antiviral medications.
Topics: Antiviral Agents; ATP-Binding Cassette Transporters; Biological Transport; Female; Guanine; Hepatitis C; Humans; Placenta; Pregnancy; Sofosbuvir; Solute Carrier Proteins; Tenofovir; Trophoblasts | 2018 |
Tenofovir vs Entecavir for Hepatocellular Carcinoma Prevention in Patients With Chronic Hepatitis B: One of These Things Is Not Like the Other.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Republic of Korea; Tenofovir | 2019 |
Risk of Hepatocellular Carcinoma in Patients Treated With Entecavir vs Tenofovir for Chronic Hepatitis B: A Korean Nationwide Cohort Study.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Cause of Death; Databases, Factual; Female; Guanine; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Protective Factors; Republic of Korea; Risk Factors; Tenofovir; Time Factors; Treatment Outcome | 2019 |
Assessment of histopathological alterations in patients with chronic hepatitis B infection following long-term oral antiviral therapy.
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Female; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Liver; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Tenofovir | 2018 |
HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Female; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hong Kong; Humans; Liver Neoplasms; Male; Middle Aged; Outcome and Process Assessment, Health Care; Retrospective Studies; Risk Assessment; Seroepidemiologic Studies; Sustained Virologic Response; Tenofovir | 2019 |
Genotype Matters in Patients with Acute-on-chronic Liver Failure Due to Reactivation of Chronic Hepatitis B.
Topics: Acute-On-Chronic Liver Failure; Adult; Aged; Antiviral Agents; DNA, Viral; Female; Follow-Up Studies; Genotype; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Prospective Studies; Tenofovir; Viral Load; Virus Activation; Young Adult | 2018 |
Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir.
Topics: Adult; Antiviral Agents; Fatty Liver; Female; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Sustained Virologic Response; Tenofovir; Treatment Outcome | 2019 |
Chronic hepatitis B genotype E in African migrants: response to nucleos(t)ide treatment in real clinical practice.
Topics: Adult; Africa South of the Sahara; Antiviral Agents; Drug Resistance, Viral; Female; Genotype; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Nucleosides; Nucleotides; Practice Patterns, Physicians'; Spain; Tenofovir; Transients and Migrants; Treatment Outcome; Viral Load | 2018 |
Combining hepatitis B core-related and surface antigens at end of nucleos(t)ide analogue treatment to predict off-therapy relapse risk.
Topics: Adult; Antiviral Agents; Biomarkers; DNA, Viral; Female; Guanine; Hepatitis B Core Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Incidence; Male; Middle Aged; Prospective Studies; Recurrence; Tenofovir; Withholding Treatment | 2019 |
Hepatitis B virus relapse rates in chronic hepatitis B patients who discontinue either entecavir or tenofovir.
Topics: Adult; Antiviral Agents; Female; Guanine; Hepatitis B, Chronic; Humans; Male; Medication Adherence; Middle Aged; Prospective Studies; Recurrence; Retrospective Studies; Tenofovir; Viral Load; Young Adult | 2019 |
Letter: chronic kidney disease risk in patients with chronic hepatitis B-authors' reply.
Topics: Guanine; Hepatitis B; Hepatitis B, Chronic; Humans; Renal Insufficiency, Chronic; Tenofovir | 2018 |
Letter: chronic kidney disease risk in patients with chronic hepatitis B.
Topics: Guanine; Hepatitis B, Chronic; Humans; Renal Insufficiency, Chronic; Tenofovir | 2018 |
How does hepatic steatosis affect the outcome of patients with chronic hepatitis B?
Topics: Fatty Liver; Guanine; Hepatitis B, Chronic; Humans; Tenofovir | 2019 |
Prediction model for hepatocellular carcinoma risk in treatment-naive chronic hepatitis B patients receiving entecavir/tenofovir.
Topics: Adult; Age Factors; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Guanine; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Proportional Hazards Models; Reproducibility of Results; Risk Assessment; Serum Albumin; Sex Factors; Tenofovir | 2019 |
Antiviral therapy and the development of osteopenia/osteoporosis among Asians with chronic hepatitis B.
Topics: Adult; Antiviral Agents; Asian People; Bone Diseases, Metabolic; Female; Follow-Up Studies; Guanine; Hepatitis B, Chronic; Humans; Incidence; Male; Middle Aged; Osteoporosis; Proportional Hazards Models; Retrospective Studies; Tenofovir; Treatment Outcome; United States | 2019 |
Clinical outcomes in patients with hepatitis D, cirrhosis and persistent hepatitis B virus replication, and receiving long-term tenofovir or entecavir.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Guanine; Hepatitis B; Hepatitis B virus; Hepatitis D, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Prospective Studies; Tenofovir; Treatment Outcome | 2019 |
Letter: distinct hepatitis B virus relapse rates after discontinuing tenofovir and entecavir therapy in chronic hepatitis B patients.
Topics: Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Recurrence; Tenofovir | 2019 |
Letter: distinct hepatitis B virus relapse rates after discontinuing tenofovir and entecavir therapy in chronic hepatitis B patients-author's reply.
Topics: Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Recurrence; Tenofovir | 2019 |
A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Genotype; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Prognosis; Propensity Score; Republic of Korea; Retrospective Studies; Tenofovir; Treatment Outcome | 2019 |
Efficacy of tenofovir and entecavir in patients who relapsed after pegylated interferon therapy.
Topics: Adult; Antiviral Agents; DNA, Viral; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Tenofovir; Treatment Outcome; Viral Load | 2019 |
Lower Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Republic of Korea; Tenofovir | 2019 |
Lower Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B-in Reply.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Republic of Korea; Tenofovir | 2019 |
Lower Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Republic of Korea; Tenofovir | 2019 |
Lower Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Republic of Korea; Tenofovir | 2019 |
Long-term Nucleotide Analogue Treatment Has Higher Levels of Renal Toxicities than Does Entecavir in Patients with Chronic Hepatitis B.
Topics: Adenine; Adult; Aged; Antiviral Agents; Chemical and Drug Induced Liver Injury; Female; Glomerular Filtration Rate; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Incidence; Male; Middle Aged; Nucleotides; Organophosphonates; Proportional Hazards Models; Retrospective Studies; Tenofovir; Time Factors; Treatment Outcome | 2020 |
Efficacy and safety of long-term therapy with nucleos(t)ide analogues in chronic hepatitis B.
Topics: Antiviral Agents; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Nucleic Acid Synthesis Inhibitors; Telbivudine; Tenofovir; Time Factors; Treatment Outcome | 2019 |
A case of entecavir-induced Fanconi syndrome.
Topics: Acidosis; Acute Kidney Injury; Adenine; Aged; Alanine; Antiviral Agents; Fanconi Syndrome; Guanine; Hepatitis B, Chronic; Humans; Hypokalemia; Hypophosphatemia; Male; Nucleosides; Tenofovir; Treatment Outcome; Withholding Treatment | 2019 |
Residual risk of HCC during long-term oral nucleos(t)ide analogues (NUCs) in patients with CHB - Is one NUC better than the other?
Topics: Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Prognosis; Republic of Korea; Tenofovir | 2019 |
Minimal increases of serum alpha-foetoprotein herald HCC detection in Caucasian HBV cirrhotic patients under long-term oral therapy.
Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B, Chronic; Humans; Italy; Liver Cirrhosis; Liver Neoplasms; Longitudinal Studies; Male; Middle Aged; Tenofovir; Young Adult | 2019 |
Comparison of risk of hepatocellular carcinoma between tenofovir and entecavir: One direction or no direction.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Prognosis; Republic of Korea; Tenofovir | 2019 |
Letter: clinical outcomes after long-term entecavir or tenofovir treatment in patients with hepatitis D and advanced fibrosis.
Topics: Guanine; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis D; Humans; Liver Cirrhosis; Tenofovir; Virus Replication | 2019 |
Reply to: "Comparison of risk of hepatocellular carcinoma between tenofovir and entecavir: One direction or no direction".
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Prognosis; Republic of Korea; Tenofovir | 2019 |
Investigation of hepatitis B virus (HBV) rtS78T/sC69* mutation in a large cohort of chronic HBV-infected patients with nucleoside/nucleotide analogue treatment.
Topics: Adult; Antiviral Agents; Cohort Studies; DNA, Viral; Drug Resistance, Multiple, Viral; Female; Genotype; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Mutation; Nucleosides; RNA-Directed DNA Polymerase; Tenofovir; Viral Proteins | 2019 |
Effectiveness of tenofovir and entecavir in nucleos(t)ide analogue-naive chronic hepatitis B: A protocol for systematic review and meta-analysis.
Topics: Antiviral Agents; Guanine; Hepatitis B, Chronic; Humans; Meta-Analysis as Topic; Systematic Reviews as Topic; Tenofovir | 2019 |
Clinical factors leading to a change in management in chronic hepatitis B patients managed in a tertiary setting.
Topics: Adult; Antiviral Agents; Costs and Cost Analysis; Disease Management; DNA, Viral; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Tenofovir | 2020 |
Entecavir resistance mutations rtL180M/T184L/M204V combined with rtA200V lead to tenofovir resistance.
Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Middle Aged; Mutation; RNA-Directed DNA Polymerase; Tenofovir; Viral Proteins | 2020 |
Immunomodulatory Mechanism of Acyclic Nucleoside Phosphates in Treatment of Hepatitis B Virus Infection.
Topics: Adenine; Adult; Aged; Antiviral Agents; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunomodulation; Interferon-alpha; Interleukin-10; Interleukin-12; Lamivudine; Leukocytes, Mononuclear; Lipopolysaccharides; Male; Nucleosides; Organophosphonates; Proto-Oncogene Proteins c-akt; Tenofovir | 2020 |
Tenofovir is a more suitable treatment than entecavir for chronic hepatitis B patients carrying naturally occurring rtM204I mutations.
Topics: Adult; DNA Mutational Analysis; DNA Probes; DNA, Viral; Drug Resistance, Viral; Feasibility Studies; Female; Gene Products, pol; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Mutation; Oligonucleotides; Real-Time Polymerase Chain Reaction; Retrospective Studies; Tenofovir | 2019 |
First line nucleos(t)ide analog monotherapy is more cost-effective than combination strategies in hepatitis B e antigen-positive chronic hepatitis B patients in China.
Topics: Antiviral Agents; Cost-Benefit Analysis; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Markov Chains; Tenofovir | 2019 |
Tenofovir Is Associated With Lower Risk of Hepatocellular Carcinoma Than Entecavir in Patients With Chronic HBV Infection in China.
Topics: Adult; Aftercare; Antiviral Agents; Carcinoma, Hepatocellular; China; Disease Progression; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Incidence; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Tenofovir; Treatment Outcome | 2020 |
Incidence and predictors of retreatment in chronic hepatitis B patients after discontinuation of entecavir or tenofovir treatment.
Topics: Adult; Antiviral Agents; Female; Follow-Up Studies; Guanine; Hepatitis B, Chronic; Humans; Incidence; Male; Middle Aged; Prospective Studies; Recurrence; Retreatment; Retrospective Studies; Taiwan; Tenofovir; Treatment Outcome; Withholding Treatment | 2019 |
Tenofovir monotherapy versus tenofovir plus entecavir combination therapy in HBeAg-positive chronic hepatitis patients with partial virological response to entecavir.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Creatinine; DNA, Viral; Drug Therapy, Combination; Female; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Tenofovir; Treatment Outcome; Young Adult | 2020 |
Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis B.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; China; Cohort Studies; Disease Progression; Female; Guanine; Hepatitis B, Chronic; Hong Kong; Humans; International Cooperation; Japan; Liver Neoplasms; Male; Middle Aged; Proportional Hazards Models; Republic of Korea; Retrospective Studies; Taiwan; Tenofovir; Treatment Outcome; United States | 2020 |
Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naïve patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cause of Death; Female; Guanine; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Propensity Score; Republic of Korea; Risk; Tenofovir | 2020 |
Pregenomic HBV RNA and Hepatitis B Core-Related Antigen Predict Outcomes in Hepatitis B e Antigen-Negative Chronic Hepatitis B Patients Suppressed on Nucleos(T)ide Analogue Therapy.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Biomarkers; Female; Guanine; Hepatitis B Core Antigens; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Nucleosides; Predictive Value of Tests; Retrospective Studies; RNA; RNA, Viral; Tenofovir; Treatment Outcome; Young Adult | 2020 |
Comments on 'Entecavir resistance mutations rtL180M/T184L/M204V combined with rtA200V lead to tenofovir resistance'.
Topics: Guanine; Hepatitis B, Chronic; Humans; Mutation; Tenofovir | 2020 |
Is Tenofovir Superior to Entecavir in Reducing the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B? The Controversy Continues.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; China; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Tenofovir | 2020 |
Reply to: "Comment on - A multi-center study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in the Republic of Korea".
Topics: Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Prognosis; Republic of Korea; Tenofovir | 2020 |
Comment on - A multi-center study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in the Republic of Korea.
Topics: Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Prognosis; Republic of Korea; Tenofovir | 2020 |
Significance of switching of the nucleos(t)ide analog used to treat Japanese patients with chronic hepatitis B virus infection from entecavir to tenofovir alafenamide fumarate.
Topics: Adenine; Aged; Alanine; Antibodies, Viral; Antiviral Agents; Female; Fumarates; Genotype; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Japan; Male; Medication Adherence; Middle Aged; Multivariate Analysis; Surveys and Questionnaires; Tenofovir; Transaminases; Treatment Outcome | 2020 |
Response to comments on: Entecavir resistance mutations rtL180M/T184L/M204V combined with rtA200V lead to tenofovir resistance.
Topics: Guanine; Hepatitis B, Chronic; Humans; Mutation; Tenofovir | 2020 |
Tenofovir may be superior to entecavir for preventing hepatocellular carcinoma and mortality in individuals chronically infected with HBV: a meta-analysis.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Propensity Score; Republic of Korea; Tenofovir | 2020 |
Tenofovir for the Prevention of HCC in Patients With Cirrhosis.
Topics: Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Tenofovir | 2020 |
Reassessing the accuracy of PAGE-B-related scores to predict hepatocellular carcinoma development in patients with chronic hepatitis B.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Hong Kong; Humans; Incidence; Liver Neoplasms; Male; Middle Aged; Prognosis; Research Design; Retrospective Studies; Risk Assessment; Risk Factors; Serologic Tests; Tenofovir | 2020 |
Model for End-Stage Liver Disease With Additional Criteria to Predict Short-Term Mortality in Severe Flares of Chronic Hepatitis B.
Topics: Acute-On-Chronic Liver Failure; Antiviral Agents; End Stage Liver Disease; Female; Guanine; Hepatitis B, Chronic; Hong Kong; Humans; Liver Function Tests; Male; Middle Aged; Patient Selection; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Severity of Illness Index; Tenofovir | 2020 |
Letter: is tenofovir superior to entecavir for hepatocellular carcinoma prevention in chronic hepatitis B?
Topics: Carcinoma, Hepatocellular; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis D; Humans; Liver Cirrhosis; Liver Neoplasms; Tenofovir; Virus Replication | 2020 |
Letter: is tenofovir superior to entecavir for hepatocellular carcinoma prevention in chronic hepatitis B? Authors' reply.
Topics: Carcinoma, Hepatocellular; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis D; Humans; Liver Cirrhosis; Liver Neoplasms; Tenofovir; Virus Replication | 2020 |
Earlier Alanine Aminotransferase Normalization During Antiviral Treatment Is Independently Associated With Lower Risk of Hepatocellular Carcinoma in Chronic Hepatitis B.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Risk; Tenofovir; Treatment Outcome | 2020 |
Inhibitory Effect of Nucleos(t)ide Analogs on Telomerase Activity and Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Telomerase; Tenofovir | 2020 |
The Administration of Tenofovir Disoproxil Fumarate for Pregnant Japanese Women with Chronic Hepatitis B.
Topics: Adult; Antiviral Agents; Child; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Japan; Male; Mothers; Pregnancy; Pregnancy Complications; Prenatal Care; Tenofovir; Viral Load | 2020 |
Validation of hepatocellular carcinoma risk scores in Japanese chronic hepatitis B cohort receiving nucleot(s)ide analog.
Topics: Adenine; Adult; Alanine; Antiviral Agents; Asian People; Carcinoma, Hepatocellular; Cohort Studies; Female; Guanine; Hepatitis B, Chronic; Humans; Japan; Liver Neoplasms; Male; Middle Aged; Nucleotides; Platelet Count; Research Design; Risk; Tenofovir; Time Factors | 2020 |
Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B.
Topics: Administration, Oral; Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Female; Follow-Up Studies; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Incidence; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Risk Factors; Tenofovir; Treatment Outcome; White People; Young Adult | 2020 |
Hepatocellular Carcinoma Risk Steadily Persists over Time Despite Long-Term Antiviral Therapy for Hepatitis B: A Multicenter Study.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Incidence; Liver; Liver Neoplasms; Male; Middle Aged; Molecular Typing; Republic of Korea; Risk Adjustment; Risk Factors; Tenofovir; Time Factors | 2020 |
Comparison of medication adherence and satisfaction between entecavir and tenofovir alafenamide therapy in chronic hepatitis B.
Topics: Antiviral Agents; Drug Substitution; Guanine; Hepatitis B, Chronic; Humans; Medication Adherence; Patient Satisfaction; Retrospective Studies; Surveys and Questionnaires; Tenofovir | 2020 |
Does regression in treatment-induced liver fibrosis reflect noninvasive tests? Assessing treatment results of hepatitis B patients who took potent antiviral drugs for 5 years.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Biomarkers; Biopsy; Blood Platelets; Female; Guanine; Hepatitis B, Chronic; Humans; Liver; Liver Cirrhosis; Male; Mean Platelet Volume; Middle Aged; Platelet Count; Retrospective Studies; RNA, Viral; Tenofovir; Treatment Outcome | 2020 |
Factors associated with improvement in MELD score after antiviral treatment in patients with chronic hepatitis B.
Topics: Age Factors; Aged; Alanine Transaminase; Antiviral Agents; Female; Guanine; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Liver Failure; Male; Middle Aged; Research Design; Retrospective Studies; Serum Albumin; Survival Rate; Tenofovir; Treatment Outcome | 2020 |
Tenofovir versus entecavir in prevention of hepatocellular carcinoma and mortality in patients with chronic hepatitis B.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Propensity Score; Republic of Korea; Tenofovir | 2020 |
Optimal drug administration manner would rescue partial virological response in chronic hepatitis B patients with entecavir or tenofovir treatment.
Topics: Antiviral Agents; DNA, Viral; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Tenofovir; Treatment Outcome; Viral Load | 2020 |
[Evaluation of Histological Response in Chronic Hepatitis B Patients with Tenofovir or Entecavir Therapy].
Topics: Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver; Retrospective Studies; Tenofovir; Treatment Outcome; Turkey | 2020 |
Hepatitis B core antibody and liver stiffness measurements predict HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients with minimally elevated alanine aminotransferase (ALT) levels.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Biomarkers; Elasticity Imaging Techniques; Female; Guanine; Hepatitis B Antibodies; Hepatitis B, Chronic; Humans; Liver; Male; Prospective Studies; Seroconversion; Telbivudine; Tenofovir | 2020 |
No Difference in Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Virus Infection Treated With Entecavir vs Tenofovir.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Retrospective Studies; Tenofovir; Treatment Outcome | 2020 |
Comparison of the on-treatment risks for hepatocellular carcinoma between entecavir and tenofovir: A propensity score matching analysis.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Middle Aged; Propensity Score; Retrospective Studies; Risk; Tenofovir | 2020 |
Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; China; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Tenofovir | 2020 |
Is Tenofovir Associated with a Lower Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Compared With Entecavir?
Topics: Antiviral Agents; Carcinoma, Hepatocellular; China; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Tenofovir | 2020 |
Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Female; Follow-Up Studies; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Neoplasms; Male; Middle Aged; Sustained Virologic Response; Tenofovir | 2020 |
No difference in hepatocellular carcinoma risk between chronic hepatitis B patients treated with entecavir versus tenofovir.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Middle Aged; Propensity Score; Proportional Hazards Models; Retrospective Studies; Risk Factors; Tenofovir | 2021 |
Reply.
Topics: Carcinoma, Hepatocellular; China; Guanine; Hepatitis B virus; Humans; Liver Neoplasms; Tenofovir | 2020 |
Comparison of the impact of tenofovir alafenamide and entecavir on declines of hepatitis B surface antigen levels.
Topics: Alanine; Antiviral Agents; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Tenofovir; Treatment Outcome | 2021 |
Renal safety of tenofovir disoproxil fumarate and entecavir with hepatitis B immunoglobulin in liver transplant patients.
Topics: Antiviral Agents; Guanine; Hepatitis Antibodies; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Transplantation; Tenofovir; Treatment Outcome | 2020 |
Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
Topics: Adenine; Alanine; Antiviral Agents; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Retrospective Studies; Tenofovir; Treatment Outcome | 2020 |
Cumulative incidence of hepatocellular carcinoma and hepatitis B surface antigen Seroclearance after Nucleos(t) ide analogue-induced hepatitis B e antigen Seroclearance.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Tenofovir; Young Adult | 2020 |
Tenofovir Versus Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma After Surgical Resection.
Topics: Aged; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease-Free Survival; Follow-Up Studies; Guanine; Hepatectomy; Hepatitis B, Chronic; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Retrospective Studies; Tenofovir | 2021 |
Associations of HBV Genotype B vs C Infection With Relapse After Cessation of Entecavir or Tenofovir Therapy.
Topics: Antiviral Agents; DNA, Viral; Genotype; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Neoplasm Recurrence, Local; Retrospective Studies; Tenofovir; Treatment Outcome | 2020 |
Incidence and Factors Associated With HBV Relapse After Cessation of Entecavir or Tenofovir in Patients With HBsAg Below 100 IU/mL.
Topics: Antigens, Surface; Antiviral Agents; DNA, Viral; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Incidence; Recurrence; Tenofovir; Treatment Outcome | 2020 |
HBV flare associated with immunosuppressive treatments: it is still dangerous in the third-generation antivirals era.
Topics: Alanine Transaminase; Antiviral Agents; Female; Guanine; Hepatitis B; Humans; Immunosuppressive Agents; Liver Transplantation; Male; Middle Aged; Retrospective Studies; Symptom Flare Up; Tenofovir | 2020 |
Entecavir and tenofovir on renal function in patients with hepatitis B virus-related hepatocellular carcinoma.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Creatinine; Female; Glomerular Filtration Rate; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kidney; Kidney Function Tests; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Tenofovir; Treatment Outcome | 2020 |
Comparison of tenofovir and entecavir in the development of acute kidney injury in cirrhotic chronic hepatitis B patients with refractory ascites.
Topics: Acute Kidney Injury; Antiviral Agents; Ascites; Guanine; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Retrospective Studies; Tenofovir; Treatment Outcome | 2021 |
Predictive score for hepatocellular carcinoma after hepatitis B e antigen loss in patients treated with entecavir or tenofovir.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Tenofovir | 2020 |
Comparative efficacy of the front-line anti-HBV drugs in nucleos(t)ide analogue-naive chronic hepatitis B: A protocol for systematic review and network meta-analysis.
Topics: Antiviral Agents; Guanine; Hepatitis B; Hepatitis B virus; Humans; Meta-Analysis as Topic; Patient Selection; Randomized Controlled Trials as Topic; Systematic Reviews as Topic; Tenofovir | 2020 |
High Risk of Clinical Relapse in Patients With Chronic Hepatitis B Virus Infection After Cessation of Prophylactic Antiviral Therapy for Rituximab-Containing Chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Antiviral Agents; DNA, Viral; Female; Guanine; Hematologic Neoplasms; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Failure; Male; Middle Aged; Recurrence; Retrospective Studies; Risk Factors; Rituximab; Tenofovir; Viral Load; Virus Activation; Withholding Treatment; Young Adult | 2020 |
Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Elasticity Imaging Techniques; Female; Follow-Up Studies; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Incidence; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Risk Assessment; Tenofovir; White People | 2020 |
Treatment with tenofovir disoproxil fumarate or entecavir in chronic hepatitis B virus-infected patients with renal impairment: results from a 7-year, multicentre retrospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Female; Guanine; Hepatitis B, Chronic; Humans; Male; Middle Aged; Renal Insufficiency; Retrospective Studies; Tenofovir; Treatment Outcome; Young Adult | 2020 |
The Risk of Acute Kidney Injury in Hepatitis B Virus-Related Acute on Chronic Liver Failure with Tenofovir Treatment.
Topics: Acute Kidney Injury; Acute-On-Chronic Liver Failure; Adult; Antiviral Agents; Female; Guanine; Hepatitis B; Humans; Male; Middle Aged; Retrospective Studies; Risk Factors; Tenofovir; Treatment Outcome | 2020 |
REPLY.
Topics: Carcinoma, Hepatocellular; Guanine; Hepatitis B virus; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Tenofovir | 2021 |
Letter to the Editor: Re: Tenofovir Versus Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma After Surgical Resection.
Topics: Carcinoma, Hepatocellular; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Tenofovir | 2021 |
REPLY.
Topics: Carcinoma, Hepatocellular; Guanine; Hepatitis B virus; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Tenofovir | 2021 |
Nucleoside analogs assisted with Chinese compound prescription in treating hepatic fibrosis of chronic hepatitis B patients: A protocol of systematic review and meta-analysis.
Topics: Antiviral Agents; China; Databases, Factual; DNA Viruses; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Guanine; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Liver Function Tests; Male; Meta-Analysis as Topic; Nucleosides; Quality of Life; Randomized Controlled Trials as Topic; Systematic Review as Topic; Tenofovir | 2020 |
Is tenofovir and entecavir combination therapy still the optimal treatment for chronic hepatitis B patients with prior suboptimal response?
Topics: Adenine; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Organophosphonates; Telbivudine; Tenofovir | 2020 |
Application of EASL 2017 criteria for switching hepatitis B patients from tenofovir disoproxil to entecavir or tenofovir alafenamide.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Comorbidity; Drug Resistance, Viral; Female; Guanine; Hepatitis B, Chronic; Humans; Male; Middle Aged; Practice Guidelines as Topic; Retrospective Studies; Tenofovir | 2020 |
Hepatocellular carcinoma and death and transplantation in chronic hepatitis B treated with entecavir or tenofovir disoproxil fumarate.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Female; Follow-Up Studies; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Retrospective Studies; Survival Rate; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2020 |
Is tenofovir more effective than entecavir to prevent hepatocellular carcinoma? The controversy goes on.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Humans; Liver Neoplasms; Tenofovir | 2020 |
Editorial: tenofovir disoproxil fumarate vs entecavir in patients with chronic hepatitis B and renal impairment-still an open issue.
Topics: Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Retrospective Studies; Tenofovir | 2020 |
Optimal drug administration manner would rescue partial virological response in chronic hepatitis B patients with entecavir or tenofovir treatment: Methodological issues.
Topics: Guanine; Hepatitis B, Chronic; Humans; Pharmaceutical Preparations; Tenofovir | 2020 |
Rely to: 'Optimal drug administration manner would rescue partial virological response in chronic hepatitis B patients with entecavir or tenofovir treatment: Methodological issues'.
Topics: Guanine; Hepatitis B, Chronic; Humans; Pharmaceutical Preparations; Tenofovir | 2021 |
Reply to: "Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B".
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Tenofovir | 2021 |
Hepatocellular carcinoma risk with antivirals for chronic hepatitis B: no longer confounding.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Tenofovir | 2020 |
Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Tenofovir | 2021 |
Letter to the Editor: Tenofovir vs. Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma After Surgical Resection.
Topics: Carcinoma, Hepatocellular; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Tenofovir | 2021 |
Validation of risk prediction scores for hepatocellular carcinoma in patients with chronic hepatitis B treated with entecavir or tenofovir.
Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B, Chronic; Humans; Infant, Newborn; Liver Neoplasms; Male; Retrospective Studies; Tenofovir | 2021 |
HCC risk reduction with oral nucleos(t)ide analogues in patients with chronic hepatitis B: Not perfect, not good enough.
Topics: Adenine; Administration, Oral; Alanine; Carcinoma, Hepatocellular; DNA, Viral; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Nucleotides; Tenofovir | 2020 |
Five-year comparative risk of hepatocellular carcinoma development under entecavir or tenofovir treatment-naïve patients with chronic hepatitis B-related compensated cirrhosis in Taiwan.
Topics: Adult; Aged; alpha-Fetoproteins; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Guanine; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Longitudinal Studies; Male; Middle Aged; Retrospective Studies; Taiwan; Tenofovir | 2020 |
HBV RNA Profiles in Patients With Chronic Hepatitis B Under Different Disease Phases and Antiviral Therapy.
Topics: Adult; Antiviral Agents; Biomarkers; Female; Guanine; Hepatitis B Core Antigens; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hong Kong; Humans; Male; Middle Aged; RNA, Viral; Tenofovir; Treatment Outcome | 2021 |
Additional more factors should be included in predicting risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.
Topics: Carcinoma, Hepatocellular; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Liver Neoplasms; Tenofovir | 2021 |
Authors' response: Additional more factors should be included in predicting risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.
Topics: Carcinoma, Hepatocellular; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Tenofovir | 2021 |
Switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with low-level viraemia.
Topics: Adenine; Alanine; Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Prospective Studies; Tenofovir; Treatment Outcome; Viremia | 2021 |
The 48-week safety and therapeutic effects of tenofovir alafenamide in hbv-related acute-on-chronic liver failure: A prospective cohort study.
Topics: Acute-On-Chronic Liver Failure; Alanine; Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Prospective Studies; Tenofovir; Treatment Outcome | 2021 |
Risk of hepatocellular carcinoma with tenofovir versus entecavir in chronic hepatitis B.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Tenofovir | 2021 |
Risk of hepatocellular carcinoma with tenofovir versus entecavir in chronic hepatitis B - Authors' reply.
Topics: Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Tenofovir | 2021 |
Editorial: similar risk of hepatocellular carcinoma in chronic hepatitis B patients treated with tenofovir or entecavir-new clues from Europe. Authors' reply.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Europe; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Tenofovir | 2021 |
Editorial: similar risk of hepatocellar carcinoma in chronic hepatitis B patients treated with tenofovir or entecavir-new clues from Europe.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Europe; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Tenofovir | 2021 |
Multiple drug-resistant HBV mutation may contribute to poor response of adefovir + entecavir in entecavir-resistant patients.
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Mutation; Organophosphonates; RNA-Directed DNA Polymerase; Tenofovir; Viral Load; Virus Replication | 2021 |
Serological and virological response in patients with hepatitis B virus genotype E treated with entecavir or tenofovir: a prospective study.
Topics: Adult; Antiviral Agents; Female; Genotype; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Prospective Studies; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2021 |
Validation of the HCC-RESCUE score to predict hepatocellular carcinoma risk in Caucasian chronic hepatitis B patients under entecavir or tenofovir therapy.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Tenofovir | 2021 |
Antiviral Therapy Reduces Risk of Cirrhosis in Noncirrhotic HBV Patients Among 4 Urban Safety-Net Health Systems.
Topics: Adult; Aged; Alanine; Antiviral Agents; Asian; Black or African American; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B, Chronic; Humans; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Mortality; Propensity Score; Proportional Hazards Models; Retrospective Studies; Safety-net Providers; Tenofovir; United States; Urban Population; White People | 2021 |
Another oral antiviral treatment, but still far away from hepatitis B virus cure.
Topics: Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Maleates; Organophosphonates; Tenofovir | 2021 |
Effects of Tenofovir vs Entecavir on Risk of Hepatocellular Carcinoma in Patients With CHB: A Comment for Moving Forward.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Humans; Liver Neoplasms; Tenofovir | 2022 |
A Prospective Study Evaluating Changes in Histology, Clinical and Virologic Outcomes in HBV-HIV Co-infected Adults in North America.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Liver; Male; Middle Aged; North America; Prospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Young Adult | 2021 |
Aspirin Reduces the Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Receiving Oral Nucleos(t)ide Analog.
Topics: Adult; Aged; Alanine; Antiviral Agents; Aspirin; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; Guanine; Hepatitis B, Chronic; Hong Kong; Humans; Incidence; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Tenofovir | 2021 |
The efficacies of entecavir and tenofovir in terms of enhancing prognosis after curative treatment of hepatitis B virus-related hepatocellular carcinoma.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Tenofovir; Treatment Outcome | 2021 |
Letter: tenofovir may be superior to entecavir for treatment-naïve chronic hepatitis B patients-authors' reply.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Tenofovir | 2021 |
Letter: tenofovir versus entecavir for hepatocellular carcinoma prevention in chronic hepatitis B-related compensated cirrhosis.
Topics: Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Taiwan; Tenofovir | 2021 |
Letter: tenofovir may be superior to entecavir for treatment-naïve chronic hepatitis B patients.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Tenofovir | 2021 |
Letter: tenofovir versus entecavir for hepatocellular carcinoma prevention in chronic hepatitis B-related compensated cirrhosis-authors' reply.
Topics: Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Taiwan; Tenofovir | 2021 |
Entecavir versus Tenofovir for the Prevention of Hepatocellular Carcinoma in Treatment-naïve Chronic Hepatitis B Patients in Korea.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Databases, Factual; Female; Guanine; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Male; Middle Aged; Proportional Hazards Models; Republic of Korea; Retrospective Studies; Tenofovir; Young Adult | 2021 |
Prevention of HBV Recurrence After Liver Transplant: Long-Term Results.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Drug Administration Schedule; Female; Guanine; Hepatitis B; Hepatitis B Antibodies; Hepatitis B virus; Humans; Immunoglobulins; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Recurrence; Retrospective Studies; Tenofovir | 2021 |
Antiviral therapy after curative treatment of hepatocellular carcinoma in patients with chronic hepatitis B infection: Is tenofovir or entecavir preferred?
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Tenofovir | 2021 |
Tenofovir is Associated With Higher Risk of Kidney Function Decline Than Entecavir in Patients With Chronic Hepatitis B.
Topics: Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kidney; Retrospective Studies; Tenofovir; Treatment Outcome | 2022 |
Outcomes of Sequential Therapy With Tenofovir Alafenamide After Long-term Entecavir.
Topics: Antiviral Agents; Biomarkers; Comorbidity; Drug Resistance, Viral; Female; Guanine; Hepatitis B, Chronic; Humans; Liver Function Tests; Male; Middle Aged; Retrospective Studies; Tenofovir | 2021 |
Comparison of the Efficacy of Entecavir and Tenofovir in Reducing Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients: A Real-Life Study in Turkey.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Risk Factors; Tenofovir; Turkey | 2021 |
Predictors of Virological Suppression After Clinical Relapse in Patients Who Discontinued Entecavir or Tenofovir.
Topics: Antiviral Agents; DNA, Viral; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Recurrence; Tenofovir; Treatment Outcome | 2022 |
Efficacy of entecavir versus tenofovir in preventing hepatocellular carcinoma in patients with chronic hepatitis B with maintained virologic response.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Pharmaceutical Preparations; Retrospective Studies; Tenofovir; Treatment Outcome | 2021 |
Baseline serum hepatitis B core antibody level predicts HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B after antiviral treatment.
Topics: Adult; Antiviral Agents; Biomarkers; Female; Guanine; Hepatitis B Antibodies; Hepatitis B Core Antigens; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Logistic Models; Male; Multivariate Analysis; Retrospective Studies; ROC Curve; Tenofovir | 2021 |
Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B.
Topics: Alanine; Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Retrospective Studies; Tenofovir; Treatment Outcome | 2021 |
Long-term effects of entecavir and tenofovir treatment on the fibrotic burden in patients with chronic hepatitis B.
Topics: Antiviral Agents; Fibrosis; Guanine; Hepatitis B, Chronic; Humans; Tenofovir; Treatment Outcome | 2022 |
Association between HBs Ag quantification and the risk of hepatocellular carcinoma in patients treated with tenofovir disoproxil fumarate or entecavir.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Middle Aged; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Tenofovir | 2021 |
An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B.
Topics: Adult; Antiviral Agents; Artificial Intelligence; Asian People; Carcinoma, Hepatocellular; Cohort Studies; Computer Simulation; Female; Follow-Up Studies; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Middle Aged; Republic of Korea; Tenofovir; White People | 2022 |
Association between chronic hepatitis B infection and COVID-19 outcomes: A Korean nationwide cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Case-Control Studies; Cohort Studies; COVID-19; Databases, Factual; Female; Guanine; Hepatitis B, Chronic; Humans; Male; Middle Aged; Odds Ratio; Republic of Korea; Risk; Severity of Illness Index; Tenofovir; Young Adult | 2021 |
[Study on mining of signals of adverse drug reactions of entecavir and tenofovir disoproxil based on the US FAERS database].
Topics: Adverse Drug Reaction Reporting Systems; Drug-Related Side Effects and Adverse Reactions; Female; Guanine; Humans; Infant, Newborn; Male; Tenofovir; United States; United States Food and Drug Administration | 2021 |
Comparison of nucleoside and nucleotide analogs in the recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection: A multicenter study.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Female; Guanine; Hepatectomy; Hepatitis B virus; Humans; Liver Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Nucleosides; Nucleotides; Prognosis; Retrospective Studies; Survival Analysis; Tenofovir | 2021 |
Real-World Single-Center Comparison of the Safety and Efficacy of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide in Patients with Chronic Hepatitis B.
Topics: Alanine; Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Tenofovir; Treatment Outcome | 2022 |
Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study).
Topics: Adult; Age Factors; Antiviral Agents; Asian People; Cohort Studies; DNA, Viral; Female; Follow-Up Studies; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Nucleosides; Race Factors; Recurrence; Retreatment; Tenofovir; White People | 2022 |
Efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in treatment-naive hepatitis B patients.
Topics: Aged; Alanine; Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Tenofovir; Treatment Outcome | 2021 |
Longitudinal renal changes in chronic hepatitis B patients treated with entecavir versus TDF: a REAL-B study.
Topics: Adult; Antiviral Agents; Female; Guanine; Hepatitis B, Chronic; Humans; Kidney; Male; Middle Aged; Retrospective Studies; Tenofovir; Treatment Outcome | 2022 |
Earlier and Higher Rate of Hepatitis B Virus Relapse After Discontinuing Tenofovir Versus Entecavir in Hepatitis B e Antigen-Positive Patients.
Topics: Antiviral Agents; DNA, Viral; Guanine; Hepatitis B Core Antigens; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Recurrence; Tenofovir; Treatment Outcome | 2022 |
Off-tenofovir hepatitis flares in HBeAg-negative patients occur earlier, more frequent and severe than those off-entecavir therapies.
Topics: Antiviral Agents; DNA, Viral; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Retrospective Studies; Symptom Flare Up; Tenofovir; Treatment Outcome | 2022 |
Tenofovir vs. entecavir on recurrence of hepatitis B virus-related hepatocellular carcinoma beyond Milan criteria after hepatectomy.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatectomy; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Retrospective Studies; Tenofovir | 2021 |
Effects of Long-Term Tenofovir and Entecavir Treatment on Bone Mineral Density in Patients with Chronic Hepatitis B.
Topics: Adenine; Antiviral Agents; Bone Density; Guanine; Hepatitis B, Chronic; Humans; Prospective Studies; Tenofovir; Treatment Outcome | 2022 |
Impact of switching to tenofovir alafenamide fumarate in patients with entecavir-treated chronic hepatitis B.
Topics: Adenine; Alanine; Antiviral Agents; Fumarates; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Retrospective Studies; Tenofovir; Treatment Outcome | 2021 |
Risk of hepatocellular carcinoma in treatment-naïve chronic hepatitis B patients receiving tenofovir disoproxil fumarate versus entecavir in the United States.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Retrospective Studies; Tenofovir; Treatment Outcome; United States | 2022 |
Tenofovir vs. entecavir on prognosis of hepatitis B virus-related hepatocellular carcinoma after curative resection.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Prognosis; Retrospective Studies; Tenofovir; Treatment Outcome | 2022 |
Superiority of tenofovir alafenamide fumarate over entecavir for serum HBsAg level reduction in patients with chronic HBV infection: A 144-week outcome study after switching of the nucleos(t)ide analog.
Topics: Aged; Alanine; Antiviral Agents; Drug Substitution; Female; Follow-Up Studies; Fumarates; Genotype; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Nucleosides; Prospective Studies; Tenofovir; Treatment Outcome | 2022 |
Tenofovir vs. Entecavir on Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma after Radiofrequency Ablation.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Radiofrequency Ablation; Retrospective Studies; Tenofovir; Treatment Outcome | 2022 |
Renal safety of tenofovir disoproxil fumarate and entecavir in liver transplant patients: a nationwide Korean registry study.
Topics: Adult; Antiviral Agents; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kidney; Kidney Diseases; Liver Transplantation; Registries; Republic of Korea; Retrospective Studies; Tenofovir; Treatment Outcome | 2022 |
Prognosis Comparison Between Chronic Hepatitis B Patients Receiving a Finite Course of Tenofovir and Entecavir Treatment: A Nationwide Cohort Study in Taiwan.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Guanine; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Prognosis; Taiwan; Tenofovir; Treatment Outcome | 2022 |
Editorial: risk of hepatocellular carcinoma with tenofovir vs entecavir-A "knock-out" is yet to be delivered-Authors' reply.
Topics: Carcinoma, Hepatocellular; Guanine; Humans; Liver Neoplasms; Tenofovir | 2022 |
Editorial: risk of hepatocellular carcinoma with tenofovir vs entecavir-a "knock-out" is yet to be delivered.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Humans; Liver Neoplasms; Tenofovir | 2022 |
Comparable outcomes of decompensated chronic hepatitis B patients treated with entecavir or tenofovir: an 8-year cohort study.
Topics: Antiviral Agents; Cohort Studies; End Stage Liver Disease; Female; Guanine; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Severity of Illness Index; Tenofovir; Treatment Outcome | 2022 |
Kinetics in HBsAg after Stopping Entecavir or Tenofovir in Patients with Virological Relapse but Not Clinical Relapse.
Topics: Antiviral Agents; DNA, Viral; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kinetics; Recurrence; Tenofovir; Treatment Outcome | 2022 |
Real-life impact of tenofovir disoproxil fumarate and entecavir therapy on lipid profile, glucose, and uric acid in chronic hepatitis B patients.
Topics: Antiviral Agents; Glucose; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lipids; Retrospective Studies; Tenofovir; Treatment Outcome; Uric Acid | 2022 |
Association of tenofovir and entecavir use with prognosis after surgical resection for hepatitis B virus-related hepatocellular carcinoma.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Prognosis; Tenofovir; Treatment Outcome | 2022 |
Does Hepatic Steatosis Influence the Virological Response with Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir Disoproxil Fumarate?
Topics: Adult; Antiviral Agents; DNA, Viral; Fatty Liver; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Tenofovir; Treatment Outcome | 2022 |
Similar risk of kidney function decline between tenofovir alafenamide and besifovir dipivoxil maleate in chronic hepatitis B.
Topics: Adenine; Alanine; Antiviral Agents; Guanine; Hepatitis B; Hepatitis B, Chronic; Humans; Kidney; Longitudinal Studies; Maleates; Organophosphonates; Renal Insufficiency, Chronic; Retrospective Studies; Tenofovir; Treatment Outcome | 2022 |
Efficacy and Safety of Peginterferon
Topics: Antiviral Agents; Genotype; Guanine; Hepatitis B, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Tenofovir; Treatment Outcome | 2022 |